# EDGAR Filing Document

**Accession Number:** 0001180145
**File Stem:** 0001180145-23-000016
**Filing Date:** 2023-2
**Character Count:** 541879
**Document Hash:** 1538c3c4bcf36c8ae6f7a1e074a2557b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001180145-23-000016.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001180145-23-000016

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 66

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cardiovascular Systems Inc
- **CENTRAL INDEX KEY:** 0001180145
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 411698056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-52082
- **FILM NUMBER:** 23606845

**BUSINESS ADDRESS:**
- **STREET 1:** 1225 OLD HWY 8 NW
- **CITY:** ST. PAUL
- **STATE:** MN
- **ZIP:** 55112
- **BUSINESS PHONE:** 651-259-1600

**MAIL ADDRESS:**
- **STREET 1:** 1225 OLD HWY 8 NW
- **CITY:** ST. PAUL
- **STATE:** MN
- **ZIP:** 55112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REPLIDYNE INC
- **DATE OF NAME CHANGE:** 20020813

?xml version="1.0" ? csii-20221231

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_____________________________________________________

**FORM 10-Q**

_____________________________________________________

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended December 31, 2022** 

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ___________ to ___________

**Commission File No. 000-52082**

____________________________________________________

**CARDIOVASCULAR SYSTEMS, INC.**

**(Exact name of registrant as specified in its charter)**

____________________________________________________

---

| | |
|:---|:---|
| **Delaware** | **41-1698056** |
| **(State or other jurisdiction of** | **(IRS Employer** |
| **incorporation or organization)** | **Identification No.)** |

---

**1225 Old Highway 8 Northwest**

**St. Paul, Minnesota 55112-6416**

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (651) 259-1600**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, One-tenth of One Cent ($0.001) Par Value Per Share | CSII | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ⌧

The number of shares outstanding of the registrant's Common Stock, $0.001 par value per share, as of February 7, 2023 was: 41,958,938 shares.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**Cardiovascular Systems, Inc.**

**Table of Contents**

---

| | |
|:---|:---|
| | **PAGE** |
| <u>[PART I. FINANCIAL INFORMATION](#i55f58fa254f047908acf2fcb3687b73f_10)</u> | |
| <u>[ITEM 1. Consolidated Financial Statements (unaudited)](#i55f58fa254f047908acf2fcb3687b73f_13)</u> | <u>[3](#i55f58fa254f047908acf2fcb3687b73f_13)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Consolidated Balance Sheets](#i55f58fa254f047908acf2fcb3687b73f_16)</u> | <u>[3](#i55f58fa254f047908acf2fcb3687b73f_16)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Operations](#i55f58fa254f047908acf2fcb3687b73f_19)</u> | <u>[4](#i55f58fa254f047908acf2fcb3687b73f_19)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Comprehensive Income](#i55f58fa254f047908acf2fcb3687b73f_22)</u> | <u>[5](#i55f58fa254f047908acf2fcb3687b73f_22)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Changes in Stockholders' Equity](#i55f58fa254f047908acf2fcb3687b73f_25)</u> | <u>[6](#i55f58fa254f047908acf2fcb3687b73f_25)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Cash Flows](#i55f58fa254f047908acf2fcb3687b73f_28)</u> | <u>[8](#i55f58fa254f047908acf2fcb3687b73f_28)</u> |
| <u>[Notes to Consolidated Financial Statements](#i55f58fa254f047908acf2fcb3687b73f_31)</u> | <u>[9](#i55f58fa254f047908acf2fcb3687b73f_31)</u> |
| <u>[ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i55f58fa254f047908acf2fcb3687b73f_67)</u> | <u>[19](#i55f58fa254f047908acf2fcb3687b73f_67)</u> |
| <u>[ITEM 3. Quantitative and Qualitative Disclosures About Market Risk](#i55f58fa254f047908acf2fcb3687b73f_97)</u> | <u>[29](#i55f58fa254f047908acf2fcb3687b73f_97)</u> |
| <u>[ITEM 4. Controls and Procedures](#i55f58fa254f047908acf2fcb3687b73f_100)</u> | <u>[30](#i55f58fa254f047908acf2fcb3687b73f_100)</u> |
| <u>[PART II. OTHER INFORMATION](#i55f58fa254f047908acf2fcb3687b73f_103)</u> | |
| <u>[ITEM 1. Legal Proceedings](#i55f58fa254f047908acf2fcb3687b73f_106)</u> | <u>[31](#i55f58fa254f047908acf2fcb3687b73f_106)</u> |
| <u>[ITEM 1A. Risk Factors](#i55f58fa254f047908acf2fcb3687b73f_109)</u> | <u>[31](#i55f58fa254f047908acf2fcb3687b73f_109)</u> |
| <u>[ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds](#i55f58fa254f047908acf2fcb3687b73f_112)</u> | <u>[33](#i55f58fa254f047908acf2fcb3687b73f_112)</u> |
| <u>[ITEM 3. Defaults Upon Senior Securities](#i55f58fa254f047908acf2fcb3687b73f_115)</u> | <u>[34](#i55f58fa254f047908acf2fcb3687b73f_115)</u> |
| <u>[ITEM 4. Mine Safety Disclosures](#i55f58fa254f047908acf2fcb3687b73f_118)</u> | <u>[34](#i55f58fa254f047908acf2fcb3687b73f_118)</u> |
| <u>[ITEM 5. Other Information](#i55f58fa254f047908acf2fcb3687b73f_121)</u> | <u>[34](#i55f58fa254f047908acf2fcb3687b73f_121)</u> |
| <u>[ITEM 6. Exhibits](#i55f58fa254f047908acf2fcb3687b73f_124)</u> | <u>[34](#i55f58fa254f047908acf2fcb3687b73f_124)</u> |
| <u>[Signatures](#i55f58fa254f047908acf2fcb3687b73f_127)</u> | <u>[36](#i55f58fa254f047908acf2fcb3687b73f_127)</u> |

---

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**PART I. — FINANCIAL INFORMATION**

**ITEM 1.&nbsp;&nbsp;&nbsp;&nbsp;CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**Cardiovascular Systems, Inc.**

**Consolidated Balance Sheets**

**(Dollars in thousands, except per share and share amounts)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **December 31,<br>2022** | **June 30,<br>2022** |
| **ASSETS** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $59843 | $66424 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 72159 | 93409 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 40232 | 39678 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 41191 | 34567 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 8535 | 7768 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 221960 | 241846 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 30002 | 29035 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 15043 | 15734 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Strategic investments | 42034 | 33425 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 2467 | 2637 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $311506 | $322677 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $17087 | $14383 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 19149 | 23464 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 525 | 2107 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 36761 | 39954 |
| Long-term liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing obligation | 20117 | 20298 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 3365 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 11874 | 12945 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 72117 | 73197 |
| Commitments and contingencies (see Note 9) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 41,965,948 at December 31, 2022 and 40,965,202 at June 30, 2022, respectively | 40 | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid in capital | 682932 | 673388 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | (170) | (268) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (443413) | (423680) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 239389 | 249480 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $311506 | $322677 |

---

*The accompanying notes are an integral part of these unaudited consolidated financial statements.*

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**Cardiovascular Systems, Inc.**

**Consolidated Statements of Operations**

**(Dollars in thousands, except per share and share amounts)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net revenues | $61453 | $59135 | $121126 | $117505 |
| Cost of goods sold | 18461 | 18073 | 35159 | 32381 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 42992 | 41062 | 85967 | 85124 |
| Expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 41642 | 40402 | 86117 | 82253 |
| &nbsp;&nbsp;&nbsp;Research and development | 9533 | 8873 | 18589 | 18895 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 345 | 346 | 691 | 650 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total expenses | 51520 | 49621 | 105397 | 101798 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from operations | (8528) | (8559) | (19430) | (16674) |
| Other (income) expense, net: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 404 | 409 | 810 | 819 |
| &nbsp;&nbsp;&nbsp;Interest income and other, net | (1093) | (64) | (1751) | (107) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (income) expense, net | (689) | 345 | (941) | 712 |
| Loss before income taxes | (7839) | (8904) | (18489) | (17386) |
| Provision for income taxes | 49 | 63 | 30 | 199 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(7888) | $(8967) | $(18519) | $(17585) |
| Basic and diluted earnings per share | $(0.20) | $(0.23) | $(0.47) | $(0.45) |
| Basic and diluted weighted average shares outstanding | 39663565 | 39199593 | 39635293 | 39143533 |

---

*The accompanying notes are an integral part of these unaudited consolidated financial statements.*

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**Cardiovascular Systems, Inc.**

**Consolidated Statements of Comprehensive Income**

**(Dollars in thousands)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net loss | $(7888) | $(8967) | $(18519) | $(17585) |
| Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;Unrealized gain (loss) on available-for-sale debt securities | 103 | (52) | 106 | (69) |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | (2) |  | (8) |  |
| Comprehensive loss | $(7787) | $(9019) | $(18421) | $(17654) |

---

*The accompanying notes are an integral part of these unaudited consolidated financial statements.*

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**Cardiovascular Systems, Inc.**

**Consolidated Statements of Changes in Stockholders' Equity**

**(Dollars in thousands, except per share amounts)**

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Additional<br>Paid In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income** | **Accumulated<br>Deficit** | **Total** |
| | **Common Stock** | **Additional<br>Paid In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income** | **Accumulated<br>Deficit** | **Total** |
| **Balances at June 30, 2022** | $40 | $673388 | $(268) | $(423680) | $249480 |
| Stock-based compensation related to restricted stock awards, net |  | 4324 |  |  | 4324 |
| Shares withheld for payroll taxes |  |  |  | (1191) | (1191) |
| Employee stock purchase plan activity |  | 174 |  |  | 174 |
| Unrealized gain on available-for-sale debt securities |  |  | 3 |  | 3 |
| Foreign currency translation adjustments |  |  | (6) |  | (6) |
| Net loss |  |  |  | (10631) | (10631) |
| **Balances at September 30, 2022** | $40 | $677886 | $(271) | $(435502) | $242153 |
| Stock-based compensation related to restricted stock awards, net |  | 3547 |  |  | 3547 |
| Shares withheld for payroll taxes |  |  |  | (23) | (23) |
| Employee stock purchase plan activity |  | 1499 |  |  | 1499 |
| Unrealized gain on available-for-sale debt securities |  |  | 103 |  | 103 |
| Foreign currency translation adjustments |  |  | (2) |  | (2) |
| Net loss |  |  |  | (7888) | (7888) |
| **Balances at December 31, 2022** | $40 | $682932 | $(170) | $(443413) | $239389 |

---

*The accompanying notes are an integral part of these unaudited consolidated financial statements.*

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**Cardiovascular Systems, Inc.**

**Consolidated Statements of Changes in Stockholders' Equity**

**(Dollars in thousands, except per share amounts)**

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Additional<br>Paid In<br>Capital** | **Accumulated Other Comprehensive Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| | **Common Stock** | **Additional<br>Paid In<br>Capital** | **Accumulated Other Comprehensive Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| **Balances at June 30, 2021** | $39 | $652288 | $11 | $(381380) | $270958 |
| Stock-based compensation related to restricted stock awards, net |  | 5523 |  |  | 5523 |
| Shares withheld for payroll taxes |  |  |  | (4990) | (4990) |
| Employee stock purchase plan activity |  | 324 |  |  | 324 |
| Unrealized loss on available-for-sale debt securities |  |  | (17) |  | (17) |
| Exercise of stock options |  | 12 |  |  | 12 |
| Net loss |  |  |  | (8618) | (8618) |
| **Balances at September 30, 2021** | $39 | $658147 | $(6) | $(394988) | $263192 |
| Stock-based compensation related to restricted stock awards, net |  | 3659 |  |  | 3659 |
| Shares withheld for payroll taxes |  |  |  | (161) | (161) |
| Employee stock purchase plan activity |  | 1854 |  |  | 1854 |
| Unrealized loss on available-for-sale debt securities |  |  | (52) |  | (52) |
| Net loss |  |  |  | (8967) | (8967) |
| **Balances at December 31, 2021** | $39 | $663660 | $(58) | $(404116) | $259525 |

---

*The accompanying notes are an integral part of these unaudited consolidated financial statements.*

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**Cardiovascular Systems, Inc.**

**Consolidated Statements of Cash Flows**

**(Dollars in thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **December 31,** | **December 31,** |
| | **2022** | **2021** |
| **Cash flows from operating activities** |  |  |
| Net loss | $(18519) | $(17585) |
| Adjustments to reconcile net loss to net cash from operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation of property and equipment | 1797 | 1895 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 691 | 650 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 7985 | 9912 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for doubtful accounts | 50 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of premium (accretion of discount) on marketable securities | (615) | 800 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (69) | (26) |
| Changes in assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (612) | 5089 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (6624) | 642 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (278) | 950 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 2667 | (1525) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (5456) | (11996) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 1783 | (1121) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (17200) | (12315) |
| **Cash flows from investing activities** |  |  |
| Purchases of property and equipment | (2727) | (2426) |
| Acquisitions |  | (1700) |
| Investments in strategic ventures | (8540) | (8999) |
| Purchases of marketable securities | (52523) | (50844) |
| Sales of marketable securities | 14389 | 6817 |
| Maturities of marketable securities | 59875 | 68261 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | 10474 | 11109 |
| **Cash flows from financing activities** |  |  |
| Proceeds from employee stock purchase plan | 1499 | 1242 |
| Payments of employee taxes related to vested restricted stock | (1214) | (5151) |
| Exercise of stock options |  | 12 |
| Principal payments made on financing obligation | (140) | (102) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | 145 | (3999) |
| Net change in cash and cash equivalents | (6581) | (5205) |
| **Cash and cash equivalents** |  |  |
| Beginning of period | 66424 | 71070 |
| End of period | $59843 | $65865 |

---

*The accompanying notes are an integral part of these unaudited consolidated financial statements.* 

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**CARDIOVASCULAR SYSTEMS, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(For the Six Months Ended December 31, 2022 and 2021)**

**(Dollars in thousands, except per share and share amounts)**

**(Unaudited)**

**1. Basis of Presentation**

Cardiovascular Systems, Inc. (the "Company"), based in St. Paul, Minnesota, is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company's Orbital Atherectomy Systems ("OAS") treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The Company prepared the unaudited interim consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America ("GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial statements. The year-end consolidated balance sheet was derived from the Company's audited consolidated financial statements, but does not include all disclosures as required by GAAP. These interim consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary for a fair statement of the Company's consolidated financial position, the results of its operations, its changes in stockholders' equity, and its cash flows for the interim periods. These interim consolidated financial statements should be read in conjunction with the consolidated annual financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended June 30, 2022. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

The preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company has been impacted by the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on the Company's customers and markets. The Company has made estimates of the impact of COVID-19 within these consolidated financial statements and there may be changes to those estimates in future periods. Actual results could differ from those estimates.

**2. Selected Consolidated Financial Statement Information**

***Accounts Receivable, Net***

Accounts receivable consists of the following:

---

| | | |
|:---|:---|:---|
| | **December 31,**<br>**2022** | **June 30,**<br>**2022** |
| Accounts receivable | $41504 | $40974 |
| Less: Allowance for doubtful accounts | (1272) | (1296) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | $40232 | $39678 |

---

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

***Inventories***

Inventories consist of the following:

---

| | | |
|:---|:---|:---|
| | **December 31,**<br>**2022** | **June 30,**<br>**2022** |
| Raw materials | $16340 | $13780 |
| Work in process | 2404 | 2785 |
| Finished goods | 22447 | 18002 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | $41191 | $34567 |

---

The total inventory reserve at December 31, 2022 and June 30, 2022 was $3,313 and $4,128, respectively.

***Property and Equipment, Net***

Property and equipment consists of the following:

---

| | | |
|:---|:---|:---|
| | **December 31,**<br>**2022** | **June 30,**<br>**2022** |
| Land | $572 | $572 |
| Building | 22420 | 22420 |
| Equipment | 25400 | 24340 |
| Furniture | 3376 | 3376 |
| Leasehold improvements | 812 | 812 |
| Construction in progress | 4376 | 2670 |
|  | 56956 | 54190 |
| Less: Accumulated depreciation | (26954) | (25155) |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | $30002 | $29035 |

---

***Accrued Expenses***

Accrued expenses consist of the following:

---

| | | |
|:---|:---|:---|
| | **December 31,**<br>**2022** | **June 30,**<br>**2022** |
| Commissions | 6513 | 8104 |
| Salaries and bonus | 5675 | 8082 |
| Accrued vacation | 2336 | 2345 |
| Accrued excise, sales and other taxes | 847 | 953 |
| Clinical studies | 1009 | 1082 |
| Other | 2769 | 2898 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | $19149 | $23464 |

---

***Other Liabilities***

*WIRION Acquisition Consideration*

Following the successful completion of the manufacturing transfer of the WIRION system to the Company, the Company has agreed to pay an additional consideration of $10,000, half of which may be paid by the Company through an issuance of shares of its common stock. The Company reviewed this liability in response to the voluntary recall of the WIRION system and determined that it remains probable and appropriately recorded in other liabilities as of December 31, 2022, although this payment will be made at a later date than originally anticipated due to the recall.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**3. Revenue**

The following table disaggregates the Company's net revenues by product category and geography for the following periods:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| **<u>Product Category</u>** | **2022** | **2021** | **2022** | **2021** |
| Peripheral | $38452 | $38903 | $77236 | $77912 |
| Coronary | 23001 | 20232 | 43890 | 39593 |
| Total net revenues | $61453 | $59135 | $121126 | $117505 |
| **<u>Geography</u>** |  |  |  |  |
| United States | $56329 | $55471 | $111356 | $110513 |
| International | 5124 | 3664 | 9770 | 6992 |
| Total net revenues | $61453 | $59135 | $121126 | $117505 |

---

Revenue of $2,107 was recognized in the six months ended December 31, 2022 that was deferred as of June 30, 2022. On December 13, 2022, we signed a distribution agreement with Otsuka Medical Devices Co., Ltd. ("Otsuka"). Effective February 1, 2023 upon expiration of Medikit's distribution agreement, Otsuka became our exclusive Japan distributor. The Company received a $4,000 upfront payment which the Company has recorded as deferred revenue and classified as current and long-term based on its expectation of when revenue will be recognized. Revenue of $110 was recognized in the three months ended December 31, 2022 related to this upfront payment. As of December 31, 2022 and June 30, 2022, the Company had a liability of $991 and $1,315, respectively, related to estimates of variable consideration which are recorded within accounts payable on the consolidated balance sheet.

**4. Intangible Assets**

The Company's finite-lived intangible assets are stated at cost less accumulated amortization and include developed technology and trade name assets acquired in asset acquisitions, as well as costs incurred to obtain patents. Developed technology and trade name assets are amortized over 10 years to 15 years. Patent costs are amortized beginning at the time of patent approval over a useful life not exceeding 20 years.

The components of intangible assets, net are as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** | **June 30, 2022** | **June 30, 2022** | **June 30, 2022** |
| | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** |
| Developed technology | $17324 | $(3771) | $13553 | $17324 | $(3165) | $14159 |
| Patents | 1866 | (963) | 903 | 1866 | (903) | 963 |
| Trade name | 760 | (173) | 587 | 760 | (148) | 612 |
| &nbsp;&nbsp;Total intangible assets, net | $19950 | $(4907) | $15043 | $19950 | $(4216) | $15734 |

---

Amortization expense expected for the next five years and thereafter is as follows:

---

| | |
|:---|:---|
| Remainder of fiscal 2023 | $690 |
| Fiscal 2024 | 1377 |
| Fiscal 2025 | 1374 |
| Fiscal 2026 | 1373 |
| Fiscal 2027 | 1371 |
| Thereafter | 8858 |
|  | $15043 |

---

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**5. Debt**

***Revolving Credit Facility***

In March 2017, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank ("SVB"). In March 2020, the Company entered into the First Amendment to the Loan Agreement (the "Amendment"). The Amendment extended the maturity date of the Loan Agreement by two years, to March 31, 2022, and increased the maximum amount available under the senior, secured revolving credit facility (the "Revolver") to $50,000 (the "Maximum Dollar Amount"). In March 2022, the Company entered into the Second Amendment to the Loan Agreement (the "Second Amendment"). The Second Amendment extended the maturity date of the Loan Agreement by one year, to March 31, 2023.

Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.75%. Interest on borrowings is due monthly and the principal balance is due at maturity. Upon the Revolver's maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. The Company will incur a fee equal to 1.5% of the Maximum Dollar Amount upon termination of the Loan Agreement, as amended by the Second Amendment (the "Amended Loan Agreement"), or the Revolver for any reason prior to the date that is fifteen days prior to the maturity date, unless refinanced with SVB.

The Company's obligations under the Amended Loan Agreement are secured by certain of the Company's assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include the Company's intellectual property, but the Company has agreed not to encumber its intellectual property without the consent of SVB. The Amended Loan Agreement contains customary covenants limiting the Company's ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of its business. In addition, the Amended Loan Agreement contains financial covenants requiring the Company to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10,000 or (ii) minimum trailing three-month Adjusted EBITDA of $1,000. If the Company does not comply with the various covenants under the Amended Loan Agreement or an event of default under the Amended Loan Agreement occurs, such as a material adverse change, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights and the other terms and conditions of the Amended Loan Agreement, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral.

The Company is required to pay a fee equal to 0.15% per annum on the unused portion of the Revolver, payable quarterly in arrears. The Company is not obligated to draw any funds under the Revolver and has not done so under the Revolver since entering into the Loan Agreement. No amounts are outstanding as of December 31, 2022.

***Financing Obligation***

In connection with the sale of the Company's headquarters facility in St. Paul, Minnesota (the "Facility"), the Company entered into a Lease Agreement to lease the Facility. The Lease Agreement has an initial term of 15 years, with four consecutive renewal options of 5 years each at the Company's option, with a base annual rent in the first year of $1,638 and annual escalations of 3% thereafter. Rent during subsequent renewal terms will be at the then fair market rental rate. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Facility as a financing transaction where the assets remain on the Company's balance sheet and a financing obligation was recorded for $20,944. As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. The effective interest rate is 7.89%. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

Payments under the initial term of the Lease Agreement as of December 31, 2022 are as follows:

---

| | |
|:---|:---|
| Remainder of fiscal 2023 | $963 |
| Fiscal 2024 | 1970 |
| Fiscal 2025 | 2029 |
| Fiscal 2026 | 2090 |
| Fiscal 2027 | 2153 |
| Thereafter | 11133 |
|  | $20338 |

---

**6. Marketable Securities & Fair Value Measurements**

The Company's marketable securities are classified on the consolidated balance sheet as follows:

---

| | | |
|:---|:---|:---|
| | **December 31,**<br>**2022** | **June 30,**<br>**2022** |
| Short-term available-for-sale debt securities | $69688 | $88375 |
| Long-term available-for-sale debt securities | 2331 | 4810 |
| Available-for-sale debt securities | 72019 | 93185 |
| Mutual funds | 140 | 224 |
| &nbsp;&nbsp;Total marketable securities | $72159 | $93409 |

---

Available-for-sale debt securities are invested in the following financial instruments:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **As of December 31, 2022** | **As of December 31, 2022** | **As of December 31, 2022** |
| |<br>**Amortized Cost** | **Unrealized Gains** | **Unrealized Losses** | **Fair Value** |
| Commercial paper | $34221 | $— | $— | $34221 |
| U.S. government securities | 17004 | 1 | (40) | 16965 |
| Corporate debt | 18601 |  | (99) | 18502 |
| Asset backed securities | 2354 |  | (23) | 2331 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total available-for-sale debt securities | $72180 | $1 | $(162) | $72019 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **As of June 30, 2022** | **As of June 30, 2022** | **As of June 30, 2022** |
| |<br>**Amortized Cost** | **Unrealized Gains** | **Unrealized Losses** | **Fair Value** |
| Commercial paper | $36800 | $— | $— | $36800 |
| U.S. government securities | 14994 |  | (67) | 14927 |
| Corporate debt | 27193 |  | (142) | 27051 |
| Asset backed securities | 14465 |  | (58) | 14407 |
| &nbsp;&nbsp;Total available-for-sale debt securities | $93452 | $— | $(267) | $93185 |

---

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

The following table provides information by level for the Company's marketable securities that were measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Fair Value Measurements as of December 31, 2022**<br>**Using Inputs Considered as** | **Fair Value Measurements as of December 31, 2022**<br>**Using Inputs Considered as** | **Fair Value Measurements as of December 31, 2022**<br>**Using Inputs Considered as** |
| |<br>**Fair Value** | **Level 1** | **Level 2** | **Level 3** |
| Commercial paper | $34221 | $— | $34221 | $— |
| U.S. government securities | 16965 |  | 16965 |  |
| Corporate debt | 18502 |  | 18502 |  |
| Asset backed securities | 2331 |  | 2331 |  |
| Mutual funds | 140 | 81 | 59 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $72159 | $81 | $72078 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Fair Value Measurements as of June 30, 2022** <br>**Using Inputs Considered as** | **Fair Value Measurements as of June 30, 2022** <br>**Using Inputs Considered as** | **Fair Value Measurements as of June 30, 2022** <br>**Using Inputs Considered as** |
| |<br>**Fair Value** | **Level 1** | **Level 2** | **Level 3** |
| Commercial paper | $36800 | $— | $36800 | $— |
| U.S. government securities | 14927 |  | 14927 |  |
| Corporate debt | 27051 |  | 27051 |  |
| Asset backed securities | 14407 |  | 14407 |  |
| Mutual funds | 224 | 108 | 116 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | $93409 | $108 | $93301 | $— |

---

The Company's marketable securities classified within Level 1 are valued using real-time quotes for transactions in active exchange markets. Marketable securities within Level 2 are valued using readily available pricing sources. There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended December 31, 2022. Any transfers between levels would be recognized on the date of the event or when a change in circumstances causes a transfer.

*Strategic Investments*

The Company holds equity investments that do not have readily determined fair values. The Company has elected to measure these investments at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is reviewed each reporting period by performing a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired.

As of December 31, 2022 and June 30, 2022, the carrying value of these investments was $12,503 and $12,333, respectively. During the six months ended December 31, 2022, no impairment indicators were noted. The Company is committed to funding an additional $1,200 into these investments in the future. The Company holds options to acquire all outstanding equity or certain developed technologies with respect to some of these strategic investments.

The Company also holds strategic investments accounted for as available-for-sale debt securities, which had carrying values and approximated fair values of $29,531 and $21,092 as of December 31, 2022 and June 30, 2022, respectively. On December 30, 2022, the Company entered into a Loan Agreement (the "CVT Loan Agreement") with Chansu Vascular Technologies, LLC ("CVT") pursuant to which the Company agreed to loan to CVT up to the principal amount of $49,653, of which the principal amount of $19,653 was outstanding as of the date of such agreement. In January 2023, the Company advanced an additional $15,000 to CVT pursuant to the terms of the CVT Loan Agreement and is obligated to make additional advances of $5,000 on or after July 1, 2023 and $10,000 after CVT's achievement of a development milestone related to its medical device candidate. The principal amounts outstanding pursuant to the CVT Loan Agreement accrue interest at the rate of 4.35% per annum and all principal and accrued and unpaid interest are due and payable on June 30, 2024. CVT's obligations under the CVT Loan Agreement are secured by its assets. The fair values of these investments are measured using Level 3 inputs and are not included in the tables above. Impairment is assessed similar to the Company's other strategic investments and no impairment indicators were noted during the six months ended December 31, 2022.

**7. Stock-Based Compensation**

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

On November 15, 2017, the Company's stockholders approved the 2017 Equity Incentive Plan (the "Original 2017 Plan") for the purpose of granting equity awards to employees, directors and consultants. On March 12, 2020, the Company's Board of Directors approved the Amended and Restated 2017 Equity Incentive Plan, which amended and restated the Original 2017 Plan (the "Amended 2017 Plan"). On August 19, 2021, the Company's Board of Directors adopted a further amendment to the Amended 2017 Plan (as amended, the "2017 Plan"), which was approved by the Company's stockholders on November 11, 2021, that increased the number of shares available for issuance under the 2017 Plan by 1,700,000 shares. As amended to date, the 2017 Plan allows for the granting of up to 3,607,523 shares of common stock as approved by the Board of Directors or committees thereof in the form of nonqualified or incentive stock options, restricted stock awards, restricted stock unit awards, performance share awards, performance unit awards or stock appreciation rights to officers, directors, consultants and employees of the Company. As of December 31, 2022, there were 1,120,174 shares available for grant under the 2017 Plan.

Equity awards classified as restricted stock and performance-based restricted stock are treated as issued shares when granted; however, these shares are not included in the computation of basic weighted average shares outstanding. When shares vest, unless the holder elects to pay the payroll tax liability in cash or through a sale of shares, the Company withholds the appropriate amount of shares to settle the payroll tax liability, on behalf of the individual receiving the shares, as an adjustment to accumulated deficit.

*Restricted Stock*

The value of each restricted stock award is equal to the fair market value of the Company's common stock at the date of grant. Vesting of time-based restricted stock awards ranges from one year to three years. The estimated fair value of restricted stock awards, including the effect of estimated forfeitures, is recognized on a straight-line basis over the restricted stock's vesting period.

Restricted stock award activity for the six months ended December 31, 2022 is as follows:

---

| | | |
|:---|:---|:---|
| | **Number of<br>Shares** | **Weighted<br>Average Fair<br>Value** |
| Outstanding at June 30, 2022 | 678899 | $28.88 |
| &nbsp;&nbsp;Granted | 669890 | $16.48 |
| &nbsp;&nbsp;Forfeited | (90695) | $23.14 |
| &nbsp;&nbsp;Vested | (194830) | $36.23 |
| Outstanding at December 31, 2022 | 1063264 | $20.21 |

---

The Company also grants performance-based restricted stock awards to certain executives and other management, as summarized below.

*Performance-Based Restricted Stock - Total Shareholder Return*

In August 2022, the Company granted an aggregate maximum of 303,272 shares that vest based on the Company's total shareholder return relative to total shareholder return of the Company's peer group (a market condition), as measured by the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2022 compared to the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2025. Vesting of these awards will be determined on the date that the Company's Annual Report on Form 10-K for the fiscal year ending June 30, 2025 is filed.

To calculate the estimated fair value of these restricted stock awards with market conditions, the Company uses a Monte Carlo simulation, which uses the expected average stock prices to estimate the expected number of shares that will vest. The Monte Carlo simulation resulted in an aggregate fair value of approximately $2,800, which the Company will recognize as expense using the straight-line method over the period that the awards are expected to vest. Stock-based compensation expense related to an award with a market condition will be recognized regardless of whether the market condition is satisfied, provided that the requisite service has been provided.

Performance-based restricted stock awards granted in fiscal 2022 and 2021 that are outstanding vest based on the Company's total shareholder return relative to total shareholder return of the Company's peer group (a market condition), as measured by the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2021 and July 1, 2020, respectively, compared to the closing prices of the stock of the Company and the peer group members for the 90 trading days preceding July 1, 2024 and July 1, 2023, respectively.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

*Performance-Based Restricted Stock - Revenue*

In August 2022, the Company granted an aggregate maximum of 303,244 shares that vest based on the Company's average annual revenue growth during the performance period. Annual revenue growth is measured as the percentage increase in the revenue reported in the Form 10-K for each of the fiscal years ending June 30, 2023, 2024 and 2025, compared to the revenue reported in the Form 10-K for each preceding fiscal year. Vesting of these awards will be determined on the date that the Company's Annual Report on Form 10-K for the fiscal year ending June 30, 2025 is filed. The Company recognizes expense for awards with performance conditions when it concludes that it is probable that the performance condition will be achieved. Probability is assessed at each reporting period and expense is adjusted for such changes accordingly with a cumulative catch up adjustment.

Performance-based restricted stock award activity for the six months ended December 31, 2022 is as follows:

---

| | | |
|:---|:---|:---|
| | **Number of<br>Shares** | **Weighted<br>Average Fair<br>Value** |
| Outstanding at June 30, 2022 | 744215 | $19.89 |
| &nbsp;&nbsp;Granted | 606516 | $12.73 |
| &nbsp;&nbsp;Forfeited | (242733) | $27.79 |
| &nbsp;&nbsp;Vested |  | $— |
| Outstanding at December 31, 2022 | 1107998 | $14.24 |

---

Unrecognized stock compensation related to unvested stock awards outstanding as of December 31, 2022 was $20,982.

**8. Leases**

The Company leases its Texas manufacturing facility under an operating lease agreement which expires in April 2026. The Company also leases office equipment under lease agreements that expire at various dates through December 2026. As discussed in Note 5, the Company also leases its Minnesota headquarters facility which is accounted for as a financing obligation.

Operating lease right-of-use assets and liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement dates. The Company considers fixed or variable payment terms, prepayments, incentives, and options to extend, terminate or purchase. Renewal, termination or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised. The Company uses its incremental borrowing rate based on information available at the lease commencement date in determining the present value of lease payments unless the lease provides an implicit interest rate.

Operating lease cost is classified within the consolidated statement of operations based on the nature of the leased asset. The Company's operating lease cost was $269 and $258 for the six months ended December 31, 2022 and 2021, respectively. Cash paid for operating lease liabilities approximated operating lease cost for the six months ended December 31, 2022. There were $29 and $54 of operating lease right-of-use assets obtained in exchange for new lease liabilities during the six months ended December 31, 2022 and 2021, respectively.

---

| | | |
|:---|:---|:---|
| | **December 31,**<br>**2022** | **June 30,**<br>**2022** |
| **Right-of-use assets** |  |  |
| &nbsp;&nbsp;Other assets | $1636 | $1852 |
| **Operating lease liabilities** |  |  |
| &nbsp;&nbsp;Accrued expenses | 522 | 526 |
| &nbsp;&nbsp;Other liabilities | 1114 | 1326 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating lease liabilities | $1636 | $1852 |

---

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

Future minimum lease payments under the agreements as of December 31, 2022 are as follows:

---

| | |
|:---|:---|
| Remainder of fiscal 2023 | $270 |
| Fiscal 2024 | 514 |
| Fiscal 2025 | 503 |
| Fiscal 2026 | 416 |
| Fiscal 2027 | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease payments | 1707 |
| Less imputed interest | (71) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating lease liabilities | $1636 |

---

As of December 31, 2022, the weighted average remaining lease term for operating leases was 3.3 years and the weighted average discount rate used to determine operating lease liabilities was 2.55%.

**9. Commitment and Contingencies**

In the ordinary conduct of business, the Company is subject to various lawsuits and claims covering a wide range of matters including, but not limited to, employment claims, commercial disputes and product liability claims. While the outcome of these matters is uncertain, the Company does not believe there are any significant matters as of December 31, 2022 that are probable or estimable, for which the outcome could have a material adverse impact on its consolidated balance sheets or statements of operations.

**10. Earnings Per Share**

The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations (in thousands except share and per share amounts):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Numerator |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(7888) | $(8967) | $(18519) | $(17585) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income allocated to participating securities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss available to common stockholders | $(7888) | $(8967) | $(18519) | $(17585) |
| Denominator |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted average common shares outstanding – basic | 39663565 | 39199593 | 39635293 | 39143533 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive stock options<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive restricted stock units<sup>(2)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of performance-based restricted stock awards<sup>(3)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Weighted average common shares outstanding – diluted | 39663565 | 39199593 | 39635293 | 39143533 |
| Earnings per common share – basic and diluted | $(0.20) | $(0.23) | $(0.47) | $(0.45) |

---

(1)At December 31, 2022 and 2021, 67,938 and 79,188 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share for all periods presented because those shares are anti-dilutive.

(2)At December 31, 2022 and 2021, 279,657 and 310,415 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share for all periods presented because those shares are anti-dilutive.

(3)At December 31, 2022 and 2021, 1,107,998 and 820,586 performance-based restricted stock awards, respectively, were outstanding. The effect of the potential vesting of these awards has been excluded from the calculation of diluted loss per share for all periods presented because those shares are anti-dilutive.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**11. Subsequent Events**

On February 8, 2023, the Company entered into an Agreement and Plan of Merger (the "Abbott Merger Agreement") with Abbott Laboratories, an Illinois corporation ("Abbott"), and Cobra Acquisition Co., a Delaware corporation and a direct, wholly-owned subsidiary of Abbott ("Merger Sub"). The Abbott Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Abbott Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of Abbott (the "Abbott Transaction"). At the effective time of the Abbott Transaction, each share of the Company's common stock issued and outstanding immediately prior to the effective time, subject to certain exceptions set forth in the Abbott Merger Agreement, will automatically convert into and be exchangeable for the right to receive $20.00 per share in cash, without interest.

The boards of directors of both the Company and Abbott have unanimously approved the Abbott Merger Agreement and the Abbott Transaction. The Company's board of directors unanimously recommended that the Company's stockholders vote to adopt the Abbott Merger Agreement and approve the transactions contemplated thereby, including the Abbott Transaction, and directed that the adoption of the Abbott Merger Agreement be submitted to a vote of the stockholders.

The closing of the Abbott Transaction is subject to the affirmative vote of the holders of a majority of the outstanding shares of the Company's common stock to adopt the Abbott Merger Agreement, the expiration or termination of any waiting period (and extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and various other closing conditions.

The Abbott Merger Agreement includes certain termination provisions for both the Company and Abbott and provides that (i) in connection with the termination of the Abbott Merger Agreement under certain specified circumstances related to a change in the recommendation of the Company, the entry into an agreement for a superior proposal or the breach of certain of the Company's covenants under the Abbott Merger Agreement, the Company may be required to pay Abbott a termination fee of $26,500,000, and (ii) in connection with the termination of the Abbott Merger Agreement after November 8, 2023 (or as such date might be extended under the Abbott Merger Agreement) under certain specified circumstances related to antitrust laws or due to the consummation of the Abbott Transaction being permanently enjoined under antitrust laws, Abbott may be required to pay the Company a termination fee of $26,500,000.

Additional information about the Abbott Merger Agreement and the Abbott Transaction will be set forth in the Company's preliminary and definitive proxy statements relating to the transaction that will be filed with the SEC.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing under Item 1 of Part I of this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" discussed in our Annual Report on Form 10-K for the year ended June 30, 2022 and subsequent Quarterly Reports on Form 10-Q, including in Item 1A of Part II of this Quarterly Report on Form 10-Q, for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

**OVERVIEW**

We are a medical technology company leading the way in the effort to successfully treat patients suffering from peripheral and coronary artery diseases, including those with arterial calcium, the most difficult form of arterial disease to treat. We are committed to clinical rigor, constant innovation and a defining drive to set the industry standard to deliver safe and effective medical devices that improve the lives of patients facing these difficult disease states. We have developed patented orbital atherectomy systems ("OAS") for both peripheral and coronary clinical applications. The primary base of our business is catheter-based platforms capable of treating a broad range of vessel sizes and plaque types, including calcified plaque, which address many of the limitations associated with other treatment alternatives.

We have observed some degree of seasonality in our business, as there tends to be a lower number of procedures that use our products during the three months ending September 30. Interventional procedure volume usually grows throughout the course of the fiscal year, with the three months ending June 30 usually representing the highest volume of cases and, therefore, the highest amount of revenue generated by us during the course of the fiscal year.

*Peripheral*

Our peripheral artery disease ("PAD") products are catheter-based platforms capable of treating a broad range of plaque types in leg arteries both above and below the knee, including calcified plaque, and address many of the limitations associated with other existing surgical, catheter and pharmacological treatment alternatives. The micro-invasive devices use small access sheaths that can provide procedural benefits, allow physicians to treat PAD patients in even the small and tortuous vessels located below the knee, and facilitate access through alternative sites in the ankle, foot and wrist, as well as in the groin.

The United States Food and Drug Administration ("FDA") has granted us 510(k) clearances for our Peripheral OAS as a therapy in patients with PAD, as discussed in Item 1 of Part I of our Annual Report on Form 10-K for the year ended June 30, 2022. We refer to these products in this Quarterly Report on Form 10-Q as the "Peripheral OAS." In addition to our Peripheral OAS, we also offer support products within the peripheral space. Peripheral sales in the United States during the six months ended December 31, 2022 represented approximately 63% of revenue.

*Coronary*

Our coronary artery disease ("CAD") product, the Diamondback 360 Coronary OAS ("Coronary OAS"), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions. The Coronary OAS design is similar to technology used in our Peripheral OAS, customized specifically for the coronary application. In addition to the Coronary OAS, we also offer support products within the coronary space as we expand treatment to a broader patient population with complex coronary artery disease.

We have received premarket approval ("PMA") from the FDA to market the Coronary OAS as a treatment for severely calcified coronary arteries. Coronary sales in the United States during the six months ended December 31, 2022 represented approximately 29% of revenue.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

*International*

We serve a growing patient population globally through an expanding distribution and sales network. Sales of our approved products in Japan have been made through our exclusive Japan distributor, Medikit Co., Ltd. ("Medikit"). On December 13, 2022, we entered into a distribution agreement with Otsuka Medical Devices Co., Ltd. Effective February 1, 2023, upon the expiration of our distribution agreement with Medikit, Otsuka became our exclusive Japan distributor. Sales of our products in the rest of the world, which primarily includes certain countries in Southeast Asia, Europe, Latin America, the Middle East and Canada, are made through a network of distributors and sales agents. International sales during the six months ended December 31, 2022 represented approximately 8% of revenue.

*Impact of COVID-19*

The COVID-19 pandemic in the United States and internationally has caused us to experience ongoing disruptions in the procedures using our products. Procedures have been postponed, and may continue to be postponed, as a result of reduced availability of physicians or lab space to treat patients, the lack of personal protective equipment and active virus test kits, different treatment prioritizations, increased cost pressures and burdens on the overall healthcare infrastructure that result in reallocation of resources, customer staffing shortages, and governmental guidelines and restrictions. In addition, patients have elected to defer or avoid treatment for procedures that use our products due to anxiety about the potential spread of COVID-19 in facilities. Finally, our personnel and the personnel of our distribution partners and sales agents experienced restrictions on their ability to access many customers, hospitals, labs and other medical facilities for sales activities, training and case support as they may have been deemed to be "non-essential" personnel by those facilities, and there has been a reduction in procedure activity in these accounts.

In addition to the impact on procedure volumes, we experienced other disruptions as a result of the COVID-19 pandemic in fiscal 2022, such as the reallocation of company resources from our strategic priorities; supply chain disruptions that limited, delayed or prevented us from acquiring the components used to develop and manufacture our products or ship those products once manufactured; and decreased employee productivity. Some of these disruptions continued into the first and second quarters of fiscal 2023, although to a lesser extent than we experienced in the first and second quarters of fiscal 2022.

Throughout the pandemic, we have operated our manufacturing facilities and continued to ship product. Most of our office-based employees have telecommuted, and our field employees have continued to support cases in clinical settings where they are able to have access. We took and continue to take several actions intended to protect the health and well-being of our workforce and our customers. We will continue to monitor developments at the local, state and national levels in order to ensure that we and our employees have current information for purposes of making decisions in the dynamic and unpredictable environment and that we comply with applicable requirements.

Throughout the COVID-19 pandemic, we have observed the impact from the spread of some variants, and the fluctuations in hospitalizations resulting from these variants. For example, there were significant disruptions in procedures that occurred in the first quarter of fiscal 2022 due to the Delta variant outbreak and in the second and third quarters of fiscal 2022 due to the Omicron variant outbreak. Many factors may increase or decrease procedure volumes, which would have an impact on our revenue and financial results, including vaccination levels and mandates, the spread of new, more viral or deadly variants of the SARS-CoV-2 virus, easing of social restrictions and government restrictions on elective and semi-elective cases, level of patient anxiety, medical facility and workforce capacity, and sales representative access to facilities to support cases. We continue to monitor the spread of variants and track hospitalizations resulting from variants of the SARS-CoV-2 virus.

**The Abbott Transaction**

On February 8, 2023, we entered into an Agreement and Plan of Merger (the "Abbott Merger Agreement") with Abbott Laboratories, an Illinois corporation ("Abbott"), and Cobra Acquisition Co., a Delaware corporation and a direct, wholly-owned subsidiary of Abbott ("Merger Sub"). The Abbott Merger Agreement provides that, upon the terms and subject to the conditions set forth in such agreement, Merger Sub will merge with and into us, and we will continue as the surviving corporation and as a wholly-owned subsidiary of Abbott (the "Abbott Transaction"). At the effective time of the Abbott Transaction, each share of our common stock issued and outstanding immediately prior to the effective time, subject to certain exceptions set forth in the Abbott Merger Agreement, will automatically convert into and be exchangeable for the right to receive $20.00 per share in cash, without interest.

The boards of directors of both the Company and Abbott have unanimously approved the Abbott Merger Agreement and the Abbott Transaction. Our board of directors unanimously recommended that our stockholders vote to adopt the Abbott Merger Agreement and approve the transactions contemplated thereby, including the Abbott Transaction, and directed that the adoption of the Abbott Merger Agreement be submitted to a vote of our stockholders.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

The closing of the Abbott Transaction is subject to the affirmative vote of the holders of a majority of our outstanding shares of common stock to adopt the Abbott Merger Agreement, the expiration or termination of any waiting period (and extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and various other closing conditions.

The Abbott Merger Agreement includes certain termination provisions for both us and Abbott and provides that (i) in connection with the termination of the Abbott Merger Agreement under certain specified circumstances related to a change in the recommendation of the Company, the entry into an agreement for a superior proposal or the breach of certain of our covenants under the Abbott Merger Agreement, we may be required to pay Abbott a termination fee of $26,500,000, and (ii) in connection with the termination of the Abbott Merger Agreement after November 8, 2023 (or as such date might be extended under the Abbott Merger Agreement) under certain specified circumstances related to antitrust laws or due to the consummation of the Abbott Transaction being permanently enjoined under antitrust laws, Abbott may be required to pay us a termination fee of $26,500,000.

Additional information about the Abbott Merger Agreement and the Abbott Transaction will be set forth in the Company's preliminary and definitive proxy statements relating to the transaction that will be filed with the SEC.

**CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES**

Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect amounts reported in those statements. Our estimates, assumptions and judgments, including those related to revenue recognition, deferred revenue and stock-based compensation, are updated as appropriate at least quarterly. We use authoritative pronouncements, our technical accounting knowledge, cumulative business experience, judgment and other factors in the selection and application of our accounting policies. While we believe that the estimates, assumptions and judgments that we use in preparing our consolidated financial statements are appropriate, these estimates, assumptions and judgments are subject to factors and uncertainties regarding their outcome. Therefore, actual results may materially differ from these estimates.

Some of our significant accounting policies require us to make subjective or complex judgments or estimates. An accounting estimate is considered to be critical if it meets both of the following criteria: (1) the estimate requires assumptions about matters that are highly uncertain at the time the accounting estimate is made, and (2) different estimates that reasonably could have been used, or changes in the estimate that are reasonably likely to occur from period to period, would have a material impact on the presentation of our financial condition, results of operations, or cash flows.

Our critical accounting policies are identified in Item 7 of Part II of our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 under the heading "Critical Accounting Policies and Significant Judgments and Estimates."

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**RESULTS OF OPERATIONS**

The following table sets forth our results of operations expressed as dollar amounts (in thousands) and the changes between the specified periods expressed as percent increases or decreases:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** | **Six Months Ended December 31,** |
| | **2022** | **2021** | **Percent<br>Change** | **2022** | **2021** | **Percent<br>Change** |
| Net revenues | $61453 | $59135 | 3.9% | $121126 | $117505 | 3.1% |
| Cost of goods sold | 18461 | 18073 | 2.1 | 35159 | 32381 | 8.6 |
| &nbsp;&nbsp;&nbsp;Gross profit | 42992 | 41062 | 4.7 | 85967 | 85124 | 1.0 |
| Expenses: |  |  |  |  |  |  |
| Selling, general and administrative | 41642 | 40402 | 3.1 | 86117 | 82253 | 4.7 |
| Research and development | 9533 | 8873 | 7.4 | 18589 | 18895 | (1.6) |
| Amortization of intangible assets | 345 | 346 | (0.3) | 691 | 650 | 6.3 |
| &nbsp;&nbsp;&nbsp;Total expenses | 51520 | 49621 | 3.8 | 105397 | 101798 | 3.5 |
| &nbsp;&nbsp;&nbsp;Loss from operations | (8528) | (8559) | (0.4) | (19430) | (16674) | (16.5) |
| Other (income) expense, net | (689) | 345 | (299.7) | (941) | 712 | (232.2) |
| &nbsp;&nbsp;&nbsp;Loss before income taxes | (7839) | (8904) | (12.0) | (18489) | (17386) | (6.3) |
| Provision for income taxes | 49 | 63 | (22.2) | 30 | 199 | (84.9) |
| &nbsp;&nbsp;&nbsp;Net loss | $(7888) | $(8967) | (12.0) | $(18519) | $(17585) | (5.3) |

---

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

***Comparison of Three Months Ended December 31, 2022 with Three Months Ended December 31, 2021***

*Net revenues.* Net revenues increased by $2.3 million, or 3.9%, from $59.1 million for the three months ended December 31, 2021 to $61.5 million for the three months ended December 31, 2022. U.S. peripheral revenues decreased $0.6 million, or 1.6%, while U.S. coronary revenues increased $1.5 million, or 8.8%. Both therapies continue to be adversely affected by labor shortages and turnover in the health care workforce. We have also been adversely affected by an increasingly competitive environment and reimbursement pressures in the office-based lab setting. Increased revenue from increased customer adoption of interventional support products offset the revenue declines from decreased case volumes, competitive pressures, and reimbursement pressures in the peripheral and coronary franchises. International revenue was $5.1 million for the three months ended December 31, 2022, compared with international revenue of $3.7 million for the three months ended December 31, 2021. Increases in international sales were driven by increased adoption in Europe and Canada, and the commencement of sales into other territories, as well as an increase in deferred revenue recognized. In the third quarter of fiscal 2023, we expect to continue growing revenue, driven by increasing the number of physicians using the devices we sell; increasing the usage per physician; the use of new and improved products, such as the Scoreflex NC scoring balloon, JADE balloons, ViperCross Microcatheters, and the 2.00 Max Crown for Peripheral OAS; and continuing expansion into new geographies, partially offset by potential decreases in average selling prices and foreign currency exchange impacts. However, ongoing factors such as staffing and supply shortages and competitive and reimbursement pressures may continue to have an adverse impact.

*Cost of Goods Sold.* Cost of goods sold was $18.5 million for the three months ended December 31, 2022, an increase of 2.1% from $18.1 million for the three months ended December 31, 2021. These amounts represent the cost of materials, labor and overhead for single-use catheters, guide wires, pumps, and other ancillary products. Gross margin increased to 70.0% for the three months ended December 31, 2022 from 69.4% for the three months ended December 31, 2021. The increase in gross margin was primarily due to a $2.8 million reserve in the three months ended December 31, 2021 related to the voluntary recall of the WIRION device. Excluding this item, gross margin decreased primarily due to increased sales of lower margin products, as well as increased inflationary costs and freight costs. We expect that gross margin in the third quarter of fiscal 2023 will be similar to the three months ended December 31, 2022 due to an expected increase in device sales offset by the continued shift of sales mix into interventional support products and international markets in addition to declining average selling prices, which will also impact gross margins. Quarterly margin fluctuations could also occur based on production volumes, timing of new product introductions, sales mix, pricing changes, the impact of inflation or other unanticipated circumstances.

*Selling, General and Administrative Expenses.* Our selling, general and administrative expenses were $41.6 million for the three months ended December 31, 2022, an increase of 3.1% from $40.4 million for the three months ended December 31, 2021. Selling, general and administrative expense increases were led by costs associated with incentive compensation expense, travel-related expenditures and legal expenditures. Selling, general and administrative expenses for the three months ended December 31, 2022 and 2021 include $3.0 million and $3.6 million, respectively, for stock-based compensation. We expect our selling, general and administrative expenses for the third quarter of fiscal 2023 to be higher than amounts incurred for the three months ended December 31, 2022. Quarterly fluctuations could occur based on the level of net revenue, which could be materially impacted by the factors noted above, as well as inflation.

*Research and Development Expenses.* Research and development expenses increased by 7.4%, from $8.9 million for the three months ended December 31, 2021 to $9.5 million for the three months ended December 31, 2022. Research and development expenses relate to specific projects to develop new products or expand into new markets, such as the development of new versions of the Peripheral and Coronary OAS, shaft designs and crown designs, and expanded product offerings, including our percutaneous ventricular assist device, and to clinical trials. The increase was primarily due to increased costs on the ECLIPSE clinical trial, initiation of the Japan Kaizen clinical study and timing of costs associated with the development activities of our percutaneous ventricular assist device. We expect an increase in research and development expense in the third quarter of fiscal 2023 from what we incurred during the three months ended December 31, 2022. Quarterly fluctuations could occur based on the number of projects and studies, the progress of such projects and studies, the rate of study enrollment, the impact of inflation, acquisitions of in process research and development and possible charges in connection with those acquisitions, and the timing of expenditures.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

***Comparison of Six Months Ended December 31, 2022 with Six Months Ended December 31, 2021***

*Net revenues.* Net revenues increased by $3.6 million, or 3.1%, from $117.5 million for the six months ended December 31, 2021 to $121.1 million for the six months ended December 31, 2022. U.S. peripheral revenues decreased $0.8 million, or 1.1% and U.S. coronary revenues increased $1.7 million, or 5.1%. Both therapies continue to be adversely affected by labor shortages and turnover in the health care workforce. We have also been adversely affected by an increasingly competitive environment and reimbursement pressures in the office-based lab setting. Increased revenue from increased customer adoption of interventional support products offset the revenue declines from decreased case volumes, competitive pressures, and reimbursement pressures in the peripheral and coronary franchises. International revenue was $9.8 million for the six months ended December 31, 2022, compared with international revenue of $7.0 million for the six months ended December 31, 2021. Increases in international sales were driven by increased adoption in Europe and Canada, and the commencement of sales into other territories, as well as an increase in deferred revenue recognized.

*Cost of Goods Sold.* Cost of goods sold was $35.2 million for the six months ended December 31, 2022, an increase of 8.6% from $32.4 million for the six months ended December 31, 2021. These amounts represent the cost of materials, labor and overhead for single-use catheters, guide wires, pumps, and other ancillary products. Gross margin decreased to 71.0% for the six months ended December 31, 2022 from 72.4% for the six months ended December 31, 2021. Excluding the $2.8 million reserve in the six months ended December 31, 2021 related to the voluntary recall of the WIRION device, the increase in cost of goods sold and decrease in gross margin were primarily due to increased sales of lower margin products, as well as increased inflationary costs and freight costs.

*Selling, General and Administrative Expenses.* Our selling, general and administrative expenses were $86.1 million for the six months ended December 31, 2022, an increase of 4.7% from $82.3 million for the six months ended December 31, 2021. Selling, general and administrative expense increases were led by costs associated with incentive compensation expense and travel-related expenditures. These increases were partially offset by lower stock compensation. Selling, general and administrative expenses for the six months ended December 31, 2022 and 2021 include $6.8 million and $8.1 million, respectively, for stock-based compensation.

*Research and Development Expenses.* Research and development expenses decreased by 1.6%, from $18.9 million for the six months ended December 31, 2021 to $18.6 million for the six months ended December 31, 2022. Research and development expenses relate to specific projects to develop new products or expand into new markets, such as the development of new versions of the Peripheral and Coronary OAS, shaft designs and crown designs, and expanded product offerings, including our percutaneous ventricular assist device, and to clinical trials. The decrease was primarily due to timing of international commercialization expenses and project spend.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**LIQUIDITY AND CAPITAL RESOURCES**

We had cash, cash equivalents and highly liquid marketable securities of $132.0 million and $159.8 million at December 31, 2022 and June 30, 2022, respectively. As of December 31, 2022, we had an accumulated deficit of $443.4 million. We have historically funded our operating losses primarily from the issuance of common and preferred stock, convertible promissory notes, and debt.

A summary of our cash flow activities (in thousands) is as follows:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **December 31,** | **December 31,** |
| | **2022** | **2021** |
| Net cash used in operating activities | $(17200) | $(12315) |
| Net cash provided by investing activities | 10474 | 11109 |
| Net cash provided by (used in) financing activities | 145 | (3999) |
| Net change in cash and cash equivalents | $(6581) | $(5205) |

---

***Changes in Liquidity***

*Operating Activities* 

Net cash used in operating activities was $17.2 million for the six months ended December 31, 2022, primarily due to the net loss of $18.5 million, and $8.5 million relating to changes in working capital as a result of the payout of annual bonuses and commissions, increased uses of cash to build inventory as we diversify our product offerings, partially offset by non-cash expenditures for the six months ended December 31, 2022.

Net cash used in operating activities was $12.3 million for the six months ended December 31, 2021, primarily due to the net loss of $17.6 million, and $8.0 million relating to changes in working capital as a result of the payout of annual bonuses and commissions, partially offset by non-cash expenditures for the six months ended December 31, 2021.

*Investing Activities*

Net cash provided by investing activities was $10.5 million for the six months ended December 31, 2022, as maturities and sales of marketable securities exceeded marketable security purchases. These amounts were partially offset by additional payments relating to strategic investments and capital expenditures as we continue to grow our business.

Net cash provided by investing activities was $11.1 million for the six months ended December 31, 2021, as maturities and sales of marketable securities exceeded marketable security purchases during this period. These amounts were partially offset by a product acquisition of peripheral microcatheters, additional payments relating to strategic investments and capital expenditures as we continue to grow our business.

*Financing Activities* 

Net cash provided by financing activities was $0.1 million for the six months ended December 31, 2022, primarily due to proceeds from employee stock purchases, partially offset by payment of payroll taxes on the employee vesting of stock awards.

Net cash used in financing activities was $4.0 million for the six months ended December 31, 2021, primarily due to the payment of payroll taxes on the employee vesting of stock awards, partially offset by proceeds from employee stock purchases.

Our future liquidity and capital requirements will be influenced by numerous factors, including whether we timely consummate the Abbott Transaction, the extent and duration of future operating losses, the level and timing of future sales and expenditures, the results and scope of ongoing research and product development programs, working capital required to support our business operations, the receipt of and time required to obtain regulatory clearances and approvals, our sales and marketing programs, the continuing acceptance of our products in the marketplace, competing technologies, market and regulatory developments, ongoing facility requirements, potential strategic transactions (including the potential acquisition of, or investments in, businesses, technologies and products), international expansion, the existence, defense and resolution of legal proceedings, and

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

the severity and duration of the COVID-19 pandemic. As discussed in the "Overview" above, the total impact of disruptions from COVID-19 has had a material impact on our financial condition and results of operations, but as the pandemic subsides, we expect our U.S. business to improve. We will continue to closely monitor our liquidity and capital resources through the disruption caused by COVID-19 and will continue to evaluate our financial position to assess additional spending reductions and our liquidity needs. As of December 31, 2022, we believe our current cash, cash equivalents and marketable securities will be sufficient to fund working capital requirements, including open purchase commitments, capital expenditures and operations for the foreseeable future, including at least the next twelve months, as well as to fund payments under our lease agreements, payments under development agreements, and funding commitments under loan agreements. If needed, we have the ability to borrow under our senior, secured revolving credit facility, which we intend to extend. We will also consider other options for potential future financings to fund our longer-term objectives. We intend to retain any future earnings to support operations and to finance the growth and development of our business. We do not anticipate paying any dividends in the foreseeable future.

***Facility Sale and Lease***

On December 29, 2016, we entered into a Purchase and Sale Agreement, as subsequently amended (collectively, the "Sale Agreement"), with Krishna Holdings, LLC ("Krishna"), providing for the sale to Krishna of our headquarters facility in St. Paul, Minnesota (the "Facility") for a cash purchase price of $21.5 million. On March 30, 2017, the sale of the Facility under the Sale Agreement closed. We received proceeds of approximately $20.9 million ($21.5 million less $556,000 of transaction expenses). In connection with the closing of the facility sale, we entered into a Lease Agreement (the "Lease Agreement") with Krishna Holdings, LLC, Apex Holdings, LLC, Kashi Associates, LLC, Keva Holdings, LLC, S&V Ventures, LLC, Polo Group LLC, SPAV Holdings LLC, Star Associates LLC, and The Global Villa, LLC. The Lease Agreement has an initial term of fifteen years, with four consecutive renewal options of five years each, with a base annual rent in the first year of $1.6 million and annual escalations of 3%. See Note 5 to our Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q for additional discussion.

***Revolving Credit Facility***

In March 2017, we entered into a Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank ("SVB"). In March 2020, we entered into the First Amendment to the Loan Agreement (the "Amendment"). The Amendment extended the maturity date of the Loan Agreement by two years, to March 31, 2022, and increased the maximum amount available under the senior, secured revolving credit facility (the "Revolver") to $50.0 million (the "Maximum Dollar Amount"). In March 2022, the Company entered into the Second Amendment to the Loan Agreement (the "Second Amendment"). The Second Amendment extended the maturity date of the Loan Agreement by one year, to March 31, 2023. We intend to seek an additional extension of the Loan Agreement.

Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.75%. Interest on borrowings is due monthly and the principal balance is due at maturity. Upon the Revolver's maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. We will incur a fee equal to 1.5% of the Maximum Dollar Amount upon termination of the Loan Agreement, as amended by the Second Amendment (the "Amended Loan Agreement"), or the Revolver for any reason prior to the date that is fifteen days prior to the maturity date, unless refinanced with SVB.

Our obligations under the Amended Loan Agreement are secured by certain of our assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include our intellectual property, but we agreed not to encumber our intellectual property without the consent of SVB. The Amended Loan Agreement contains customary covenants limiting our ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of our business. In addition, the Amended Loan Agreement contains financial covenants requiring us to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10.0 million or (ii) minimum trailing three-month Adjusted EBITDA (as defined in the Amended Loan Agreement) of $1.0 million. If we do not comply with the various covenants under the Amended Loan Agreement or an event of default under the Amended Loan Agreement occurs, such as a material adverse change, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights and the other terms and conditions of the Amended Loan Agreement, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

We are required to pay a fee equal to 0.15% per annum on the unused portion of the Revolver, payable quarterly in arrears. We are not obligated to draw any funds under the Revolver and have not done so under the Revolver since entering into the Loan Agreement. No amounts were outstanding as of December 31, 2022.

**NON-GAAP FINANCIAL INFORMATION**

To supplement our condensed consolidated financial statements prepared in accordance with GAAP, our management uses a non-GAAP financial measure referred to as "Adjusted EBITDA." Reconciliations of this non-GAAP measure to the most comparable U.S. GAAP measure for the respective periods can be found in the following table. In addition, an explanation of the manner in which our management uses this measure to conduct and evaluate our business, the economic substance behind our management's decision to use this measure, the substantive reasons why our management believes that this measure provides useful information to investors, the material limitations associated with the use of this measure and the manner in which our management compensates for those limitations is included following the reconciliation table.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net loss | $(7888) | $(8967) | $(18519) | $(17585) |
| Less: Other (income) expense, net | (689) | 345 | (941) | 712 |
| Less: Provision for income taxes | 49 | 63 | 30 | 199 |
| &nbsp;&nbsp;&nbsp;Loss from operations | (8528) | (8559) | (19430) | (16674) |
| Add: Stock-based compensation | 3547 | 4240 | 7985 | 9912 |
| Add: Depreciation and amortization | 1268 | 1287 | 2488 | 2545 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA | $(3713) | $(3032) | $(8957) | $(4217) |

---

Adjusted EBITDA decreased for the three and six months ended December 31, 2022 as compared to the three and six months ended December 31, 2021 primarily due to a greater loss from operations and lower stock compensation expense in the current year.

***Use and Economic Substance of Non-GAAP Financial Measures Used and Usefulness of Such Non-GAAP Financial Measures to Investors***

We use Adjusted EBITDA as a supplemental measure of performance and believe this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense, and stock-based compensation. Our management uses Adjusted EBITDA to analyze the underlying trends in our business, assess the performance of our core operations, establish operational goals and forecasts that are used to allocate resources and evaluate our performance period over period and in relation to our competitors' operating results. Additionally, our management is partially evaluated on the basis of Adjusted EBITDA when determining achievement of their incentive compensation performance targets. Management does not use this Adjusted EBITDA measure as a liquidity measure or in the calculation of our financial covenants under the revolving credit facility with Silicon Valley Bank.

We believe that presenting Adjusted EBITDA provides investors greater transparency to the information used by our management for its financial and operational decision-making and allows investors to see our results "through the eyes" of management. We also believe that providing this information better enables our investors to understand our operating performance and evaluate the methodology used by our management to evaluate and measure such performance.

The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Stock-based compensation. We exclude stock-based compensation expense from our non-GAAP financial measures primarily because such expense, while constituting an ongoing and recurring expense, is not an expense that requires cash settlement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Depreciation and amortization expense. We exclude depreciation and amortization expense from our non-GAAP financial measures primarily because such expenses, while constituting ongoing and recurring expenses, are not

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

expenses that require cash settlement and are not used by our management to assess the core profitability of our business operations.

Our management also believes that excluding these above items from our non-GAAP results is useful to investors to understand our operational performance, liquidity and ability to make additional investments in our company.

***Material Limitations Associated with the Use of Non-GAAP Financial Measures and Manner in which We Compensate for these Limitations***

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Some of the limitations associated with our use of these non-GAAP financial measures are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Items such as stock-based compensation do not directly affect our cash flow position; however, such items reflect economic costs to us and are not reflected in our Adjusted EBITDA, and therefore these non-GAAP measures do not reflect the full economic effect of these items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures we use. We compensate for these limitations by relying primarily upon our GAAP results and using non-GAAP financial measures only supplementally.

We provide detailed reconciliations of each non-GAAP measure to its most directly comparable GAAP measure. We encourage investors to review these reconciliations. We qualify our use of non-GAAP financial measures with cautionary statements as set forth above.

**INFLATION**

We do not believe that inflation had a material impact on our business and operating results during the periods presented.

**RECENT ACCOUNTING PRONOUNCEMENTS**

For a description of recent accounting pronouncements, see Note 1 to the Consolidated Financial Statements included in Item 8 of Part II of our Annual Report on Form 10-K for the year ended June 30, 2022.

**PRIVATE SECURITIES LITIGATION REFORM ACT**

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Such "forward-looking" information is included in this Quarterly Report on Form 10-Q and in other materials filed or to be filed by us with the SEC (as well as information included in oral statements or other written statements made or to be made by us). Forward-looking statements include all statements based on future expectations. This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, including, but not limited to, (i) our expectations regarding the impact of the COVID-19 pandemic on our operations; (ii) our expectation of continued sales of our products internationally, including the specific products to be sold, the territories in which such products will be sold, the timing of such sales, and whether such sales will be through distributors or directly by us; (iii) seasonality in our business; (iv) our expectation that we will grow revenue in the third quarter of fiscal 2023; (v) our expectation that we will incur selling, general and administrative expenses in the third quarter of fiscal 2023 that are higher than the amounts incurred in the three months ended December 31, 2022; (vi) our expectation that gross margin in the third quarter of fiscal 2023 will be similar to the gross margin in the three months ended December 31, 2022; (vii) our expectation that we will incur research and development expenses in the third quarter of fiscal 2023 that are higher than the amounts incurred in the three months ended December 31, 2022; (viii) our belief that our current cash and cash equivalents will be sufficient to fund working capital requirements, capital expenditures and operations for the foreseeable future, as well as to fund certain other anticipated expenses, and our consideration of future financing options; (ix) our intention to retain any future earnings to support operations and to finance the growth and development of our business; (x) our dividend expectations; (xi) our intention to extend our loan and security agreement; (xii) the anticipated impact of adoption of recent accounting pronouncements on our financial statements; and (xiii) the proposed transaction with Abbott.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management's beliefs and assumptions, which in turn are based on their interpretation of currently available information.

These statements involve known and unknown risks, uncertainties and other factors that may cause our results or our industry's actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These factors include the ongoing COVID-19 pandemic and the impact and scope thereof on us, our distribution partners, the supply chain and physicians and facilities, including government actions related to the COVID-19 outbreak, material delays and cancellations of procedures, delayed spending by healthcare providers, and distributor and supply chain disruptions; regulatory developments, clearances and approvals; approval of our products for distribution outside of the United States; approval of products for reimbursement and the level of reimbursement in the U.S. and foreign countries; dependence on market growth; agreements with third parties to sell their products; the ability of us and our distribution partners to successfully launch our products outside of the United States; our ability to maintain third-party supplier relationships and renew existing purchase agreements; our ability to maintain our relationships and agreements with distribution partners; the experience of physicians regarding the effectiveness and reliability of the products we sell; the reluctance of physicians, hospitals and other organizations to accept new products; the potential for unanticipated delays in enrolling medical centers and patients for clinical trials; actual clinical trial and study results; the impact of competitive products and pricing; our ability to comply with the financial covenants in our loan and security agreement and to make payments under and comply with the lease agreement for our corporate headquarters; unanticipated developments affecting our estimates regarding expenses, future revenues and capital requirements; the difficulty of successfully managing operating costs; our ability to manage our sales force strategy; actual research and development efforts and needs, including the timing of product development programs; successful collaboration on the development of new products; agreements with development partners, advisors and other third parties; the ability of us and these third parties to meet developmental, contractual and other milestones; contractual rights and obligations; technical challenges; our ability to obtain and maintain intellectual property protection for product candidates; fluctuations in results and expenses based on new product introductions, sales mix, unanticipated warranty claims, and the timing of project expenditures; our ability to manage costs; our actual financial resources and our ability to obtain additional financing; investigations or litigation threatened or initiated against us; court rulings and future actions by the FDA and other regulatory bodies; international trade developments; the effects of hurricanes, flooding, and other natural disasters on our business; the impact of federal corporate tax reform on our business, operations and financial statements; shutdowns of the U.S. federal government; the potential impact of any future strategic transactions; our and Abbott's ability to consummate the proposed transaction on a timely basis or at all; our and Abbott's ability to satisfy the conditions precedent to consummation of the proposed transaction, including the ability to secure the applicable regulatory approvals on the terms expected, at all or in a timely manner; the effect of the announcement of the proposed transaction on our ability to retain and hire key personnel and maintain relationships with our key business partners and customers, and others with whom we do business, or on our operating results and businesses generally; the response of competitors to the proposed Abbott transaction; risks associated with the disruption of our management's attention from ongoing business operations due to the proposed Abbott transaction; significant costs associated with the proposed transaction; potential litigation relating to the proposed Abbott transaction; restrictions during the pendency of the proposed Abbott transaction that may impact our ability to conduct our business; and general economic conditions. These and additional risks and uncertainties are described more fully in our Annual Report on Form 10-K for the year ended June 30, 2022 and subsequent Quarterly Reports on Form 10-Q, including in Item 1A of Part II of this Quarterly Report on Form 10-Q. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis and retrieval system (EDGAR) at www.sec.gov.

You should read these risk factors and the other cautionary statements made in this Quarterly Report on Form 10-Q as being applicable to all related forward-looking statements wherever they appear in this Quarterly Report on Form 10-Q. We cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should read this Quarterly Report on Form 10-Q completely. Other than as required by law, we undertake no obligation to update these forward-looking statements, even though our situation may change in the future.

**ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Other than the negative impact the COVID-19 pandemic has had and will continue to have on our business and results of operations as discussed elsewhere in this Quarterly Report on Form 10-Q, there have been no material changes in our primary risk exposures or management of market risks from those disclosed in our Annual Report on Form 10-K for the year ended June 30, 2022.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

Our Chief Executive Officer and Chief Financial Officer, referred to collectively herein as the Certifying Officers, are responsible for establishing and maintaining our disclosure controls and procedures. The Certifying Officers have reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of December 31, 2022. Based on that review and evaluation, which included inquiries made to certain other of our employees, the Certifying Officers have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures, as designed and implemented, are effective.

**Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II. — OTHER INFORMATION**

**ITEM 1.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS**

None.

**ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS**

In addition to the other information set forth in this Quarterly Report on Form 10-Q, including the important information in the section entitled "Private Securities Litigation Reform Act," you should carefully consider the "Risk Factors" in our Annual Report on Form 10-K for the year ended June 30, 2022 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in this Quarterly Report on Form 10-Q and materially adversely affect our business, financial condition and/or future operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also might materially adversely affect our business, financial condition and/or operating results. In addition, you should consider the following risk factors:

***The completion of the Abbott Transaction is subject to a number of conditions, many of which are largely outside of the parties' control, and, if these conditions are not satisfied or waived on a timely basis, the Abbott Merger Agreement may be terminated and the Abbott Transaction may not be completed.***

The Abbott Transaction is subject to various closing conditions, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the affirmative vote of the holders of a majority of the outstanding shares of Common Stock to adopt the Abbott Merger Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the absence of any law or order restraining or otherwise prohibiting the Abbott Transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 must have expired or been terminated and all consents, approvals, authorizations or filings with any governmental authority pursuant to any other applicable competition law or foreign investment law in connection with the Abbott Transaction and the transactions contemplated by the Abbott Merger Agreement, or that are reasonably determined by Abbott to be applicable, must have been obtained, in each case, without the imposition of any Burdensome Condition (as defined in the Merger Agreement), except, in each case, as may be consented to by Abbott in its sole and absolute discretion;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• subject to specific standards, the accuracy of the representations and warranties of the other party or parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the performance or compliance in all material respects by the other party or parties of such party's or parties' covenants, obligations, and agreements under the Abbott Merger Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• with respect to Abbott's and Merger Sub's obligations to consummate the Abbott Transaction, (A) the absence of a Material Adverse Effect (as defined in the Abbott Merger Agreement) and the absence of any changes having occurred that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and (B) the absence of any pending or threatened proceeding from a governmental authority (1) seeking to restrain or prohibit the Abbott Transaction, (2) seeking from any party to the transaction damages that are material to us and our subsidiaries, taken as whole, (3) seeking to impose any Burdensome Condition (as defined in the Abbott Merger Agreement), or (4)

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

otherwise inquiring into the compliance of the Abbott Transaction with applicable competition laws or foreign investment laws.

The failure to satisfy all of the required conditions could delay the completion of the Abbott Transaction by a significant period of time or prevent it from closing. Any delay in completing the Abbott Transaction could cause the parties to not realize some or all of the benefits that are expected to be achieved if the Abbott Transaction is successfully completed within the expected timeframe. There can be no assurance that the conditions to closing of the Abbott Transaction will be satisfied or waived or that the Abbott Transaction will be completed within the expected timeframe, or at all.

***Failure to complete the Abbott Transaction could materially adversely affect the price of our common stock, as well as our future business and financial results.***

There can be no assurance that the conditions to the closing of the Abbott Transaction will be satisfied or waived or that the Abbott Transaction will be completed in timely manner, or at all. If the Abbott Transaction is not completed within the expected timeframe or at all, our ongoing business could be materially adversely affected and we will be subject to a variety of additional risks and possible consequences associated with the failure to complete the Abbott Transaction, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• upon termination of the Abbott Merger Agreement under specified circumstances, we may be required to pay Abbott a termination fee of $26,500,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• we have incurred and will continue to incur substantial transaction costs, including legal, accounting, financial advisor, filing, printing and mailing fees, regardless of whether the Abbott Transaction closes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• under the Abbott Merger Agreement, we are subject to restrictions on the conduct of our business prior to the closing of the Abbott Transaction, which may adversely affect our ability to execute our business strategies; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the proposed Abbott Transaction, whether or not it closes, will significantly divert the attention of certain of our management and other key employees from ongoing business activities, including the pursuit of other opportunities that could be beneficial to us as an independent company.

If the Abbott Transaction is not completed, these risks could materially affect our business and financial results and the trading price of our common stock, including to the extent that the market price of our common stock is positively affected by a market assumption that the Abbott Transaction will be completed.

***While the Abbott Transaction is pending, we will be subject to several business uncertainties and contractual restrictions that could adversely affect our business and operations.***

In connection with the pending Abbott Transaction, some customers, vendors, distributors or other third parties with which we have important business relationships may react unfavorably, including by delaying or deferring decisions concerning their business relationships or transactions with us, which could adversely affect our revenues, earnings, funds from operations, cash flows, expenses and prospects, regardless of whether the Abbott Transaction is completed. In addition, due to restrictions in the Abbott Merger Agreement on the conduct of our business prior to completing the Abbott Transaction, we are unable, without Abbott's prior written consent, during the pendency of the Abbott Transaction, to pursue strategic transactions, undertake significant capital projects, undertake certain significant financing transactions and otherwise pursue other actions, even if such actions would prove beneficial, and may cause us to forego certain opportunities we might otherwise wish to pursue. Abbott may withhold its consent of these items for any reason. In addition, the pendency of the Abbott Transaction may make it more difficult for us to effectively retain and incentivize key personnel and may cause distractions from our strategy and day-to-day operations for our current employees and management.

***We will incur substantial transaction fees and costs in connection with the Abbott Transaction that could adversely affect our business and operations if the Abbott Transaction is not completed.***

We have incurred and expects to incur significant non-recurring transaction fees, which include legal and advisory fees and substantial costs associated with completing the Abbott Transaction, and which could adversely affect our business operations and cash position if the Abbott Transaction is not completed.

***The termination fee and restrictions on solicitation contained in the Abbott Merger Agreement may discourage other companies from trying to acquire us while the Abbott Transaction is pending.***

The Abbott Merger Agreement prohibits us from soliciting, initiating, knowingly encouraging or knowingly facilitating any competing acquisition proposals, subject to certain limited exceptions. The Abbott Merger Agreement also contains certain

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

termination rights, including, but not limited to, our right to terminate the Abbott Merger Agreement to accept a Superior Proposal (as defined in the Abbott Merger Agreement), subject to and in accordance with the terms and conditions of the Abbott Merger Agreement. The Abbott Merger Agreement further provides that, upon our termination of the Abbott Merger Agreement to enter into an alternative acquisition agreement that is the subject of a Superior Proposal, we will be required to pay Abbott a termination fee of $26,500,000 in cash. The termination fees and restrictions in the Abbott Merger Agreement relating to acquisition proposals by third parties, including with respect to the process such third parties would need to follow, could discourage other companies from trying to acquire us, even though those other companies might be willing to offer greater value to our stockholders than they will receive in the Abbott Transaction.

***Litigation against us, Abbott, or the members of their respective boards could prevent or delay the completion of the Abbott Transaction or result in the payment of damages following completion of the Abbott Transaction.***

It is possible that lawsuits may be filed by certain of our stockholders challenging the Abbott Transaction. The outcome of such lawsuits cannot be assured, including the amount of costs associated with defending these claims or any other liabilities that may be incurred in connection with the litigation of these claims. If a plaintiff in any such lawsuits is successful in obtaining an injunction prohibiting the parties from completing the Abbott Transaction, such injunction may delay the consummation of the Abbott Transaction in the expected timeframe, or may prevent the Abbott Transaction from being consummated at all. Whether or not any such plaintiff's claim is successful, this type of litigation can result in significant costs and divert management's attention and resources from the closing of the Abbott Transaction and ongoing business activities, which could adversely affect our operations.

***Uncertainty about the Abbott Transaction may adversely affect the relationships between us and our customers, suppliers, distributors, business partners, vendors and employees, whether or not the Abbott Transaction is completed.***

In response to the announcement of the Abbott Transaction, existing or prospective customers, suppliers, distributors, business partners, vendors and other of our third party relationships may delay, defer or cease providing goods or services or continuing work on strategic programs, delay or defer other decisions concerning our business, refuse to extend credit to us or extend the terms of material contracts, or otherwise seek to change the terms on which they do business with us. Any such delays or changes to terms could materially adversely harm our business.

In addition, as a result of the Abbott Transaction, current and prospective employees could experience uncertainty about their future with us. These uncertainties may impair our ability to retain, recruit or motivate key management and technical, manufacturing, and other personnel.

If the Abbott Merger is not consummated by November 8, 2023 (with is subject to up to extensions of up to three successive 90-day periods by Abbott in certain circumstances), either we or Abbott may terminate the Abbott Merger Agreement, subject to certain exceptions. In the event the Abbott Merger Agreement is terminated by either party, we will have incurred significant costs and will have diverted significant management focus and resources from other strategic opportunities and ongoing business activities without realizing the anticipated benefits of the Abbott Transaction, which could be materially adverse to us.

**ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

*Company Repurchases of Equity Securities*

The following table presents information with respect to purchases made by us of our common stock during the second quarter of fiscal 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as part of Publicly Announced Plans or Programs** | **Approximate Dollar Value of Shares that May Yet Be Purchased under the Plan or Programs** |
| October 1 to October 31, 2022<sup>(1)</sup> |  | $— | N/A | N/A |
| November 1 to November 30, 2022<sup>(1)</sup> | 1569 | 14.67 | N/A | N/A |
| December 1 to December 31, 2022 |  |  | N/A | N/A |
|  | 1569 | $14.67 |  |  |

---

<sup>(1)</sup> Comprised of shares withheld pursuant to the terms of restricted stock awards under our stock-based compensation plans to offset tax withholding obligations that occur upon vesting and release of shares. The value of the shares withheld is the closing price of our common stock on the date the relevant transaction occurs.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp;MINE SAFETY DISCLOSURES**

None.

**ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION**

None.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 2.1 | <u>[Agreement and Plan of Merger, dated as of February 8, 2023, by and among the Company, Abbott Laboratories, and Cobra Acquisition Co. (previously filed with the SEC as an Exhibit to and incorporated herein by reference from the Company's Current Report on Form 8-K filed February 9, 2023).](https://www.sec.gov/Archives/edgar/data/1180145/000118014523000012/mergeragreement8-kexhibit.htm)</u> |
| 10.1\*† | <u>[Loan Agreement, dated as of December 30, 2022, by and between the Company and Chansu Vascular Technologies, LLC.](aex101csixcvtloanagreement.htm)</u> |
| 10.2\*† | <u>[First Amended and Restated Acquisition Option Agreement, dated as of December 30, 2022, by and among the Company, Chansu Vascular Technologies, LLC, and the members of Chansu Vascular Technologies, LLC.](aex102csivitessefirstamend.htm)</u> |
| 10.3\*† | <u>[Product Development Agreement, dated as of January 2](aex103csiprojectvitessedev.htm)[9](aex103csiprojectvitessedev.htm)[, 202](aex103csiprojectvitessedev.htm)[1](aex103csiprojectvitessedev.htm)[, by and between the Company and Chansu Vascular Technologies, LLC.](aex103csiprojectvitessedev.htm)</u> |
| 31.1\* | <u>[Certification of Chairman, President and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](a10-qex311q2fy23.htm)</u> |
| 31.2\* | <u>[Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](a10-qex312q2fy23.htm)</u> |
| 32.1\*\* | <u>[Certification of Chairman, President and Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](a10-qex321q2fy23.htm)</u> |
| 32.2\*\* | <u>[Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](a10-qex322q2fy23.htm)</u> |
| 101\* | Financial statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended December 31, 2022, formatted in Inline XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Changes in Stockholders' Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to Financial Statements. |
| 104\* | Cover page interactive data file (formatted in Inline XBRL and contained in Exhibit 101). |

---

_______________________

\*&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith.

\*\*&nbsp;&nbsp;&nbsp;&nbsp;Furnished herewith.

†&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted exhibit or schedule will be furnished supplementally to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any document so furnished.

------

**<u>[**Table of Contents**](#i55f58fa254f047908acf2fcb3687b73f_7)</u>**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: February 9, 2023 |  | CARDIOVASCULAR SYSTEMS, INC. |
|  | By | /s/ Scott R. Ward |
|  |  | Scott R. Ward |
|  |  | Chairman, President and Chief Executive Officer |
|  |  | (Principal Executive Officer) |
|  | By | /s/ Jeffrey S. Points |
|  |  | Jeffrey S. Points |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial and Accounting Officer) |

---

## Exhibit 10.1

**Exhibit 10.1**

**Execution Version**

**LOAN AGREEMENT**

This LOAN AGREEMENT (this "<u>Agreement</u>"), dated as of December 30, 2022 (the "<u>Closing Date</u>"), is between CHANSU VASCULAR TECHNOLOGIES, LLC, a Delaware limited liability company (the "<u>Borrower</u>") and CARDIOVASCULAR SYSTEMS, INC., a Delaware corporation (together with its successors and assigns, the "<u>Lender</u>"). The parties hereto agree as follows:

**ARTICLE I**

**<br><u>DEFINITIONS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. As used in this Agreement:

"<u>Affiliate</u>" of any Person means any other Person directly or indirectly controlling, controlled by or under common control with such Person, including, without limitation, such Person's Subsidiaries. A Person shall be deemed to control another Person if the controlling Person owns 50% or more of any class of Equity Interests of the controlled Person or possesses, directly or indirectly, the power to direct or cause the direction of the management or policies of the controlled Person, whether through ownership of Equity Interests, by contract or otherwise.

"<u>Anti-Corruption Laws</u>" means the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder, and any other anti-corruption law applicable to the Borrower and its Subsidiaries.

"<u>Authorized Officer</u>" means any of the Chief Executive Officer and the Chief Financial Officer of the Borrower, acting singly.

"<u>Borrowing Notice</u>" means irrevocable notice in the form of <u>Exhibit A</u>.

"<u>Business Day</u>" means a day other than a Saturday, Sunday, or other day on which commercial banks in Minneapolis, Minnesota are authorized or required by law to close.

"<u>Capital Expenditures</u>" means, without duplication, any expenditures for purchase or other acquisition of any Property that would be classified as a fixed or capital asset on a consolidated balance sheet of the Borrower and its Subsidiaries prepared in accordance with GAAP.

"<u>Change of Control</u>" means (a) Philippe Marco ceases to own, free and clear of all Liens or other encumbrances, at least 50% of the outstanding voting Equity Interests of the Borrower on a fully diluted basis; or (b) Philippe Marco ceases to be the Chief Executive Officer of the Borrower.

"<u>Code</u>" means the Internal Revenue Code of 1986.

"<u>Collateral</u>" means all Property now existing or hereafter acquired in which a Lien is, may be, or is required to be granted to secure the Obligations.

------

"<u>Collateral Documents</u>" means, collectively, the Security Agreement and all other agreements, instruments and documents now or hereafter executed that create, perfect or evidence Liens upon the Collateral as security for payment of the Obligations.

"<u>Commitment</u>" means the obligation, if any, of the Lender to make Term Loans to the Borrower in an aggregate principal amount outstanding at any time not to exceed the Commitment Amount upon the terms and subject to the conditions and limitations of this Agreement.

"<u>Commitment Amount</u>" an aggregate of $49,653,000.

"<u>Commitment Period</u>" means the period commencing on the Closing Date through and including the Commitment Termination Date.

"<u>Commitment Termination Date</u>" means the earliest to occur of (i) the date the Commitments are permanently reduced to zero pursuant to Section 2.4, (ii) the date of the termination of the Commitments pursuant to Section 6.2, and (iii) the Facility Termination Date.

"<u>Credit Extension</u>" means the making of a Term Loan.

"<u>CVT Product</u>" means either the PTA-DCB Product or the PTCA-DCB Product.

"<u>Default</u>" means any of the events specified in Article VI which constitute an Event of Default or which, upon the giving of notice, the lapse of time, or both, pursuant to Article VI, would, unless cured or waived, become an Event of Default.

**"**<u>Default Rate</u>**"** means any interest payable pursuant to Section 2.7.

"<u>Development Agreement</u>" means the Product Development Agreement dated January 29, 2021 between Borrower and Lender.

"<u>Dollar</u>" and "<u>$</u>" mean the lawful currency of the United States of America.

"<u>Equity Incentive Plan</u>" means the Chansu Vascular Technologies, LLC 2020 Equity Incentive Plan.

"<u>Equity Interests</u>" means all shares, interests or other equivalents, however designated, of or in a corporation, limited liability company, or partnership, whether or not voting, including but not limited to common stock, member interests, partnership interests, warrants, preferred stock, convertible debentures, and all agreements, instruments and documents convertible, in whole or in part, into any one or more of the foregoing.

"<u>ERISA</u>" means the Employee Retirement Income Security Act of 1974.

"<u>ERISA Affiliate</u>" means any trade or business (whether or not incorporated) that, together with the Borrower, is treated as a single employer under Section 414(b) or (c) of the Code or, solely for purposes of Section 302 of ERISA and Section 412 of the Code, is treated as a single employer under Section 414 of the Code.

------

"<u>ERISA Event</u>" means (a) any "reportable event," as defined in Section 4043 of ERISA or the regulations issued thereunder with respect to a Plan (other than an event for which the 30-day notice period is waived); (b) the failure with respect to any Plan to satisfy the "minimum funding standard" (as defined in Section 412 of the Code or Section 302 of ERISA), whether or not waived; (c) the filing pursuant to Section 412(c) of the Code or Section 303 of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan; (d) the incurrence by the Borrower or any of its ERISA Affiliates of any liability under Title IV of ERISA with respect to the termination of any Plan; (e) the receipt by the Borrower or any ERISA Affiliate from the PBGC or a plan administrator of any notice relating to an intention to terminate any Plan or to appoint a trustee to administer any Plan; (f) the incurrence by the Borrower or any of its ERISA Affiliates of any liability with respect to the withdrawal or partial withdrawal of the Borrower or any of its ERISA Affiliates from any Plan or Multiemployer Plan; or (g) the receipt by the Borrower or any ERISA Affiliate of any notice, or the receipt by any Multiemployer Plan from the Borrower or any ERISA Affiliate of any notice, concerning the imposition upon the Borrower or any of its ERISA Affiliates of withdrawal liability under Section 4201 of ERISA or a determination that a Multiemployer Plan is, or is expected to be, insolvent within the meaning of Title IV of ERISA.

"<u>Event of Default</u>" has the meaning set forth in Section 6.1(a).

"<u>Existing Loan Agreement</u>" means that certain Loan Agreement dated as of January 29, 2021, between the Borrower and the Lender, as amended by the First Amendment to Loan Agreement dated October 13, 2022.

"<u>Exposure</u>" means, at any time, the aggregate principal amount of the Term Loans outstanding.

"<u>Facility Termination Date</u>" means June 30, 2024, or any earlier date on which the Commitment Amount is reduced to zero or the Commitment is otherwise terminated pursuant to the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;"<u>GAAP</u>" means generally accepted accounting principles as in effect from time to time in the United States, applied in a manner consistent with that used in preparing the financial statements referred to in Section 4.4, subject to Section 1.2.

"<u>Governmental Authority</u>" means the government of the United States of America or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies).

"<u>Incentive Units</u>" has the meaning set forth in the Equity Incentive Plan.

"<u>Indebtedness</u>" of any Person means, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by or otherwise in respect of bonds, debentures, notes or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid, (d) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all obligations of such Person in respect of the deferred purchase price of property or services (excluding current

------

accounts payable incurred in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (g) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (h) all obligations, contingent or otherwise, of such Person in respect of bankers' acceptances, (i) all net payment obligations, contingent or otherwise, of such Person under swaps, and (j) all guarantees by such Person of any of the foregoing. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person's ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.

"<u>Indemnitee</u>" means the Lender, its affiliates, and each of their directors, officers, employees, agents, advisors, and representatives.

"<u>Interest Payment Date</u>" has the meaning set forth in Section 2.9.

"<u>Investment</u>" of a Person means (a) any loan, advance (other than commission, travel and similar advances to officers and employees made in the ordinary course of business), extension of credit (other than accounts receivable arising in the ordinary course of business on terms customary in the trade) or contribution of capital by such Person; (b) Equity Interests, bonds, mutual funds, notes, debentures or other securities (including warrants or options to purchase securities) owned by such Person; (c) any deposit accounts and certificates of deposit owned by such Person; (d) structured notes, derivative financial instruments and other similar instruments or contracts owned by such Person; and (e) the acquisition, directly or indirectly, of (i) any going-concern business or all or substantially all of the assets of any Person or division, whether through purchase of assets, merger or otherwise or (ii) at least a majority of the Equity Interests (by percentage or voting power) of any Person.

"<u>Law</u>" means, collectively, all international, foreign, federal, state, provincial, and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.

"<u>Lien</u>" means any mortgage, pledge, hypothecation, encumbrance, lien (statutory or other), charge, or other security interest.

"<u>Loan Documents</u>" means this Agreement, the Collateral Documents and any other document or agreement now or in the future executed by the Borrower for the benefit of the Lender in connection with this Agreement.

"<u>Material Adverse Effect</u>" means a material adverse effect on (a) the business, Property, liabilities (actual and contingent), operations or condition (financial or otherwise), results of

------

operations, or prospects of the Borrower taken as a whole, (b) the ability of the Borrower to perform its obligations under the Loan Documents, or (c) the validity or enforceability of any of the Loan Documents or the rights or remedies of the Lender under the Loan Documents.

"<u>Material Indebtedness</u>" means Indebtedness of the Borrower in an outstanding principal amount of $100,000 or more in the aggregate.

"<u>Material Indebtedness Agreement</u>" means any agreement under which any Material Indebtedness was created or is governed or that provides for the incurrence of Material Indebtedness.

"<u>Multiemployer Plan</u>" means a Plan that constitutes a "multiemployer plan" within the meaning of Section 3(37) or ERISA.

"<u>Obligations</u>" means (a) all unpaid principal of and accrued and unpaid interest on the Term Loans, (b) all accrued and unpaid fees, and (c) all expenses, reimbursements, indemnities and other obligations of the Borrower to any Indemnitee arising under the Loan Documents (including interest and fees accruing during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding);

"<u>OFAC</u>" means the U.S. Department of the Treasury's Office of Foreign Assets Control, and any successor thereto.

"<u>Paid in Full</u>" means, with respect to any or all of the Obligations, as the context requires, that each of the following events has occurred, as applicable: (a) the indefeasible payment or repayment in full in immediately available funds of (i) the principal amount of all outstanding Term Loans, (ii) all accrued and unpaid interest, fees, or other charges owing in respect of any Term Loan or Commitment or otherwise under any Loan Document, and (iii) all accrued and unpaid costs and expenses payable by the Borrower to the Lender pursuant to any Loan Document, whether or not demand has been made therefor, including any and all indemnification and reimbursement claims that have been asserted by any such Person prior to such time, (b) the indefeasible payment or repayment in full in immediately available funds or all other outstanding Obligations other than unasserted contingent indemnification and contingent reimbursement obligations and (c) the termination in writing of all of the Commitments.

"<u>PBGC</u>" means the Pension Benefit Guaranty Corporation, or any successor thereto.

"<u>Person</u>" means any individual, corporation, limited liability company, trust, joint venture, association, company, limited or general partnership, unincorporated organization, Governmental Authority, or other entity.

"<u>Plan</u>" means an employee pension benefit plan covered by Title IV of ERISA or subject to the minimum funding standards under Section 412 of the Code or Section 302 of ERISA as to which the Borrower or any ERISA Affiliate may have any liability.

"<u>Property</u>" of a Person means all property, whether real, personal, tangible, intangible, or mixed, of such Person, or other assets owned, leased or operated by such Person.

------

"<u>PTA-DCB Product</u>" has the meaning set forth in the Development Agreement.

"<u>PTCA-DCB Product</u>" has the meaning set forth in the Development Agreement.

"<u>Restricted Payment</u>" means any dividend or other distribution (whether in cash, Equity Interests, or other Property) with respect to any Equity Interest in the Borrower, or any payment (whether in cash, Equity Interests, or other Property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such Equity Interests or any option, warrant or other right to acquire any such Equity Interest.

"<u>Sanctions</u>" means sanctions administered or enforced from time to time by the U.S. government, including those administered by OFAC, the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty's Treasury or other relevant sanctions authority.

"<u>Second FIH Study Milestone</u>" has the meaning set forth in the Development Agreement.

"<u>Security Agreement</u>" means the Amended and Restated Security Agreement dated as of the Closing Date by and among the Borrower and the Lender.

"<u>Solvent</u>" means, with respect to any Person on a particular date, that on such date (a) the present fair salable value of the property and assets of such Person exceeds the debts and liabilities, including contingent liabilities, of such Person, (b) the present fair salable value of the property and assets of the such Person is greater than the amount that will be required to pay the probable liability of such Person on its debts and other liabilities, including contingent liabilities, as such debts and other liabilities become absolute and matured, (c) such Person does not intend to incur, or believe (nor should it reasonably believe) that it will incur, debts and liabilities, including contingent liabilities, beyond its ability to pay such debts and liabilities as they become absolute and matured, and (d) such Person does not have unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted; provided, that the amount of contingent liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.

"<u>Subsidiary</u>" of a Person means any corporation, partnership, limited liability company, association, joint venture, or similar business organization more than 50% of the outstanding Equity Interests having ordinary voting power of which at the time is owned or controlled, directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries. Unless otherwise expressly provided, "Subsidiary" means a Subsidiary of the Borrower.

"<u>Taxes</u>" means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

"<u>Term Loan</u>" means a loan made by the Lender to the Borrower pursuant to Section 2.1.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Interpretation</u>. The foregoing definitions apply equally to the singular and plural forms of the defined terms. In this Agreement, in the computation of a period from a specified date to a later specified date, unless otherwise stated the word "from" means "from and including" and the words "to" and "until" mean "to but excluding." The words "hereof," "herein," and "hereunder" refer to this Agreement as a whole and not to any particular provision. References to Sections, Articles, Exhibits, and Schedules are to this Agreement unless otherwise expressly provided. The words "include," "includes" and "including" shall be deemed to be followed by the phrase "without limitation." Unless the context otherwise clearly requires, "or" has the inclusive meaning represented by the phrase "and/or." All covenants, terms, definitions or other provisions incorporated by reference into this Agreement are so incorporated as if fully set forth herein, and such incorporation includes all necessary definitions and related provisions but includes only amendments agreed to by the Lender and survives any termination of such other agreements until the Obligations are irrevocably Paid in Full and the Commitment is terminated. Any reference to any Law includes all statutory and regulatory provisions consolidating, amending, replacing or interpreting such Law and, unless otherwise specified, refers to such Law as amended, modified, supplemented, replaced, or succeeded from time to time. References to any document, instrument or agreement (a) include all exhibits, schedules and other attachments thereto, (b) include all documents, instruments or agreements issued or executed in replacement thereof, to the extent permitted hereby and (c) mean such document, instrument or agreement, or replacement or predecessor thereto, as amended, supplemented, restated or otherwise modified from time to time to the extent not otherwise stated herein or prohibited hereby and in effect at any given time. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction's laws): (x) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (y) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time. All accounting terms used herein must be interpreted and all accounting determinations hereunder must be made in accordance with GAAP in a manner consistent with that used in preparing the financial statements referred to in Section 4.4.

**ARTICLE II<br><u>THE TERM LOANS</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. &nbsp;&nbsp;&nbsp;&nbsp;<u>Term Loans</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;The Lender and the Borrower agree that the outstanding principal amount of the Existing Loan Agreement is $19,653,000 and interest thereon accrued to the Closing Date is $235,551 (collectively, the "<u>Existing Loan Obligations</u>"). Subject to the terms of this Agreement and in reliance on the representations and warranties of the Borrower herein, each of the parties hereto hereby agree that (i) upon the Closing Date, the Existing Loan Agreement shall be terminated, provided, however, the Liens created thereunder shall continue under the Security Agreement, (ii) the Existing Loan Obligations shall be, from and following the Closing Date, continued and reconstituted as the Term Loans (as described below) and interest and fees, as applicable, under this Agreement, and (iii) the Lender shall make additional Term Loans as set forth below.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The Lender, on the terms and conditions set forth in this Agreement, will make Term Loans to the Borrower in U.S. Dollars as follows: (i) on or before January 6, 2023, and subject to the conditions set forth in Section 3.1, a Credit Extension in cash in the amount of $15,000,000, which, together with the Existing Loan Obligations, shall be deemed to be the initial Credit Extension (the "<u>Initial Credit Extension</u>"); (ii) on or after July 1, 2023, after Lender's receipt of the Borrowing Notice in accordance with Section 2.5 and subject to the conditions set forth in Section 3.2, a second Credit Extension in the amount of $5,000,000 (the "<u>Second Credit Extension</u>"); and (iii) on or after the Lender's receipt of satisfactory evidence that the Second FIH Study Milestone has occurred and receipt of the Borrowing Notice in accordance with Section 2.5, and subject to the conditions set forth in Section 3.2, an additional Credit Extension in the amount of $10,000,000 (the "<u>Milestone Credit Extension</u>"); provided, that the aggregate amount of Term Loans advanced shall not exceed the Commitment and no Term Loan is required to be made following end of the Commitment Period. Any amount borrowed under this Section 2.1 and subsequently repaid or prepaid may not be re-borrowed. Subject to Section 2.4, all amounts owed hereunder with respect to the Term Loans shall be Paid in Full no later than the Facility Termination Date. The Lender's Commitment shall (x) automatically and permanently be reduced by the amount of each Term Loan made hereunder, and (y) terminate immediately and without further action by any Person on the Commitment Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Required Payments; Termination</u>. If at any time the Exposure exceeds the Commitment Amount, the Borrower must immediately make a payment on the Term Loans in an amount sufficient to eliminate such excess. The Borrower must pay all unpaid Obligations under the Loan Documents in full on the Facility Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>. The proceeds of the Term Loans shall be applied by the Borrower to finance product development activities and clinical testing of CVT Products and related operating expenses of the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Prepayments</u>. The Borrower may prepay the Term Loans in whole at any time. Any prepayment of principal shall be accompanied by a payment of interest accrued to date thereon.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Borrowing Requests</u>. If the Borrower desires that the Lender make a Credit Extension in accordance with Section 2.1, the Borrower shall give the Lender a fully executed Borrowing Notice no later than 11:00 a.m. (Minnesota time) at least two Business Days in advance of the proposed borrowing which must be a Business Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Interest Rates</u>. Interest on each Term Loan shall accrue at a per annum rate equal to 4.35%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rates Applicable After Event of Default</u>. Notwithstanding anything to the contrary in Section 2.6, during the continuance of an Event of Default, at the option of the Lender (or, in the case of an Event of Default under Section 6.1(b), (g), or (h), automatically), the Term Loans shall bear interest at the rate otherwise applicable thereto plus 5.0% *per annum*.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Method of Payment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;All payments of the Obligations under this Agreement and the other Loan Documents shall be made, without setoff, deduction, or counterclaim, in immediately available funds to the Lender at the Lender's address specified pursuant to Section 7.1 by 12:00 p.m. (Minnesota time) on the date when due. The Lender may charge the account of the Borrower with the Lender for each payment of Obligations as it becomes due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Principal of the Term Loans is payable on the Facility Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Interest Payment Dates; Interest and Fee Basis</u>. Interest is payable on the final maturity date of such Term Loan, plus a final interest payment with the final payment of principal on the Facility Termination Date (each an "<u>Interest Payment Date</u>"). Interest accrued pursuant to Section 2.7 is payable on demand. Interest and fees hereunder are calculated for actual days elapsed on the basis of a 360-day year. Interest is payable for the day a Term Loan is made but not for the day of any payment on the amount paid if payment is received before 12:00 p.m. (Minnesota time). If any payment of principal of or interest on a Term Loan becomes due on a day that is not a Business Day, such payment shall be made on the next succeeding Business Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10. &nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Interest.</u> Notwithstanding any provision in any Loan Document, the total liability of the Borrower for payment of interest pursuant hereto, including late charges, shall not at any time exceed the maximum non-usurious rate of interest permitted by applicable Law stated as a rate per annum, and if any payments by the Borrower include interest in excess of such rate, the Lender will apply the excess first to reduce the unpaid balance of the Obligations, then to reduce the balance of any other Indebtedness of the Borrower to the Lender, then to the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Net Payment</u>. All payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, costs or charges.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Application of Prepayments</u>. Any voluntary prepayments of Term Loans pursuant to Section 2.4 shall be applied as follows:

*first*, to the payment of all fees, and all expenses specified in Section 7.3(a), in each case to the full extent thereof;

*second*, to the payment of any accrued interest at the Default Rate, if any;

*third*, to the payment of any accrued interest (other than Default Rate interest);

*fourth*, to the payment of the applicable premium, if any, on any Term Loan or Commitment;

*fifth*, to prepay Term Loans (in accordance with the respective outstanding principal amounts thereof) and shall be further applied in inverse order of maturity to reduce the remaining scheduled installments (if any) of principal of the Term Loans; and

*sixth*, to payment of any remaining Obligations then due and payable.

------

**ARTICLE III**

**<u>CONDITIONS PRECEDENT</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Initial Credit Extension</u>. As a condition to Lender's obligation to make the Initial Credit Extension, each of the following conditions shall have occurred on or prior to the Closing Date:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Executed Counterparts</u>. The Lender shall have received each Loan Document executed by the Borrower, together with such other instruments and documents as the Lender has requested to obtain a perfected, first-priority Lien on the Collateral.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Lien searches</u>. The Lender shall have received the title and lien searches, evidence of insurance, endorsements, appraisals, and other due diligence as the Lender has required with respect to the Collateral and Property of the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Corporate Documents</u>. The Lender shall have received evidence regarding the organization, power and authority, and authorization of the Borrower with respect to the Loan Documents or the transactions contemplated thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Certificates</u>. The Lender shall have received such customary certificates of resolutions or other action, incumbency certificates and/or other certificates of responsible officers of the Borrower as the Lender has required evidencing the identity, authority and capacity of each responsible officer thereof authorized to act as a responsible officer in connection with the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Expense Reimbursement</u>. The Borrower shall have reimbursed the Lender for all costs and expenses incurred by the Lender and its affiliates as of the Closing Date (including the reasonable fees, charges and disbursements of counsel for drafting, negotiating and administrating initial documentation for the transaction contemplated herein, regardless whether the Initial Credit Extension occurs or not) in connection with due diligence, preparation, negotiation, execution and delivery of the Loan Documents, up to $10,000 in the aggregate (the "<u>Reimbursement Amount</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u>. The Lender shall have received, in form and substance satisfactory to the Lender, evidence that the insurance policies and endorsements required by Section 5.6 hereof are in full force and effect, together with appropriate evidence showing lender loss payable and/or additional insured clauses or endorsements in favor of the Lender.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;The Lender shall have received such other agreements, documents, instruments and certificates as the Lender has required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Each Credit Extension</u>. The Lender shall not be required to make any Credit Extension unless on the date thereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &nbsp;&nbsp;&nbsp;&nbsp;No Default exists or would result therefrom.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties in Article IV are true and correct.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &nbsp;&nbsp;&nbsp;&nbsp;The Lender shall have received a Borrowing Notice, which constitutes a representation and warranty by the Borrower that the conditions in Section 3.2(a) and (b) have been satisfied.

**ARTICLE IV<br><u>REPRESENTATIONS AND WARRANTIES</u>**

The Borrower represents and warrants to the Lender that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Existence and Standing</u>. The Borrower is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware and has all necessary organizational power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as it is currently conducted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization and Validity</u>. The Borrower has all necessary organizational power and authority to enter into the Loan Documents to which it is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by the Borrower of the Loan Documents, the performance by the Borrower of its obligations hereunder and thereunder and the consummation by the Borrower of the transactions contemplated hereby and thereby have been duly authorized by all requisite organizational action on the part of the Borrower. The Loan Documents have been duly executed and delivered by the Borrower constitute the legal, valid and binding obligations of the Borrower, enforceable against the Borrower in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflict; Government Consents</u>. The execution, delivery and performance by the Borrower of the Loan Documents, and the consummation of the transactions contemplated thereby do not and will not: (a) result in a violation or breach of any provision of the articles of formation or other organizational documents of the Borrower; (b) result in a violation or breach of any provision of any Law, order, writ, judgment, injunction, decree or award binding on the Borrower; or (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of or the creation of any Lien, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under or result in the acceleration or create in any party the right to accelerate, terminate, modify or cancel any agreement to which the Borrower is a party or subject. No consent, approval, permit, order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to the Borrower in connection with the execution and delivery of the Loan Documents and the consummation of the transactions contemplated thereby, except for such consents, approvals, permits, orders, declarations, filings or notices that have been obtained prior to the execution and delivery of the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements</u>. Except as may be indicated in the notes thereto, the unaudited consolidated financial statements of the Borrower and its Subsidiaries most recently delivered to the Lender, and their unaudited financial statements for the fiscal periods ending thereafter, were

------

prepared in accordance with the books and records of the Borrower, which books and records are complete and correct in all material respects and have been regularly kept and maintained in accordance with the Borrower's normal and customary practices and fairly present, in all material respects, the financial condition of the Borrower and its Subsidiaries as of the dates thereof and the results of operations and cash flows for the periods then ended (other than any interim financial statements delivered to the Lender which are subject to normal year-end adjustments that will not be material in amount or effect, either individually or in the aggregate).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Adverse Change</u>. Since January 29, 2021, there has been no event, occurrence or development that has had or would reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes</u>. The Borrower has filed all required Tax returns and has paid all Taxes due, except any Taxes that are being contested in good faith as to which adequate reserves have been provided in accordance with GAAP. No Tax Liens have been filed and no claims are being asserted with respect to any such Taxes. The charges, accruals and reserves on the books of the Borrower in respect of any Taxes or other governmental charges are adequate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation and Contingent Obligations</u>. There are no actions, suits, claims, investigations or other legal proceedings pending or, to the knowledge of the Borrower, threatened against or affecting the Borrower affecting any of the properties or assets related to the business or challenging the enforceability of the Loan Documents or seeks to prevent, enjoin or delay the making of any Credit Extensions. The Borrower has no material contingent obligations not provided for or disclosed in the financial statements referred to in Section 4.4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8.&nbsp;&nbsp;&nbsp;&nbsp;<u>ERISA</u>. With respect to each Plan, the Borrower and all ERISA Affiliates have paid all required minimum contributions and installments on or before the due dates provided under Section 430(j) of the Code and could not reasonably be subject to a Lien under Section 430(k) of the Code or Section 303(k) or Title IV of ERISA. Neither the Borrower nor any ERISA Affiliate has filed, pursuant to Section 412(c) of the Code or Section 302(c) of ERISA, an application for a waiver of the minimum funding standard. No ERISA Event has occurred or is reasonably expected to occur.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Accuracy of Information</u>. No information, exhibit or report furnished by the Borrower to the Lender contained any material misstatement of fact or omitted to state a material fact or any fact necessary to make the statements therein not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Agreements</u>. The Borrower is not in default of any material agreement, and the Borrower is not party to any Material Indebtedness Agreement, other than with the Lender.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Laws</u>. The Borrower is in compliance in all material respects with all applicable Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Ownership of Properties</u>. The Borrower has good title, free of all Liens other than Liens permitted hereunder, to all of the Property reflected in the Borrower's most recent consolidated financial statements provided to the Lender as owned by the Borrower (other than Property disposed of in a transaction permitted by Section 5.13(a)).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Plan Assets; Prohibited Transactions</u>. Each Plan conforms to and has been operated and administered in material compliance with the requirements of ERISA, the Code and all other applicable Laws. To the knowledge of the Borrower, there are no facts relating to any Plan that (a) have resulted in a "prohibited transaction" (within the meaning of Section 4975 of the Code or Section 406 of ERISA) or otherwise have resulted in or could reasonably result in the imposition of an excise tax, penalty or similar liability under ERISA or the Code; (b) have resulted in a breach of fiduciary duty or violation of Part 4 of Title I of ERISA; or (c) could reasonably result in any material liability (whether or not asserted as of the date hereof) under ERISA, the Code, any other applicable Laws or otherwise. There are no pending or, to the knowledge of the Borrower, threatened, claims (other than routine claims for benefits) or lawsuits against or with respect to any Plans. The knowledge of the Borrower, no governmental audit or examination of any Plan is pending or threatened nor are do any facts exist which would reasonably lead to any such audit or examination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Investment Company Act</u>. Neither the Borrower nor any Subsidiary is an "investment company" or a company "controlled" by an "investment company," within the meaning of the Investment Company Act of 1940.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Solvency</u>. The Borrower is, and after giving effect to the transactions contemplated by this Agreement, will be, on either an unconsolidated basis or a consolidated basis, Solvent, and the Company has and will have assets which, fairly valued, exceed its indebtedness, liabilities or obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Anti-Corruption Laws; Sanctions; Anti-Terrorism Laws</u>. The Borrower and its directors, officers, and employees and, to the knowledge of the Borrower, the agents of the Borrower are in compliance with Anti-Corruption Laws and all applicable Sanctions in all material respects. The Borrower has implemented and maintain in effect policies and procedures designed to ensure compliance with Anti-Corruption Laws and applicable Sanctions. Neither the Borrower nor any director, officer, employee, agent, or affiliate of the Borrower is an individual or entity that is, or is 50% or more owned (individually or in the aggregate, directly or indirectly) or controlled by individuals or entities (including any agency, political subdivision or instrumentality of any government) that are (a) the target of any Sanctions or (b) located, organized or resident in a country or territory that is the subject of Sanctions (currently Crimea, Cuba, Iran, North Korea and Syria).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.17.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Subsidiaries</u>. The Borrower does not own, or have any ownership interest in, any other Person.

**ARTICLE V**

**COVENANTS**

Until (a) Obligations under the Loan Documents have been irrevocably Paid in Full and (b) the Lender no longer has any commitment to provide any financial accommodations under any Loan Document:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Reporting</u>. The Borrower will furnish to the Lender:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;within 90 days after the close of each of its fiscal years, for itself and its Subsidiaries, consolidated and consolidating unaudited balance sheets as at the close of such fiscal year and consolidated and consolidating profit and loss and reconciliation of surplus statements and a statement of cash flows for such fiscal year, all certified by an Authorized Officer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;within 30 days after the close of each quarterly period of each of its fiscal years, for itself and its Subsidiaries, consolidated and consolidating unaudited balance sheets as at the close of each such period and consolidated and consolidating profit and loss and reconciliation of surplus statements and a statement of cash flows for the period from the beginning of such fiscal year to the end of such quarter, all certified by an Authorized Officer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;promptly upon the furnishing thereof to the equity holders or board of directors, forecasts, commercial updates and any financial data and information concerning the Borrower and its Subsidiaries that is distributed to the Borrower's equity holders and/or board of directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;together with the financial statements required under Section 5.1(a) and 5.1(b), a compliance certificate in substantially the form of <u>Exhibit B</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;promptly upon the furnishing thereof to the equity holders of the Borrower, copies of all financial statements, reports, proxy statements, and other materials so furnished; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;such other information as the Lender from time to time reasonably requests.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>. The Borrower will, and will cause each Subsidiary to, use the proceeds of the Credit Extensions to finance product development activities and clinical testing of CVT Products and related operating expenses of the Borrower. The Borrower will not, directly or indirectly, use the proceeds of the Term Loans, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person, (a) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws or (b)(i) to fund any activities or business of or with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions, or (ii) in any other manner that would result in a violation of Sanctions by any Person (including any Person participating in the Term Loans, whether as Lender, underwriter, advisor, investor, or otherwise).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Material Events</u>. The Borrower will, and will cause each Subsidiary to, give notice to the Lender, promptly and in any event within five days after an officer of the Borrower obtains knowledge thereof, of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;any Default or Event of Default;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;the commencement of any action or proceeding by or before any arbitrator or Governmental Authority affecting the Borrower or affiliate thereof that seeks to prevent, enjoin, or delay a Credit Extension or is otherwise material;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;with respect to a Plan, (i) any failure to pay all required minimum contributions and installments on or before the due dates provided under Section 430(j) of the

------

Code or (ii) the filing pursuant to Section 412(c) of the Code or Section 302(c) of ERISA, of an application for a waiver of the minimum funding standard; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &nbsp;&nbsp;&nbsp;&nbsp;any other development, financial or otherwise, that would reasonably be expected to have a Material Adverse Effect.

Each notice delivered under this Section 5.3 must be accompanied by a statement of an officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Conduct of Business</u>. The Borrower will, and will cause each Subsidiary to, carry on and conduct its business in substantially the same manner and fields of enterprise as it is conducted in on the Closing Date, do all things necessary to remain duly incorporated or organized, validly existing and in good standing in its jurisdiction of incorporation or organization, maintain all requisite authority to conduct its business in each jurisdiction in which its business is conducted, and keep in full force and effect all rights, contracts, intellectual property, permits, licenses, franchises, and other authorizations material to the conduct of its business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes and Obligations</u>. The Borrower will, and will cause each Subsidiary to, timely file complete and correct federal and applicable foreign, state and local tax returns required by Law. The Borrower will, and will cause each Subsidiary to, and pay when due all its obligations, including without limitation Taxes upon it or its income, profits or Property, except those being contested in good faith by appropriate proceedings, with respect to which adequate reserves have been set aside in accordance with GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u>. The Borrower will, and will cause each Subsidiary to, maintain with financially sound and reputable insurance companies insurance on all their Property, liability insurance and environmental insurance in such amounts, subject to such deductibles and self-insurance retentions and covering such Properties and risks as is consistent with sound business practice, and the Borrower will furnish to the Lender upon request full information as to the insurance carried. The Lender shall be named as lender loss payee and additional insured with respect to any such insurance, and each provider of any such insurance must agree to give the Lender 30 days' prior written notice before such policy is cancelled.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Laws and Material Contractual Obligations</u>. The Borrower will, and will cause each Subsidiary to, (a) comply in all material respects with all Laws and (b) perform in all material respects its obligations under material agreements to which it is a party. The Borrower will maintain in effect and enforce policies and procedures designed to ensure compliance by the Borrower and its directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions. The Borrower will not, and will not permit any Subsidiary to, use or allow any tenants or subtenants to use its Property for any business activity that violates any Law or that supports a business that violates any Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Maintenance of Properties</u>. The Borrower will, and will cause each Subsidiary to, do all things necessary to maintain, preserve, protect and keep its Property in good repair, working order and condition, ordinary wear and tear excepted, and make all repairs, renewals and replacements necessary to properly conduct its business at all times.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Books and Records; Inspection</u>. The Borrower will, and will cause each Subsidiary to, keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions related to its business and activities. The Borrower will, and will cause each Subsidiary to, permit the Lender, by its representatives and agents, at the Borrower's expense, to inspect the Property, books and financial records of the Borrower, to examine and make copies of the books of accounts and other financial records of the Borrower, and to discuss the affairs, finances and accounts of the Borrower with, and to be advised as to the foregoing by, their officers at such reasonable times and intervals as the Lender designates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Indebtedness</u>. The Borrower will not, and will not permit any Subsidiary to, create, incur or suffer to exist any Indebtedness, except:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;the Obligations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness held by the Lender;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness to finance the acquisition, construction, or improvement of any fixed or capital assets, including capitalized lease obligations, and any renewal or extension of such Indebtedness that does not increase the principal amount thereof; in an aggregate principal amount not to exceed $50,000 at any time outstanding; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;other Indebtedness in an aggregate principal amount not to exceed $50,000 at any time outstanding that is subordinated to the Obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Merger</u>. The Borrower will not, and will not permit any Subsidiary to, merge or consolidate with or into any other Person, divide, or liquidate or dissolve.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Sale of Property</u>. The Borrower will not, and will not permit any Subsidiary to, lease, sell, transfer, or otherwise dispose of its Property to any other Person, except for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;sales of inventory, or used, worn-out or surplus equipment, all in the ordinary course of business;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;the sale of equipment (i) in exchange for credit against the purchase price of similar replacement equipment, or (ii) the proceeds of which are applied with reasonable promptness to the purchase price of similar replacement equipment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;any other disposition of Property the fair market value of which, together with the fair market value of all other Property disposed of pursuant to this Section 5.13(c) during the 12-month period ending with the month in which such disposition occurs, does not exceed $50,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Investments</u>. The Borrower will not, and will not permit any Subsidiary to, make or suffer to exist any Investments, or commitments therefor, or create any Subsidiary or become or remain a partner in any partnership or joint venture, except:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Investments in any Subsidiary organized under the laws of any of the United States of America or the District of Columbia (subject to Section 5.10); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;other Investments in an aggregate principal amount not to exceed $50,000 at any time outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Liens</u>. The Borrower will not, and will not permit any Subsidiary to, create, incur, or suffer to exist any Lien in, of, or on the Property of the Borrower or any Subsidiary, except (a) Liens securing Indebtedness permitted under Section 5.11(b); (b) Liens securing Indebtedness permitted under Section 5.11(c); <u>provided</u> that such Lien attaches concurrently or within 90 days after the acquisition or the completion of the construction or improvements thereof and does not extend to any other Property, and (c) Liens in favor of the Lender granted pursuant to any Collateral Document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Restricted Payments</u>. The Borrower will not, and will not permit any Subsidiary to, make any Restricted Payment, except that any Subsidiary may declare and pay dividends or make distributions to the Borrower or to a wholly-owned Subsidiary of the Borrower; provided, that, this <u>Section 5.16</u> will not restrict the issuance of Incentive Units to employees of Borrower in accordance with the Equity Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Transactions with Affiliates</u>. Other than agreements previously disclosed and provided to the Lender, the Borrower will not, and will not permit any Subsidiary to, enter into any transaction with, or make any payment or transfer to, any affiliate except in the ordinary course of business upon fair and reasonable terms no less favorable to the Borrower than the Borrower would obtain in a comparable arms-length transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Negative Pledges; Subsidiary Restrictions</u>. The Borrower will not, and will not permit any Subsidiary to, enter into any agreement or other instrument with or for the benefit of any Person other than the Lender that would (a) prohibit the Borrower from granting, or otherwise limit the ability of the Borrower to grant, to the Lender any Lien or (b) require the Borrower to grant a Lien to any other Person if the Borrower grants any Lien to the Lender. The Borrower must not, and must not permit any Subsidiary to, place or allow any restriction, directly or indirectly, on its ability to make Restricted Payments with respect to its Equity Interests. The Borrower must

------

not permit any Subsidiary to place or allow any restriction, directly or indirectly, on its ability to make loans or other cash payments to the Borrower.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.19.&nbsp;&nbsp;&nbsp;&nbsp;<u>Capital Expenditures</u>. The Borrower &nbsp;&nbsp;&nbsp;&nbsp;will not, and will not permit any Subsidiary to, expend, or be committed to expend, more than $400,000 for Capital Expenditures during any one fiscal year in the aggregate for the Borrower and its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.20.&nbsp;&nbsp;&nbsp;&nbsp;<u>Accounting Changes, Etc.</u> The Borrower shall not, and must not permit any Subsidiary to, (a) make any material change in accounting treatment or reporting practices or change its fiscal year or (b) amend any of its organizational documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.21.&nbsp;&nbsp;&nbsp;&nbsp;<u>Board Observer</u> The Lender shall have the right to designate an observer to the board of directors of the Borrower. Such observer shall receive all information provided to all of the Borrower's directors and shall have the right to attend all meetings of the board of directors of the Borrower and its committees.

**ARTICLE VI<br><u>DEFAULTS AND REMEDIES</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.&nbsp;&nbsp;&nbsp;&nbsp;Events of Default. Each of the following events is an "<u>Event of Default</u>":

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;any representation or warranty made or deemed made by or on behalf of the Borrower in connection with any Loan Document shall prove to have been materially false on the date made or deemed made;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;nonpayment of principal when due and payable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;nonpayment of interest, fees, or any other Obligation (other than an amount referred to in paragraph (b) of this Section 6.1) when due and payable, and such nonpayment continues for more than five (5) days;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;the failure by Borrower to perform or observe any covenant, condition or agreement set forth in Sections 5.2, 5.11, 5.12, 5.13, 5.14, 5.15, 5.16, 5.17, 5.18, 5.19, 5.20 or 5.21;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;the failure by Borrower to perform or observe any covenant, condition or agreement set forth in this Agreement (other than those specified in paragraphs, (b), (c) or (d) of this Section 6.1) and such failure shall continue unremedied for a period of ten days;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;any default in respect of any Material Indebtedness and such default is not remedied within any applicable grace period relating thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;the Borrower (i) has an order for relief entered with respect to it under the federal bankruptcy Laws, (ii) makes an assignment for the benefit of creditors, (iii) applies for, seeks, consents to, or acquiesces in the appointment of a receiver, custodian, trustee, examiner, liquidator or similar official for it or any of its Property, (iv) institutes any proceeding seeking an order for relief under the federal bankruptcy Laws or seeking to adjudicate it a bankrupt or insolvent, or seeking dissolution, winding up, liquidation, reorganization, arrangement, adjustment

------

or composition of it or its debts under any Law relating to bankruptcy, insolvency or reorganization or relief of debtors or fails to file an answer or other pleading denying the material allegations of any such proceeding filed against it, (v) takes any action to authorize or effect any of the foregoing actions set forth in this Section 6.1(g), (vi) fails to contest in good faith any appointment or proceeding described in this Section 6.1(g), or (vii) fails to pay, or admits in writing its inability to pay, its debts generally as they become due;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;without the application, approval or consent of the Borrower, a receiver, trustee, examiner, liquidator or similar official is appointed for the Borrower or any of its Property, or a proceeding described in Section 6.1(g) is instituted against the Borrower, and such appointment continues undischarged or such proceeding continues undismissed or unstayed for 30 days;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;any Governmental Authority condemns, seizes or otherwise appropriates, or takes custody or control of, all or any portion of the Property of the Borrower;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;the Borrower fails within 30 days to pay, obtain a stay with respect to, or otherwise discharge one or more (i) judgments or orders for the payment of money more than $250,000 in the aggregate or (ii) nonmonetary judgments or orders that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;(i) with respect to a Plan, the Borrower or an ERISA Affiliate is subject to a Lien pursuant to Section 430(k) of the Code or Section 303(k) of ERISA or Title IV of ERISA, or (ii) an ERISA Event that, in the opinion of the Lender, when taken together with all other ERISA Events, could reasonably be expected to result in liability in excess of $25,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;(i) any Loan Document fails to remain in full force or effect or any action is taken to discontinue or to assert the invalidity or unenforceability of any Loan Document; or (ii) any Collateral Document fails to create a valid and perfected first-priority security interest in any Collateral, except as permitted by the Loan Documents, or fails to remain in full force and effect, or any action is taken to discontinue or to assert the invalidity or unenforceability of any Collateral Document;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp;any Change of Control; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;&nbsp;&nbsp;&nbsp;any occurrence or event that has a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Acceleration; Remedies</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;If any Event of Default described in Section 6.1(g) or (h) occurs, the Commitment shall automatically terminate and the Obligations under this Agreement and the other Loan Documents shall immediately become due and payable without any action by the Lender. If any other Event of Default occurs, and with respect to Sections 6.1(c), (e), (f) and (j) remains uncured for the respective cure periods set forth therein, the Lender may terminate the Commitment or declare the Obligations under this Agreement and the other Loan Documents to be due and payable, or both, whereupon such Obligations shall become immediately due and payable, without presentment, demand, protest or notice of any kind, all of which the Borrower hereby waives.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence and during the continuation of any Event of Default, and with respect to Sections 6.1(c), (e), (f) and (j) remains uncured for the respective cure periods set forth therein, the Lender may exercise all rights and remedies under the Loan Documents and enforce all other rights and remedies under applicable Law. The Lender may apply any amounts it receives on account of the Obligations in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Preservation of Rights</u>. No delay or omission of the Lender to exercise any right under the Loan Documents will impair such right or be construed to be a waiver of any Event of Default or an acquiescence therein, and any Credit Extension notwithstanding an Event of Default or the inability of the Borrower to satisfy the conditions precedent to such Credit Extension shall not constitute a waiver or acquiescence. Any single or partial exercise of any such right shall not preclude other or further exercise thereof or the exercise of any other right. All remedies in the Loan Documents or under applicable Law afforded are cumulative and available to the Lender until (a) the Obligations have been irrevocably paid and performed in full and (b) the Commitment has terminated.

**ARTICLE VII**

**GENERAL PROVISIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Except in the case of notices and other communications expressly permitted to be given by telephone, all notices and other communications provided for herein must be in writing and must be delivered by hand or overnight courier service, mailed by certified or registered mail as follows: (a) if to the Borrower, at 715 North Pastoria Avenue, Sunnyvale, CA, 94085, Attention: Chief Executive Officer and at 4725 College Park, Suite 200, San Antonio, TX. 78249, Attention: Chief Financial Officer; and (b) if to the Lender, at 1225 Old Highway 8 NW, St. Paul, MN 55112, Attention: Chief Financial Officer. Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent by facsimile shall be deemed to have been given when sent (or, if not sent during normal business hours for the recipient, at the opening of business on the next business day for the recipient), except that notices to the Lender under Article II shall not be effective until actually received. Notwithstanding the foregoing, the Lender or the Borrower may, in its discretion, agree to accept electronic communications pursuant to procedures approved by it or as it otherwise determines. Any party hereto may change its address or facsimile number above by notice to the other party hereto as provided in this Section 7.1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Modifications</u>. Notwithstanding any provision to the contrary herein, no amendment, modification, or waiver of any provision of any Loan Document or consent to any departure therefrom is effective unless in writing and signed by the Lender, and then such amendment, modification, waiver, or consent is effective only in the specific instance and for the purpose for which given.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Expenses; Indemnity; Damage Waiver</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Other than the Reimbursement Amount and except as otherwise provided herein, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses.

------

Notwithstanding the foregoing, the Borrower shall reimburse the Lender on demand for all out-of-pocket costs, expenses and fees (including reasonable expenses and fees of its external counsel) incurred by the Lender in connection with the enforcement of the Lender's rights hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;The Borrower shall indemnify each Indemnitee against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the reasonable fees, charges and disbursements of counsel for any Indemnitee), incurred by or asserted against any Indemnitee by any Person arising out of, in connection with, or as a result of (i) the execution, delivery, or performance by Borrower of any Loan Document, (ii) the use of the proceeds by Borrower of any Credit Extension, (iii) any environmental liability related in any way to the Borrower, or (iv) any claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower, and regardless of whether any Indemnitee is a party thereto; <u>provided</u> that such indemnity shall not be available to the extent that such losses, claims, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of the applicable Indemnitee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by applicable Law, the Borrower hereby waives any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, the transactions contemplated by the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;All amounts due under this Section 7.3 are payable promptly after demand therefor. The obligations under this Section 7.3 shall survive the termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. The Loan Documents are binding upon and inure to the benefit of the Borrower and the Lender and their respective successors and assigns, except that the Borrower may not assign its rights or obligations under the Loan Documents without the prior written consent of the Lender. The Lender may at any time sell, assign, transfer, grant participations in, or otherwise dispose of any portion of its rights and obligations under the Loan Documents to any other Person. This Agreement confers no right or benefit upon any Person other than the parties to this Agreement and their permitted successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Setoff</u>. In addition to, and without limitation of, any rights of the Lender under applicable Law, if any Event of Default occurs, the Borrower authorizes the Lender to offset and apply all such deposits and other amounts toward the payment of the Obligations, whether or not the Obligations, or any part thereof, are then due and regardless of the existence or adequacy of any collateral, guaranty or any other security, right or remedy available to the Lender.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments Set Aside</u>. If any payment by or on behalf of the Borrower to the Lender, or the Lender's exercise of its right of setoff, is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Lender in its discretion) to be repaid to a trustee, receiver or any other party, the obligation originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. All covenants, agreements, representations and warranties made by the Borrower in any Loan Document or pursuant thereto shall be considered to have been relied upon by the Lender and shall survive the execution and delivery thereof and the Credit Extensions, regardless of any investigation made by or on behalf of the Lender and notwithstanding that the Lender may have had notice of any default at the time of any Credit Extension, and shall continue in full force and effect as long as any Obligation or the Commitment remains outstanding. Sections 7.3, and 7.7 shall survive and remain in full force and effect regardless of the consummation of the Credit Extensions, the payment of the Obligations, the expiration or termination of the Commitment or the termination of any Loan Document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governmental Regulation</u>. Anything in this Agreement to the contrary notwithstanding, the Lender need not extend credit to the Borrower in violation of any Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. Section headings are for convenience of reference only and shall not govern the interpretation of any of the provisions of the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. The Loan Documents embody the entire agreement and understanding between the Borrower and the Lender and supersede all prior agreements and understandings between the Borrower and the Lender relating to the subject matter thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability of Provisions</u>. Any provision in any Loan Document that is held to be inoperative, unenforceable, or invalid in any jurisdiction shall, as to that jurisdiction, be inoperative, unenforceable, or invalid without affecting the remaining provisions in that jurisdiction or the operation, enforceability, or validity of that provision in any other jurisdiction, and to this end the provisions of all Loan Documents are severable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.12.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Advisory or Fiduciary Responsibility</u>. In connection with all aspects of each transaction contemplated hereby, (a)(i) no fiduciary, advisory, or agency relationship is intended to be or has been created, irrespective of whether the Lender has advised or is advising the Borrower on other matters, (ii) any services regarding this Agreement provided by the Lender are arm's-length commercial transactions between the Borrower and affiliates, on the one hand, and the Lender, on the other hand, (iii) the Borrower has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (iv) the Borrower is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated by the Loan Documents; and (b)(i) the Lender is acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Borrower or any of its affiliates, or any other Person, (ii) the Lender has no obligation to the Borrower or any of its affiliates with respect to the transactions contemplated hereby except as expressly set forth in the Loan Documents, and (iii) the Lender and its affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower and its affiliates, and the Lender has no obligation to disclose any of such interests to the Borrower or its affiliates. To the fullest extent permitted by Law, the Borrower waives and releases any claims that it may have against the Lender with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts; Effectiveness</u>. This Agreement may be executed in counterparts (and by different parties in different counterparts), each of which is an original, but all of which when taken together are a single contract. Delivery of an executed counterpart of a signature page of any Loan Document by electronic format (e.g., "pdf") is effective as delivery of a manually executed counterpart.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Execution of Assignments; Electronic Records</u>. The words "execution," "signed," "signature," and words of like import shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other state laws based on the Uniform Electronic Transactions Act ("<u>UETA</u>"). The Lender may, on behalf of the Borrower, create a microfilm or optical disk or other electronic image of this Agreement and any or all of the Loan Documents. The Lender may store each such electronic image in its electronic form and then destroy the paper original as part of the Lender's normal business practices, with the electronic image deemed to be an original and of the same legal effect, validity, and enforceability as the paper original. The Lender is authorized, when appropriate, to convert any instrument into a "transferable record" under UETA, with the image of such instrument in the Lender's possession constituting an "authoritative copy" under UETA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. This Agreement and the other Loan Documents and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement or any other Loan Document (except, as to any other Loan Document, as expressly set forth therein) and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the law of the State of Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. The Borrower irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against the Lender or any other Indemnitee in any way relating to any Loan Document in any forum other than the courts of the State of Delaware or of the United States of America for the District of Delaware, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such state court or, to the fullest extent permitted by Applicable Law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or in any other Loan Document shall affect any right of the Lender to bring any action or proceeding against the Borrower or its properties in the courts of any jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver of Venue</u>. The Borrower irrevocably and unconditionally waives, to the fullest extent permitted by applicable Law, any objection to the laying of venue of any action or proceeding arising out of or relating to any Loan Document in any court referred to in Section 7.16. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by Applicable Law, the defense of an inconvenient forum in any such action or proceeding.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Service of Process</u>. Each party hereto irrevocably consents to service of process in the manner provided for notices in Section 7.1. Nothing in this Agreement shall affect the right of any party hereto to serve process in any other manner permitted by applicable Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.19&nbsp;&nbsp;&nbsp;&nbsp;<u>WAIVER OF JURY TRIAL</u>. THE BORROWER AND THE LENDER HEREBY WAIVE TRIAL BY JURY IN ANY JUDICIAL PROCEEDING INVOLVING, DIRECTLY OR INDIRECTLY, ANY MATTER (WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF, RELATED TO, OR CONNECTED WITH ANY LOAN DOCUMENT OR THE RELATIONSHIP ESTABLISHED THEREUNDER.

[Signature Pages Follow]

------

IN WITNESS WHEREOF, the Borrower and the Lender have executed this Agreement as of the date first above written.

---

| | |
|:---|:---|
| <u>BORROWER:</u> | <u>BORROWER:</u> |
| **CHANSU VASCULAR TECHNOLOGIES, LLC** | **CHANSU VASCULAR TECHNOLOGIES, LLC** |
| By: | /s/ Philippe Marco |
| Name: | Philippe Marco |
| Title: | Manager |

---

[Signature Page to Loan Agreement]

------

---

| | |
|:---|:---|
| <u>LENDER:</u> | <u>LENDER:</u> |
| **CARDIOVASCULAR SYSTEMS, INC.** | **CARDIOVASCULAR SYSTEMS, INC.** |
| By: | /s/ Scott Ward |
| Name: | Scott Ward |
| Title Officer: | Chairman, President and Chief Executive |

---

[Signature Page to Loan Agreement]

------

**EXHIBIT A: FORM OF BORROWING NOTICE**

**EXHIBIT B: FORM OF COMPLIANCE CERTIFICATE**

## Exhibit 10.2

**Exhibit 10.2**

Final Version

**FIRST AMENDED AND RESTATED**

**ACQUISITION OPTION AGREEMENT**

by and among

**CARDIOVASCULAR SYSTEMS, INC. CHANSU VASCULAR TECHNOLOGIES, LLC,**

and

**THE MEMBERS OF CHANSU VASCULAR TECHNOLOGIES, LLC,**

dated as of

December 30, 2022

------

**TABLE OF CONTENTS**

ARTICLE I Definitions...................................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;4

ARTICLE II Acquisition Option; Closing.....................................................................................&nbsp;&nbsp;&nbsp;&nbsp;12

Section 2.1&nbsp;&nbsp;&nbsp;&nbsp;Mandatory Purchase; Acquisition Option..................................................&nbsp;&nbsp;&nbsp;&nbsp;12

Section 2.2&nbsp;&nbsp;&nbsp;&nbsp;Purchase and Sale of Interests....................................................................&nbsp;&nbsp;&nbsp;&nbsp;13

Section 2.3&nbsp;&nbsp;&nbsp;&nbsp;Estimated Closing Consideration; Allocation Schedule............................&nbsp;&nbsp;&nbsp;&nbsp;13

Section 2.4&nbsp;&nbsp;&nbsp;&nbsp;Closing; Closing Deliverables...................................................................&nbsp;&nbsp;&nbsp;&nbsp;14

Section 2.5&nbsp;&nbsp;&nbsp;&nbsp;Closing Consideration Adjustment............................................................&nbsp;&nbsp;&nbsp;&nbsp;16

Section 2.6&nbsp;&nbsp;&nbsp;&nbsp;Contingent Payments.................................................................................&nbsp;&nbsp;&nbsp;&nbsp;17

Section 2.7&nbsp;&nbsp;&nbsp;&nbsp;Cash............................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;18

Section 2.8&nbsp;&nbsp;&nbsp;&nbsp;Tax.............................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;18

ARTICLE III Representations and Warranties of the Members...................................................&nbsp;&nbsp;&nbsp;&nbsp;19

Section 3.1&nbsp;&nbsp;&nbsp;&nbsp;Authority of the Members..........................................................................&nbsp;&nbsp;&nbsp;&nbsp;19

Section 3.2&nbsp;&nbsp;&nbsp;&nbsp;No Conflicts; Consents..............................................................................&nbsp;&nbsp;&nbsp;&nbsp;19

Section 3.3&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings; Governmental Orders.................................................&nbsp;&nbsp;&nbsp;&nbsp;19

Section 3.4&nbsp;&nbsp;&nbsp;&nbsp;Ownership of Interests...............................................................................&nbsp;&nbsp;&nbsp;&nbsp;19

Section 3.5&nbsp;&nbsp;&nbsp;&nbsp;Brokers.......................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;20

ARTICLE IV Representations and Warranties of the Company and the Members......................&nbsp;&nbsp;&nbsp;&nbsp;20

Section 4.1&nbsp;&nbsp;&nbsp;&nbsp;Organization and Qualification of the Company.......................................&nbsp;&nbsp;&nbsp;&nbsp;20

Section 4.2&nbsp;&nbsp;&nbsp;&nbsp;Authority of the Company.........................................................................&nbsp;&nbsp;&nbsp;&nbsp;20

Section 4.3&nbsp;&nbsp;&nbsp;&nbsp;Capitalization.............................................................................................&nbsp;&nbsp;&nbsp;&nbsp;21

Section 4.4&nbsp;&nbsp;&nbsp;&nbsp;No Subsidiaries..........................................................................................&nbsp;&nbsp;&nbsp;&nbsp;21

Section 4.5&nbsp;&nbsp;&nbsp;&nbsp;No Conflicts; Consents..............................................................................&nbsp;&nbsp;&nbsp;&nbsp;21

Section 4.6&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements..................................................................................&nbsp;&nbsp;&nbsp;&nbsp;22

Section 4.7&nbsp;&nbsp;&nbsp;&nbsp;Undisclosed Liabilities...............................................................................&nbsp;&nbsp;&nbsp;&nbsp;22

Section 4.8&nbsp;&nbsp;&nbsp;&nbsp;Absence of Certain Changes, Events and Conditions................................&nbsp;&nbsp;&nbsp;&nbsp;23

Section 4.9&nbsp;&nbsp;&nbsp;&nbsp;Material Contracts......................................................................................&nbsp;&nbsp;&nbsp;&nbsp;24

Section 4.10&nbsp;&nbsp;&nbsp;&nbsp;Title to Assets; Sufficiency of Assets; Real Property................................&nbsp;&nbsp;&nbsp;&nbsp;25

Section 4.11&nbsp;&nbsp;&nbsp;&nbsp;Intellectual Property...................................................................................&nbsp;&nbsp;&nbsp;&nbsp;26

Section 4.12&nbsp;&nbsp;&nbsp;&nbsp;Insurance....................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;29

Section 4.13&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings; Governmental Orders.................................................&nbsp;&nbsp;&nbsp;&nbsp;29

Section 4.14&nbsp;&nbsp;&nbsp;&nbsp;Compliance with Laws; Permits................................................................&nbsp;&nbsp;&nbsp;&nbsp;29

Section 4.15&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Matters.....................................................................................&nbsp;&nbsp;&nbsp;&nbsp;29

Section 4.16&nbsp;&nbsp;&nbsp;&nbsp;Environmental Matters...............................................................................&nbsp;&nbsp;&nbsp;&nbsp;32

Section 4.17&nbsp;&nbsp;&nbsp;&nbsp;Employee Benefit Matters.........................................................................&nbsp;&nbsp;&nbsp;&nbsp;32

Section 4.18&nbsp;&nbsp;&nbsp;&nbsp;Employment Matters..................................................................................&nbsp;&nbsp;&nbsp;&nbsp;34

Section 4.19&nbsp;&nbsp;&nbsp;&nbsp;Taxes..........................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;34

Section 4.20&nbsp;&nbsp;&nbsp;&nbsp;Questionable Payments..............................................................................&nbsp;&nbsp;&nbsp;&nbsp;36

Section 4.21&nbsp;&nbsp;&nbsp;&nbsp;Brokers.......................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;36

Section 4.22&nbsp;&nbsp;&nbsp;&nbsp;Solvency.....................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;37

------

Section 4.23&nbsp;&nbsp;&nbsp;&nbsp;Full Disclosure...........................................................................................&nbsp;&nbsp;&nbsp;&nbsp;37

ARTICLE V Representations and Warranties of Buyer...............................................................&nbsp;&nbsp;&nbsp;&nbsp;37

Section 5.1&nbsp;&nbsp;&nbsp;&nbsp;Organization and Authority of Buyer........................................................&nbsp;&nbsp;&nbsp;&nbsp;37

Section 5.2&nbsp;&nbsp;&nbsp;&nbsp;No Conflicts; Consents..............................................................................&nbsp;&nbsp;&nbsp;&nbsp;38

Section 5.3&nbsp;&nbsp;&nbsp;&nbsp;Investment Purpose....................................................................................&nbsp;&nbsp;&nbsp;&nbsp;38

Section 5.4&nbsp;&nbsp;&nbsp;&nbsp;Brokers.......................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;38

Section 5.5&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings......................................................................................&nbsp;&nbsp;&nbsp;&nbsp;38

ARTICLE VI Conduct By The Company and the Members Prior to the Closing Date...............&nbsp;&nbsp;&nbsp;&nbsp;38

Section 6.1&nbsp;&nbsp;&nbsp;&nbsp;Conduct of Business..................................................................................&nbsp;&nbsp;&nbsp;&nbsp;38

Section 6.2&nbsp;&nbsp;&nbsp;&nbsp;Certain Notifications..................................................................................&nbsp;&nbsp;&nbsp;&nbsp;41

ARTICLE VII Additional Agreements.........................................................................................&nbsp;&nbsp;&nbsp;&nbsp;42

Section 7.1&nbsp;&nbsp;&nbsp;&nbsp;Acquisition Proposals; No Solicitation......................................................&nbsp;&nbsp;&nbsp;&nbsp;42

Section 7.2&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality; Access to Information......................................................&nbsp;&nbsp;&nbsp;&nbsp;42

Section 7.3&nbsp;&nbsp;&nbsp;&nbsp;Public Announcements..............................................................................&nbsp;&nbsp;&nbsp;&nbsp;43

Section 7.4&nbsp;&nbsp;&nbsp;&nbsp;Third Party Consents..................................................................................&nbsp;&nbsp;&nbsp;&nbsp;43

Section 7.5&nbsp;&nbsp;&nbsp;&nbsp;Further Assurances.....................................................................................&nbsp;&nbsp;&nbsp;&nbsp;43

Section 7.6&nbsp;&nbsp;&nbsp;&nbsp;Transition Services Agreement..................................................................&nbsp;&nbsp;&nbsp;&nbsp;44

Section 7.7&nbsp;&nbsp;&nbsp;&nbsp;Transfer Taxes...........................................................................................&nbsp;&nbsp;&nbsp;&nbsp;44

Section 7.8&nbsp;&nbsp;&nbsp;&nbsp;Tax Treatment............................................................................................&nbsp;&nbsp;&nbsp;&nbsp;44

Section 7.9&nbsp;&nbsp;&nbsp;&nbsp;Release and Waiver....................................................................................&nbsp;&nbsp;&nbsp;&nbsp;45

Section 7.10&nbsp;&nbsp;&nbsp;&nbsp;Non-Competition; Non-Solicitation...........................................................&nbsp;&nbsp;&nbsp;&nbsp;46

Section 7.11&nbsp;&nbsp;&nbsp;&nbsp;Updated Disclosure Schedules...................................................................&nbsp;&nbsp;&nbsp;&nbsp;47

Section 7.12&nbsp;&nbsp;&nbsp;&nbsp;Lease Assignment......................................................................................&nbsp;&nbsp;&nbsp;&nbsp;47

Section 7.13&nbsp;&nbsp;&nbsp;&nbsp;Incentive Units...........................................................................................&nbsp;&nbsp;&nbsp;&nbsp;47

ARTICLE VIII Conditions to Closing..........................................................................................&nbsp;&nbsp;&nbsp;&nbsp;47

Section 8.1&nbsp;&nbsp;&nbsp;&nbsp;Conditions to the Obligations of Each Party..............................................&nbsp;&nbsp;&nbsp;&nbsp;47

Section 8.2&nbsp;&nbsp;&nbsp;&nbsp;Additional Conditions to the Obligations of Buyer...................................&nbsp;&nbsp;&nbsp;&nbsp;48

Section 8.3&nbsp;&nbsp;&nbsp;&nbsp;Additional Conditions to the Obligations of the Members and the Company................................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;49

ARTICLE IX Indemnification.......................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;49

Section 9.1&nbsp;&nbsp;&nbsp;&nbsp;Survival......................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;49

Section 9.2&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by the Members...............................................................&nbsp;&nbsp;&nbsp;&nbsp;49

Section 9.3&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by Buyer..........................................................................&nbsp;&nbsp;&nbsp;&nbsp;50

Section 9.4&nbsp;&nbsp;&nbsp;&nbsp;Certain Limitations....................................................................................&nbsp;&nbsp;&nbsp;&nbsp;51

Section 9.5&nbsp;&nbsp;&nbsp;&nbsp;Indemnification Procedures.......................................................................&nbsp;&nbsp;&nbsp;&nbsp;52

Section 9.6&nbsp;&nbsp;&nbsp;&nbsp;Tax Treatment of Indemnification Payments............................................&nbsp;&nbsp;&nbsp;&nbsp;54

Section 9.7&nbsp;&nbsp;&nbsp;&nbsp;Exclusive Remedies...................................................................................&nbsp;&nbsp;&nbsp;&nbsp;54

Section 9.8&nbsp;&nbsp;&nbsp;&nbsp;Payments; Escrow Release........................................................................&nbsp;&nbsp;&nbsp;&nbsp;54

------

Section 9.9&nbsp;&nbsp;&nbsp;&nbsp;Effect of Investigation................................................................................&nbsp;&nbsp;&nbsp;&nbsp;55

ARTICLE X Termination..............................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;55

Section 10.1&nbsp;&nbsp;&nbsp;&nbsp;Termination................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;55

Section 10.2&nbsp;&nbsp;&nbsp;&nbsp;Procedure and Effect of Termination.........................................................&nbsp;&nbsp;&nbsp;&nbsp;57

ARTICLE XI Miscellaneous.........................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;57

Section 11.1&nbsp;&nbsp;&nbsp;&nbsp;Expenses....................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;57

Section 11.2&nbsp;&nbsp;&nbsp;&nbsp;Notices.......................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;57

Section 11.3&nbsp;&nbsp;&nbsp;&nbsp;Interpretation..............................................................................................&nbsp;&nbsp;&nbsp;&nbsp;58

Section 11.4&nbsp;&nbsp;&nbsp;&nbsp;Actions By Members.................................................................................&nbsp;&nbsp;&nbsp;&nbsp;58

Section 11.5&nbsp;&nbsp;&nbsp;&nbsp;Headings....................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;59

Section 11.6&nbsp;&nbsp;&nbsp;&nbsp;Severability................................................................................................&nbsp;&nbsp;&nbsp;&nbsp;59

Section 11.7&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement.......................................................................................&nbsp;&nbsp;&nbsp;&nbsp;59

Section 11.8&nbsp;&nbsp;&nbsp;&nbsp;Successors and Assigns..............................................................................&nbsp;&nbsp;&nbsp;&nbsp;60

Section 11.9&nbsp;&nbsp;&nbsp;&nbsp;No Third-party Beneficiaries.....................................................................&nbsp;&nbsp;&nbsp;&nbsp;60

Section 11.10 Amendment and Modification; Waiver.....................................................&nbsp;&nbsp;&nbsp;&nbsp;60

Section 11.11 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial...........&nbsp;&nbsp;&nbsp;&nbsp;60

Section 11.12 Specific Performance.................................................................................61

Section 11.13 Counterparts...............................................................................................&nbsp;&nbsp;&nbsp;&nbsp;61

------

**FIRST AMENDED AND RESTATED ACQUISITION OPTION AGREEMENT**

This First Amended and Restated Acquisition Option Agreement (this "<u>Agreement</u>"), dated as of December 30, 2022, is entered into by and among Cardiovascular Systems, Inc., a Delaware corporation ("<u>Buyer</u>"), Chansu Vascular Technologies, LLC, a Delaware limited liability company (the "<u>Company</u>"), and the Members (as defined below) and amends and restates the Acquisition Option Agreement dated January 29, 2021 (the "<u>Original</u> <u>Agreement</u>") in its entirety.

**RECITALS**

WHEREAS, the Members own 100% of the issued and outstanding limited liability company membership interests (the "<u>Interests</u>") of the Company;

WHEREAS, Buyer and the Members have deemed it advisable and in the best interests of their respective entities and equityholders that, subject to and conditioned upon, the terms and conditions of this Agreement, Buyer and the Members consummate the transactions provided for herein in order to advance their respective long-term strategic business interests;

WHEREAS, Buyer, the Company and the Members have a mutual interest in amending the Original Agreement pursuant to the terms of this Agreement;

WHEREAS, concurrently with the execution of this Agreement, Buyer and the Company are entering into a Loan Agreement providing for loans from Buyer to the Company (the "<u>New Loan Agreement</u>"), respectively; and

WHEREAS, the Company recognizes and acknowledges that the Company will realize substantial economic benefits as a result of the New Loan Agreement and other transactions described above and that this Agreement amending and restating the Original Agreement is a condition to Buyer entering into such agreements; and

WHEREAS, Buyer, the Company and the Members desire to make certain representations, warranties, covenants and other agreements in connection with the transactions contemplated by this Agreement.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

**ARTICLE I**

**DEFINITIONS**

The following terms have the meanings specified or referre[d to in this Article I](#iad153e23c3af4c5d94fd367f56a26c38_7): "<u>Affiliate</u>" of a Person means any other Person that directly or indirectly, through

one or more intermediaries, controls, is controlled by, or is under common control with, such

4

------

Person. The term "control" (including the terms "controlled by" and "under common control with") means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

"<u>Aggregate Consideration</u>" means the aggregate consideration paid to the Members pursuant to this Agreement in consideration for the Acquisition, including (a) the Closing Date Consideration as finally determined pursuant to [Section 2.5,](#iad153e23c3af4c5d94fd367f56a26c38_37)(b) any release to the Members from the Escrow Fund pursuant to [Section 9.8](#iad153e23c3af4c5d94fd367f56a26c38_40), (c) the payment of the First Contingent Payment and Second Contingent Payment, if applicable.

"<u>Business</u>" means the design, development, implementation, support, marketing and sale by the Company of the Company Products.

"<u>Business Day</u>" means any day except Saturday, Sunday or any other day on which commercial banks located in Wilmington, Delaware are authorized or required by Law to be closed for business.

"<u>Buyer Acquisition Option Term</u>" shall mean the period (i) beginning on the later of January 1, 2024 and date of the Second FIH Study Milestone and (ii) ending on the date that is ninety (90) days after the delivery of the Updated Disclosure Schedules; <u>provided</u>, that, notwithstanding the foregoing, the Buyer Acquisition Option Term shall terminate upon delivery of a Member Acquisition Notice in accordance with Section 2.1(a).

"<u>Buyer Fundamental Representations</u>" means the representations or warranties set for[th in Section 5.1](#iad153e23c3af4c5d94fd367f56a26c38_40) (Organization and Authority of Buyer), and [Section 5.4](#iad153e23c3af4c5d94fd367f56a26c38_40) (Brokers).

"<u>Buyer Loan Amount</u>" means the amount of principal and interest outstanding under the Loan Documents as of the Closing.

"<u>Closing Date Consideration</u>" means an amount equal to (i) the Upfront Payment, *minus* (ii) the First Escrow Deposit, *minus* (iii) the Closing Indebtedness, *minus* (iv) the Transaction Expenses.

"<u>Closing Indebtedness</u>" means, as of the Closing Date: (i) any indebtedness of the Company for borrowed money or issued in substitution for or exchange of indebtedness for borrowed money (including interest and prepayment penalties or obligations computed as though payment is being made as of the Closing), (ii) any indebtedness of the Company evidenced by any note, bond, debenture or other debt security, (iii) any indebtedness for the deferred purchase price of property or services with respect to which the Company is liable, contingently or otherwise, as obligor or otherwise (including any earn outs, holdbacks, etc.), (iv) any guarantees of indebtedness or any indebtedness guaranteed in any manner by the Company (including guarantees in the form of an agreement to repurchase or reimburse, whether on a contingent basis or otherwise), (v) all remaining obligations under the Lease if not assigned in accordance with [Section 7.12](#iad153e23c3af4c5d94fd367f56a26c38_40)at or prior to the Closing, (vi) any liabilities under capitalized leases with respect to which the Company is liable, contingently or otherwise, as obligor, guarantor or otherwise, or with respect to which liabilities the Company assures a creditor against loss, (vii) any other accounts payable or current liabilities of the Company that are past due or that are not related to the operation of the Business

5

------

in the ordinary course, and (viii) any indebtedness secured by an Encumbrance on the Company's assets; provided, that Closing Indebtedness shall exclude the Buyer Loan Amount.

"<u>Code</u>" means the Internal Revenue Code of 1986, as amended.

"<u>Company Group</u>" means the Company, the Members and any of their Affiliates. "<u>Company Operating Agreement</u>" means the Limited Liability Company Operating

Agreement of the Company, dated as of June 1, 2020.

"<u>Company Products</u>" means the PTA-DCB Product and the PTCA-DCB Product.

"Contract" means any contract, agreement, lease, indenture, mortgage, note, bond

or other similar legally binding commitment.

"<u>Development Agreement</u>" means the Product Development Agreement dated as of January 29, 2021, between the Company and Buyer.

"<u>Disclosure Schedules</u>" means the Disclosure Schedules delivered by the Members and the Company concurrently with the execution and delivery of this Agreement.

"<u>Dollars or $</u>" means the lawful currency of the United States.

"<u>Equity Incentive Plan</u>" means the Chansu Vascular Technologies, LLC 2020 Equity Incentive Plan.

"<u>Employee Benefit Plan</u>" means any plan, program, agreement, policy or arrangement with respect to Business Employees, that is (a) an employee welfare benefit plan within the meaning of Section 3(1) of ERISA, (b) an employee pension benefit plan within the meaning of Section 3(2) of ERISA, (c) a stock bonus, stock purchase, stock option, restricted stock, stock appreciation right, profit sharing or similar equity-based plan or agreement, or (d) any other employment, deferred-compensation, retirement, severance, retention, change-in-control, leave, vacation, welfare-benefit, bonus, incentive or fringe-benefit plan, program, agreement or arrangement.

"<u>Encumbrance</u>" means any lien, pledge, mortgage, deed of trust, security interest, charge, claim, easement, encroachment or other similar encumbrance or restriction of any kind.

"<u>Environmental Law</u>" means any applicable Law relating to: (a) pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials.

"<u>ERISA</u>" means the Employee Retirement Income Security Act of 1974, as

amended.

6

------

"<u>Escrow Agent</u>" means Wilmington Trust N.A.

"Estimated Closing Indebtedness" means the Closing Indebtedness estimated in good faith by the Company and set forth in the Estimated Closing Date Consideration Statement.

"<u>Estimated Transaction Expenses</u>" means the Transaction Expenses estimated in good faith by the Company and set forth in the Estimated Closing Date Consideration Statement.

"<u>Event of Default</u>" has the meaning set forth in the Loan Documents.

"<u>Exercise Date</u>" shall mean the date that Buyer delivers the Buyer Acquisition

Notice.

"<u>First IDE Approval Milestone</u>" means the occurrence of the first IDE Approval

with respect to a Product; provided, that such IDE Approval occurs on or before the Target Date.

"<u>Final Indebtedness</u>" means the Closing Indebtedness as finally determined pursua[nt to Section 2.5.](#iad153e23c3af4c5d94fd367f56a26c38_37)

"<u>Final Transaction Expenses</u>" means the Transaction Expenses as finally determined pursua[nt to Section 2.5](#iad153e23c3af4c5d94fd367f56a26c38_37).

"<u>First Contingent Payment</u>" means an amount equal to $15,000,000. "<u>Fiscal Year</u>" means a fiscal year of Buyer.

"<u>GAAP</u>" means United States generally accepted accounting principles in effect from time to time.

"<u>Governmental Authority</u>" means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.

"<u>Governmental Order</u>" means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.

"<u>Hazardous Materials</u>" means: (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or man-made, that is hazardous, acutely hazardous, toxic, or words of similar import or regulatory effect under Environmental Laws; and (b) any petroleum or petroleum- derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead- containing materials, urea formaldehyde foam insulation and polychlorinated biphenyls.

"<u>Health Care Legal Requirement</u>" means any Law relating to healthcare regulatory matters and Programs, including (a) 42 U.S.C. §§ 1320a-7, 7a and 7b, which are commonly

7

------

referred to as the "Federal Fraud Statutes," (b) 42 U.S.C. § 1395nn, which is commonly referred to as the "Stark Statute," (c) 31 U.S.C. §§ 3729-3733, which is commonly referred to as the "Federal False Claims Act," (d) 42 U.S.C. §§ 1320d through 1320d-8 and 42 C.F.R. §§ 160, 162 and 164, which is commonly referred to as the "Health Insurance Portability and Accountability Act of 1996," (e) the Occupational Safety and Health Act and all regulations promulgated under such legislation, (f) the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321 et seq., as amended and all regulations promulgated thereunder, (g) applicable Laws of the United States Drug Enforcement Administration and all regulations promulgated thereunder, (h) the Physician Payments Sunshine Law, 42 U.S.C. § 13207h, (i) applicable state anti-kickback, fee-splitting and patient brokering laws, and (j) state information privacy and security Laws.

"<u>Hired Employee</u>" means any Business Employee who accepts Buyer's offer of

employment.

"IDE Approval" shall have the meaning set forth in the Development Agreement.

"Incentive Units" has the meaning set forth in the Equity Incentive Plan

"Incentive Unit Holders" means any holder of Incentive Units issued pursuant to the Equity Inventive Plan.

"<u>Knowledge of the Company</u>" or any other similar knowledge qualification, means

&nbsp;&nbsp;&nbsp;&nbsp;(i)the actual knowledge of Philippe Marco and each other member of the Company's executive management team and such knowledge as would be obtained following the exercise of reasonable inquiry by any such person; and (ii) the actual knowledge of each Member and such knowledge as would be obtained following the exercise of reasonable inquiry by such Member.

"<u>Law</u>" means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority.

"<u>Liability</u>" or "<u>Liabilities</u>" means any debt, liability or obligation of any kind or nature whatsoever, whether direct or indirect, asserted or unasserted, matured or unmatured, absolute or contingent, known or unknown, accrued or unaccrued, liquidated or unliquidated, whether or not foreseeable, and whether due or become due, whenever arising and regardless of when asserted, and, in each case, including all costs and expenses relating thereto.

"<u>Lease</u>" means the Lease Agreement between the Company and SCP-1, LP, a California limited partnership, dated as of November 6, 2020, for the office space located at 715 North Pastoria Avenue, Sunnyvale, CA, 94085.

"<u>Loan Documents</u>" means (a) the New Loan Agreement and (b) the Security Agreement, as amended between the Company, as borrower, and Buyer, as the lender.

"<u>Losses</u>" means all losses, damages, Liabilities, demands, actions or causes of action (including third party claims), charges, interest, judgments, sanctions, fines, penalties, settlements, costs or expenses, including reasonable attorneys' fees.

8

------

"<u>Material Adverse Effect</u>" means any event, occurrence, fact, condition or change that, individually or in the aggregate, is or could reasonably be expected to be materially adverse to (a) the condition (financial or otherwise) or assets of the Company; or (b) prevent the Members or the Company from consummating the transactions contemplated hereby; *provided, however,* that "Material Adverse Effect" shall not include any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in which the Business operates; (iii) any changes in financial, banking or securities markets in general, including any disruption thereof and any decline in the price of any market index or any change in prevailing interest rates; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or global health conditions (including any epidemic, pandemic, or disease outbreak (including the COVID-19 virus)); (v) any changes in applicable Laws or accounting rules (including GAAP); (vi) the public announcement or completion of the transactions contemplated by this Agreement (provided that no such announcement shall be in violation of the terms hereof); and (vii) any natural disaster or acts of God; except in the case of (i), (ii), (iii), (iv), (v) or (vii) above to the extent the same has a disproportionate effect on the Company or the Business as compared to other Persons in the industries in which the Business or the Company operates.

"<u>Members</u>" means the members of the Company who are set forth on the signature pages hereto and, solely for purposes <u>[Article II](#iad153e23c3af4c5d94fd367f56a26c38_31)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_31) <u>[Article III](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_40) <u>[Section 4.3](#iad153e23c3af4c5d94fd367f56a26c38_40)</u> and <u>[Article XI](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_40) the Incentive Unit Holders who have executed Joinder Agreements in accordance with <u>[Section 7.13](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>.

"<u>Most Recent Balance Sheet Date</u>" means, with respect to the Updated Disclosure Schedules, the last day of the last month immediately preceding the Schedule Delivery Date.

"<u>Most Recent Financials Date</u>" means, with respect to the Updated Disclosure Schedules, December 31 of the last year in which the Company has had financials prepared for its full fiscal year.

"<u>Open Source</u>" means software or similar subject matter which is subject to a license agreement such as the GNU General Public License, GNU Lesser General Public License, BSD License, MIT License, Common Public License and other licenses approved as open source licenses by the Open Source Initiative.

"<u>Permits</u>" means all permits, licenses, franchises, approvals, authorizations, consents or other similar requirements of any Governmental Authority.

"<u>Person</u>" means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.

"<u>Personally Identifiable Information</u>" means any information that alone or in combination with other information held by the Company and can be used to specifically identify an individual.

"<u>Privacy and Security Laws</u>" means Laws addressing the use, disclosure, storage, maintenance, transmission, encryption, breach or breach notification of, access to, or privacy or security of, Personally Identifiable Information.

9

------

"<u>Pro Rata Share</u>" means, with respect to each Member other than any Incentive Unit Holder, a fraction, the numerator of which is the number of Units held by such Member, and the denominator of which is the aggregate number of Units held by all Members (other than the Incentive Unit Holders), in each case, as of immediately prior to the Closing.

"<u>Program</u>" means any and all third party payors and third party payor programs, whether private, commercial or governmental, including, but not limited to, any federal or state reimbursement program, including any Medicare, Medicaid, Medicaid waiver program, TRICARE program, "Federal Health care programs" as defined in 42 U.S.C. § 1320a-7b(f) and private insurance programs.

"<u>PTA-DCB Product</u>" shall have the meaning set forth in the Development

Agreement.

"PTCA-DCB Product" shall have the meaning set forth in the Development Agreement.

"Real Property" means the real property leased or subleased by the Company Group, together with all buildings, structures and facilities located thereon.

"<u>Representative</u>" means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person.

"<u>Schedule Delivery Date</u>" shall mean the date that the Company delivers the Updated Disclosure Schedules to Buyer.

"<u>Second Contingent Payment</u>" means an amount equal to $15,000,000.

"<u>Second FIH Study Milestone</u>" shall have the meaning set forth in the Development

Agreement.

"<u>Second IDE Approval Milestone</u>" means the occurrence of the IDE Approval with

respect to the Second Product; provided, that such IDE Approval occurs on or before the Target Date.

"<u>Seller Fundamental Representations</u>" means the representations or warranties set forth in [Section 3.1](#iad153e23c3af4c5d94fd367f56a26c38_40)(Authority of the Member), [Section 3.4](#iad153e23c3af4c5d94fd367f56a26c38_40)(Ownership of Interests), [Section 3.5](#iad153e23c3af4c5d94fd367f56a26c38_40) (Brokers), [Section 4.1](#iad153e23c3af4c5d94fd367f56a26c38_40)(Organization and Qualification of the Company), [Section 4.2](#iad153e23c3af4c5d94fd367f56a26c38_40)(Authority of the Company), [Section 4.3](#iad153e23c3af4c5d94fd367f56a26c38_40) (Capitalization), [Section 4.4](#iad153e23c3af4c5d94fd367f56a26c38_40) (Subsidiaries), and [Section 4.21](#iad153e23c3af4c5d94fd367f56a26c38_40) (Brokers).

"<u>Second Product</u>" means the second Product to achieve IDE Approval. "<u>Target Date</u>" means December 31, 2023.

"<u>Taxes</u>" means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance,

10

------

environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.

"<u>Tax Return</u>" means any return, declaration, report, claim for refund, information return or statement or other document required to be filed with respect to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

"<u>Territory</u>" means worldwide.

"<u>Transaction Documents</u>" means this Agreement, the Loan Documents, the Development Agreement, the Escrow Agreement, and the Transition Services Agreement.

"<u>Transaction Expenses</u>" means, as of the Closing: (i) all out-of-pocket expenses (including all fees and expenses of counsel, accountants, investment bankers, experts and consultants to a party hereto and its Affiliates) payable by the Company or the Members or on their behalf in connection with, or related to, the authorization, preparation, negotiation, execution and performance of this Agreement and the transactions contemplated hereby, which have not been paid by the Company or the Members as of the Closing; and (ii) any transaction bonuses or other amounts payable to any employee of the Company, or any other Person, as result of the execution of this Agreement or the consummation of the transactions contemplated hereby, plus the employer's share of any employment Taxes due in connection with such payments.

"<u>Updated Disclosure Schedules</u>" shall mean updated Disclosure Schedules delivered by the Company to Buyer pursuant to Section 3.2(a).

"<u>Upfront Payment</u>" means $10,000,000; <u>provided</u>, <u>however</u>, that, in the event of Second FIH Study Milestone has not occurred on or prior to December 31, 2023, the Upfront Payment shall be reduced by twenty percent (20%) for each three (3) month period after December 31, 2023 until the date of the Second FIH Study Milestone.

Acquisition...................................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.2

Acquisition Notice.................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.1(b),

Section 2.1(b)

Acquisition Proposal...............&nbsp;&nbsp;&nbsp;&nbsp;Section 7.1(a)

Agreement......................................&nbsp;&nbsp;&nbsp;&nbsp;Preamble

Agreement Period....................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.5(c)

Allocation Agreement Period.. Section 7.8(a) Allocation Objection Notice&nbsp;&nbsp;&nbsp;&nbsp;Section 7.8(a)

Allocation Schedule&nbsp;&nbsp;&nbsp;&nbsp;Section 2.3(b)

Annual Financial Statements .. Section 4.6(a) Anti-Bribery Laws......&nbsp;&nbsp;&nbsp;&nbsp;Section 4.20(a)

Basket......................................&nbsp;&nbsp;&nbsp;&nbsp;Section 9.4(a)

Business Copyrights..............&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(b)

Business Employees..............&nbsp;&nbsp;&nbsp;&nbsp;Section 4.18(a)

Business IP............................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(b)

Business Marks......................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(b)

Business Patents....................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(b)

Buyer..............................................&nbsp;&nbsp;&nbsp;&nbsp;Preamble

Buyer Acquisition Notice.......&nbsp;&nbsp;&nbsp;&nbsp;Section 2.1(a),

Section 2.1(a)

Buyer Acquisition Option......&nbsp;&nbsp;&nbsp;&nbsp;Section 2.1(b),

Section 2.1(b)

Buyer Indemnified Parties...........&nbsp;&nbsp;&nbsp;&nbsp;Section 9.2

Cap..........................................&nbsp;&nbsp;&nbsp;&nbsp;Section 9.4(b)

Closing....................................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.4(a)

Closing Date............................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.4(a)

Closing Statement...................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.5(a)

Company.........................................&nbsp;&nbsp;&nbsp;&nbsp;Preamble

11

------

Confidentiality Agreement......&nbsp;&nbsp;&nbsp;&nbsp;Section 7.2(a)

Consents.......................................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.5

Copyrights.............................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(a)

CPA.........................................&nbsp;&nbsp;&nbsp;&nbsp;Section 7.8(a)

Direct Claim............................&nbsp;&nbsp;&nbsp;&nbsp;Section 9.5(c)

Escrow Agreement............&nbsp;&nbsp;&nbsp;&nbsp;Section 2.4(d)(iv)

Escrow Fund......................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.4(d)(iv)

Estimated Closing Date Consideration

.................................................Section 2.3(b)

Estimated Closing Date Consideration Statement.................................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.3(b)

FDA.......................................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.15(a)

Financial Statements...............&nbsp;&nbsp;&nbsp;&nbsp;Section 4.6(a)

First Escrow Deposit.........&nbsp;&nbsp;&nbsp;&nbsp;Section 2.4(d)(iv)

Fundamental Representations......&nbsp;&nbsp;&nbsp;&nbsp;Section 9.1

Indemnified Party........................&nbsp;&nbsp;&nbsp;&nbsp;Section 9.4

Indemnifying Party......................&nbsp;&nbsp;&nbsp;&nbsp;Section 9.4

Independent Auditors..............&nbsp;&nbsp;&nbsp;&nbsp;Section 2.5(c)

Insurance Policies......................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.12

Intellectual Property..............&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(a)

Interests.............................................&nbsp;&nbsp;&nbsp;&nbsp;Recitals

Interim Financial Statements....Section 4.6(a) Joinder Agreement.....................&nbsp;&nbsp;&nbsp;&nbsp;Section 7.13

Key Individuals............................&nbsp;&nbsp;&nbsp;&nbsp;Section 7.6

Mandatory Purchase................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.1(a)

Marks.....................................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(a)

Material Contracts...................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.9(a)

Member Acquisition Notice....&nbsp;&nbsp;&nbsp;&nbsp;Section 2.1(a)

Member Indemnified Parties.......&nbsp;&nbsp;&nbsp;&nbsp;Section 9.3

Most Recent Balance Sheet.....&nbsp;&nbsp;&nbsp;&nbsp;Section 4.6(a)

Objection Notice.....................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.5(b)

Patents...................................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(a)

Payor Claims.........................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.15(e)

Permitted Encumbrances.......&nbsp;&nbsp;&nbsp;&nbsp;Section 4.10(a)

Released Member Claims............&nbsp;&nbsp;&nbsp;&nbsp;Section 7.9

Required Consents...................&nbsp;&nbsp;&nbsp;&nbsp;Section 8.2(f)

Restricted Member................&nbsp;&nbsp;&nbsp;&nbsp;Section 7.10(a)

Restricted Period...................&nbsp;&nbsp;&nbsp;&nbsp;Section 7.10(a)

Second Escrow Deposit...............&nbsp;&nbsp;&nbsp;&nbsp;Section 2.6

SOL Representations...................&nbsp;&nbsp;&nbsp;&nbsp;Section 9.1

Tax Allocation Schedule.........&nbsp;&nbsp;&nbsp;&nbsp;Section 7.8(a)

Termination Date...................&nbsp;&nbsp;&nbsp;&nbsp;Section 10.1(e)

Third Escrow Deposit..................&nbsp;&nbsp;&nbsp;&nbsp;Section 2.6

Third-Party Claim...................&nbsp;&nbsp;&nbsp;&nbsp;Section 9.5(a)

Trade Secrets.........................&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11(a)

Transition Services Agreement...&nbsp;&nbsp;&nbsp;&nbsp;Section 7.6

**ARTICLE II ACQUISITION OPTION; CLOSING**

**Section 2.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Mandatory Purchase; Acquisition Option</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)At any time during the Buyer Acquisition Option Term if no Event of Default has occurred and so long as no Event of Default occurs, upon a notice provided by the Members to the Buyer (a "<u>Member Acquisition Notice</u>"), Buyer shall be required to, subject to the terms of this Agreement, purchase from the Members all, but not less than all, of the Interests, free and clear of all Encumbrances (the "<u>Mandatory Purchase</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Prior to receipt of a Member Acquisition Option pursuant to [Section 2.1(a),](#iad153e23c3af4c5d94fd367f56a26c38_31) the Members hereby grant to Buyer the irrevocable option during the Buyer Acquisition Option Term (the "<u>Buyer Acquisition Option</u>") to, subject to the terms of this Agreement and the applicable provisions of the Laws of the State of Delaware, purchase from the Members all of the Interests, free and clear of all Encumbrances by providing written notice to the Members and the Company (the "<u>Buyer Acquisition Notice</u>" and, with the Member Acquisition Notice, each an "<u>Acquisition Notice</u>") at any time during the Buyer Acquisition Option Term. Without limiting the rights of the Members pursuant to [Section 2.1(a),](#iad153e23c3af4c5d94fd367f56a26c38_31) the parties specifically and expressly acknowledge, understand and agree that Buyer shall have the sole and absolute discretion to, for any reason(s) whatsoever, exercise or not exercise, or rescind the Buyer Acquisition Option or to terminate this Agreement pursuant to<u>[Section 10.1(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>and that Buyer shall have no obligations to

12

------

inform the Members or any other party of its reason(s) therefor. Buyer shall keep, and shall cause its directors, officers, employees, agents and advisors to keep, confidential its decision to exercise or not exercise the Buyer Acquisition Option or terminate this Agreement pursuant to <u>[Section 10.1(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_40)and its reasons for such decision, unless the Company has given its prior written consent to such disclosure. Buyer may only exercise the Buyer Acquisition Option by written notice pursuant to this [Section 2.1(b)](#iad153e23c3af4c5d94fd367f56a26c38_31)and neither the Members nor any other Person shall rely on any other writings or statements regarding Buyer's expectation or intention to exercise the Buyer Acquisition Option. Neither Buyer nor any of its Affiliates shall have any liability whatsoever to the Members or any of their respective Affiliates or any other Person for any claim, loss or damage of any nature that arises out of or relates in any way to its exercise or non-exercise or rescission of the Buyer Acquisition Option or termination of this Agreement, other than its obligations hereunder. Notwithstanding the foregoing, for the avoidance of doubt, the terms of this [Section 2.1(b)](#iad153e23c3af4c5d94fd367f56a26c38_31)shall no longer apply if the Members have delivered a Member Acquisition Notice in accordance with [Section 2.1(a).](#iad153e23c3af4c5d94fd367f56a26c38_31)

**Section 2.2 <u>Purchase and Sale of Interests</u>**. Subject to the satisfaction or waiver of the conditions set forth in [Article VIII](#iad153e23c3af4c5d94fd367f56a26c38_40) and the other terms and conditions of this Agreement, in the event of a Mandatory Purchase or if Buyer exercises the Buyer Acquisition Option during the Buyer Acquisition Option Term, the Members agree to sell, assign, transfer and deliver to Buyer on the Closing Date, and Buyer agrees to purchase from the Members on the Closing Date, all of the Interests, free and clear of all Encumbrances (the "<u>Acquisition</u>").

**Section 2.3&nbsp;&nbsp;&nbsp;&nbsp;<u>Estimated Closing Consideration; Allocation Schedule</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(a)[Reserved]***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Estimated Closing Payment Statement; Allocation Schedule***: No later than three (3) Business Days prior to the Closing Date, the Company shall deliver to Buyer a (i) written statement certified by an officer of the Company (the "<u>Estimated Closing Date Consideration Statement</u>") setting forth (i) a good faith estimate of the Closing Date Consideration, which shall include a good faith estimate of each of the Closing Indebtedness and the Transaction Expenses (the "<u>Estimated Closing Date Consideration</u>"), and (ii) a schedule (as may be updated from time to time in accordance with this Agreement, the "<u>Allocation Schedule</u>") setting forth (A) the wire transfer instructions of each Member, (B) the portion of the Estimated Closing Date Consideration payable to each Incentive Unit Holder in accordance the Equity Incentive Plan, the Company Operating Agreement and the equity award, which shall represent the aggregate consideration payable to the Incentive Unit Holders hereunder, (C) the Pro Rata Share of each Member (other than the Incentive Unit Holders) and (D) the portion of the Estimated Closing Date Consideration payable to each Member (other than the Incentive Unit Holders) in accordance with such Member's Pro Rata Share. The Company shall provide a reasonable level of supporting documentation for the Estimated Closing Date Consideration Statement and any additional information reasonably requested by Buyer related thereto. To the extent that Buyer disagrees in good faith with any items set forth in the Estimated Closing Date Consideration Statement, Buyer may deliver written notice of its disagreement to the Company at least one (1) Business Day prior to the Closing Date, and Buyer and the Company shall negotiate in good faith to resolve such disagreements prior to the Closing; <u>provided</u>, <u>however</u>, that if Buyer and the Company are not able to resolve any such disagreements prior to the Closing, the amount initially proposed by the

13

------

Company shall be final for purposes of determining the Estimated Closing Date Consideration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)For all purposes of this Agreement, each Member agrees and acknowledges that Buyer shall be entitled to rely on, and neither Buyer nor any of its Affiliates (including, following the Closing, the Company) shall have any Liability with respect to the Allocation Schedule, including any updates thereto pursuant to this Agreement.

**Section 2.4&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing; Closing Deliverables</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)In the case of a Mandatory Purchase or following exercise of the Buyer Acquisition Option, if applicable, and subject to the other terms and conditions hereof, the closing of the purchase and sale referred to in Section 2.2 (the "<u>Closing</u>") shall take place at the offices of Dorsey & Whitney LLP, Suite 1500, 50 South Sixth Street, Minneapolis, Minnesota 55402, at a time and date to be specified by the parties, which shall be no later than ten (10) Business Days after the satisfaction or waiver of the conditions set forth in [Article VIII](#iad153e23c3af4c5d94fd367f56a26c38_40)(other than those that by their terms are to be satisfied or waived at the Closing), or at such other time, date and location, and by such other means as the parties hereto agree in writing. The date on which the Closing occurs is referred to herein as the "<u>Closing Date</u>."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)At the Closing, the Members shall deliver to Buyer a duly executed assignment of membership interests, in form and substance reasonably satisfactory to Buyer, effectuating the assignment of the Interests owned by the Members to Buyer; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)At the Closing, the Company shall deliver or cause to be delivered to Buyer:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)copies of all consents, waivers and approvals (if any) obtained by the Company with respect to the consummation of the Acquisition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)written resignations, effective as of the Closing Date, of any and all officers, directors and managers of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)employment termination and release agreements in a form reasonably acceptable to Buyer, duly executed by each employee of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)a copy of the certificate of formation of the Company, certified as of a date not more than five (5) Business Days prior to the Closing Date by the Secretary of State of the State of Delaware;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)a certificate of good standing of the Company, issued as of a date not more than five (5) Business Days prior to the Closing Date by the Secretary of State of the State of Delaware;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)a certificate of the secretary, assistant secretary or other authorized representative of the Company, dated as of the Closing Date, in form and substance reasonably satisfactory to Buyer, as to the following matters: (A) no amendments to the certificate of formation of the Company since the date of the certified copy thereof referenced above in[Section 2.4(c)(iv)](#iad153e23c3af4c5d94fd367f56a26c38_34); (B) the Company Operating Agreement, which shall be attached thereto;

14

------

&nbsp;&nbsp;&nbsp;&nbsp;(C) the resolutions of the Members authorizing the execution and performance of this Agreement and the consummation of the transactions contemplated hereby, which shall be attached thereto; and (D) that the Company Operating Agreement and resolutions have not been amended or modified in any respect and remain in full force and effect as of the Option Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)a certificate from the Company, dated as of the Closing Date, prepared and executed in accordance with Section 1.1445-11T(d)(2) of the Code, certifying that Buyer is not required to withhold pursuant to Section 1445 of the Code;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)evidence, in form and substance reasonably satisfactory to Buyer, of the release of all Encumbrances on the assets of the Company other than Encumbrances referenced in payoff letters from each lender to the Company evidencing the aggregate amount of Closing Indebtedness outstanding as of the Closing Date (including any interest accrued thereon and any prepayment or similar penalties and expenses associated with the prepayment of such Closing Indebtedness on the Closing Date) and an agreement that, if such aggregate amount so identified is paid to such lender on the Closing Date, such Closing Indebtedness shall be repaid in full and that all Encumbrances affecting any real or personal property of the Company shall be released;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)a duly executed copy of the Escrow Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)a duly executed copy of the Transition Services Agreement, in a form reasonably satisfactory to Buyer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)the certificate referred to in [Section 8.2(e)](#iad153e23c3af4c5d94fd367f56a26c38_40)hereof; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii)such other documents and instruments as may be reasonably

requested by Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)At the Closing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Buyer shall pay the Estimated Closing Indebtedness in accordance with the pay-off letters required by [Section 2.4(c)(viii)](#iad153e23c3af4c5d94fd367f56a26c38_34)above;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Buyer shall pay the Estimated Transaction Expenses in accordance with payment instructions delivered by the Members to Buyer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)Buyer shall pay to each Member in cash by wire transfer of immediately available funds the portion of the Estimated Closing Date Consideration set forth opposite such Member's name in the Allocation Schedule in accordance with the wire instructions set forth in the Allocation Schedule;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)Buyer shall deliver $500,000 (the "<u>First Escrow Deposit</u>") (which amount, as reduced from time to time through distributions and increased from time to time in accordance with Section 2.6 or by dividends and earnings in accordance with the Escrow Agreement, is hereinafter referred to as the "<u>Escrow Fund</u>"), by wire transfer of immediately available funds, to the Escrow Agent, pursuant to the escrow agreement among Buyer, the Members and the Escrow Agent in the form attached hereto as Exhibit A (the "Es<u>crow Agreement</u>").

15

------

Agreement;

hereof; and

(v)&nbsp;&nbsp;&nbsp;&nbsp;Buyer shall deliver a duly executed copy of the Escrow Agreement;

(v)Buyer shall deliver a duly executed copy of the Transition Services

(vi)Buyer shall deliver the certificate referred to in [Section 8.3(d)](#iad153e23c3af4c5d94fd367f56a26c38_40)

(vii)Buyer shall deliver such other documents and instruments as may

be reasonably requested by the Company.

Upon payment by Buyer of the amounts described in <u>[Section 2.4(d)(iii)](#iad153e23c3af4c5d94fd367f56a26c38_34)</u>above, Buyer shall be deemed, for all purposes, to have satisfied in full the obligations of Buyer to pay any amount due to Members pursuant to this Agreement, other than any amounts that may be due pursuant to <u>[Section 2.5(e)](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_40) <u>[Section 2.6](#iad153e23c3af4c5d94fd367f56a26c38_40)</u> or <u>[Article IX](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_40) if any, and Buyer shall have no further obligation to any Member for such payments or otherwise in respect of the transactions contemplated hereby, including the purchase of the Interests.

**Section 2.5&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing Consideration Adjustment</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)***Closing Statement Preparation***. Buyer will prepare and deliver to the Members within 90 days after the Closing Date a statement (the "<u>Closing Statement</u>") which sets forth (i) an unaudited balance sheet of the Company as of the Closing Date, and (ii) a good faith estimate of each of the Closing Indebtedness and the Transaction Expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Closing Statement Review***. Within 30 days following Buyer's delivery of the Closing Statement to the Members, the Members may give Buyer a written notice stating the Members' objections to the Closing Statement (an "<u>Objection Notice</u>"). If the Members do not give Buyer an Objection Notice within such 30 day period, then the Closing Statement will be conclusive and binding upon the parties and the Closing Indebtedness and the Transaction Expenses as set forth in the Closing Statement will constitute the Final Indebtedness and the Final Transaction Expenses, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)***Independent Auditor Review***. In the event that Buyer and the Members fail to resolve all of the issues set forth in the Objection Notice within 30 days after Buyer receives the Objection Notice (the "<u>Agreement Period</u>"), (i) Buyer and the Members will retain a firm of certified public accountants designated by Buyer and reasonably acceptable to the Members (the "<u>Independent Auditors</u>") to make the determination of the Final Indebtedness and the Final Transaction Expenses in accordance with the terms of this Agreement within the 30 day period immediately following the Agreement Period, and (ii) Buyer and the Members will each provide the Independent Auditors with their respective determinations of the Closing Indebtedness and the Transaction Expenses. The Independent Auditors will consider only those items and amounts in Buyer's and the Members' respective determinations of the Closing Indebtedness and the Transaction Expenses that are identified as being items and amounts to which Buyer and the Members have been unable to agree. In resolving any such disputed item or amount, the Independent Auditors may not assign a value to any item or amount that is higher than the highest value for such item or amount claimed by either party or lower than the lowest value for such item or amount claimed by either party. The Independent Auditors' determination of the Final

16

------

Indebtedness and the Final Transaction Expenses will be based on the definitions of "Closing Indebtedness" and the "Transaction Expenses" contained in this Agreement. Assuming compliance with the immediately preceding sentence, the determination of the Final Indebtedness and the Final Transaction Expenses by the Independent Auditors will be conclusive and binding upon the parties. The fees, costs and expenses of the Independent Auditor shall be paid shall be allocated between the Members, on the one hand, and Buyer, on the other hand, in inverse proportion as the Members and Buyer may prevail on matters resolved by the Independent Auditors, which proportionate allocations shall be determined by the Independent Auditors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)***Adjustment Payment***. Upon the determination, in accordance with this[Section 2.5](#iad153e23c3af4c5d94fd367f56a26c38_37) of the Final Indebtedness, and the Final Transaction Expenses, the Closing Date Consideration will be recalculated by increasing or decreasing the Closing Date Consideration, as applicable, using finally determined amounts in lieu of the estimates of the Final Indebtedness and Final Transaction Expenses used in the calculation of the Estimated Closing Date Consideration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)If the Closing Date Consideration as recalculated pursuant to this[Section 2.5](#iad153e23c3af4c5d94fd367f56a26c38_37) is greater than the Estimated Closing Date Consideration, then the Members shall deliver an updated Allocation Schedule setting forth the portion of such excess amount payable to each Member in accordance with the Company Operating Agreement as of immediately prior to the Closing, and within five (5) Business Days after the receipt of such updated Allocation Schedule, Buyer will pay the Members such excess amount in accordance with the allocation set forth in the updated Allocation Schedule. Such payment will be made in cash by wire transfer of immediately available funds to the account(s) set forth in the Allocation Schedule.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)If the Closing Date Consideration as recalculated pursuant to this[Section 2.5](#iad153e23c3af4c5d94fd367f56a26c38_37)is less than the Estimated Closing Date Consideration, then (i) each Member (other than the Incentive Unit Holders) will pay to Buyer such Member's Pro Rata Share of such deficiency to an account designated in writing by Buyer within five (5) Business Days after the determination of the Final Indebtedness and the Final Transaction Expenses or (ii) at Buyer's sole discretion, Buyer shall be entitled to recover such deficiency from the Escrow Fund. Such payments shall be made in cash by wire transfer to an account designated by Buyer.

**Section 2.6&nbsp;&nbsp;&nbsp;&nbsp;<u>Contingent Payments</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Following the Closing, in the event of the First IDE Approval Milestone, then, within thirty (30) Business Days following the date of the final determination that the First IDE Approval Milestone has occurred, Buyer shall pay the First Contingent Payment as follows: (i) to the Escrow Agent, the amount of $750,000 to be held in the Escrow Fund (the "<u>Second Escrow Deposit</u>"); and (ii) to the Members, the amount of $14,250,000, by wire transfer of immediately available funds in accordance with allocation set forth in the updated Allocation Schedule delivered pursuant to <u>Section 2.6(c)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Following the Closing, in the event of the Second IDE Approval Milestone, then, within thirty (30) Business Days following the date of the final determination that the Second IDE Approval Milestone has occurred, Buyer shall pay the Second Contingent Payment as follows: (i) to the Escrow Agent, the amount of $750,000 to be held in the Escrow Fund (the "<u>Third Escrow Deposit</u>"); and (ii) to the Members, the amount of $14,250,000, by

17

------

wire transfer of immediately available funds in accordance with allocation set forth in the updated Allocation Schedule delivered pursuant to <u>Section 2.6(c)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)The First Contingent Payment and the Second Contingent Payment shall represent only a contingent right to receive a payment from Buyer, subject to achievement of the First IDE Approval Milestone or the Second IDE Approval Milestone, as applicable. The First Contingent Payment and the Second Contingent Payment shall not possess any attributes of capital stock and shall not entitle the Members to any rights of any kind other than as specifically set forth herein. Any attempted assignment, pledge, hypothecation, transfer or other disposition of the right to receive such payments by any Member (other than as set forth in<u>[Section 11.8](#iad153e23c3af4c5d94fd367f56a26c38_46)</u>) shall be null and void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Each Member acknowledges that, after the Closing, (i) there can be no assurance that the First Contingent Payment or the Second Contingent Payment will be received, and (ii) Buyer owes no fiduciary duty, express or implied, to the Members, such as an implied duty of good faith and fair dealing, in the exercise of its direct control over the governance and financial control of the Company or the Business with respect to such payments but, rather, the parties intend the express provisions of this Agreement to govern their contractual relationship with respect to such payments. Notwithstanding the foregoing, Buyer agrees and covenants that Buyer, its Affiliates or anyone on their behalf, shall not take, and that they shall not permit any third party to take, any actions in bad faith in their performance of the Business or otherwise, which are intentionally undertaken with the express purpose of, and have the actual effect of preventing the First IDE Approval Milestone or the Second IDE Approval Milestone.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Notwithstanding the foregoing, at least five (5) Business Days prior to any payment of the First Contingent Payment or the Second Contingent Payment, as applicable, the Members shall deliver to Buyer an updated Allocation Schedule setting forth the portion of such amounts payable to each Member in accordance with the Company Operating Agreement as of immediately prior to the Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)Notwithstanding anything to the contrary in this Agreement, in the event that a First Contingent Payment or a Second Contingent Payment would be payable on or prior to the Closing, payments contemplated by this Agreement with respect thereto shall be made at the Closing and shall be deemed to have occurred for all purposes under this Agreement as of immediately after the Closing.

**Section 2.7 <u>Cash</u>**. For the avoidance of doubt, any cash remaining on the balance sheet of the Company as of the Closing (including any remaining proceeds of the loan issued to the Company in accordance with the Loan Documents) shall continue to remain with the Company following the Closing and will not be distributed to any of the Members.

**Section 2.8 <u>Tax</u>**. Buyer shall be entitled to deduct and withhold from any payment which comes due under this Agreement all Taxes that Buyer may be required to deduct

18

------

and withhold under any provision of Tax Law. All such withheld amounts shall be treated as paid to the Members hereunder.

**ARTICLE III**

**REPRESENTATIONS AND WARRANTIES OF THE MEMBERS**

Except as set forth in the Disclosure Schedules, the Members represent and warrant to Buyer as follows:

**Section 3.1 <u>Authority of the Members</u>.** Each Member has all necessary power and authority to enter into this Agreement, to carry out such Member's obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by each Member, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal, valid and binding obligation of such Member, enforceable against such Member in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

**Section 3.2 <u>No Conflicts; Consents</u>**. The execution, delivery and performance by each Member of this Agreement and the other Transaction Documents to which such Member is a party, and the consummation by such Member of the transactions contemplated hereby and thereby, do not and will not: (a) result in a violation or breach of any provision of any Law or Governmental Order applicable to such Member; or (b) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of or the creation of any Encumbrance, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under or result in the acceleration of any material agreement to which such Member is a party or any of its properties or other assets is subject. No consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to any Member in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby.

**Section 3.3&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Proceedings; Governmental Orders</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)There are no actions, suits, claims, investigations or other legal proceedings pending or, to the Knowledge of the Company, threatened against or by any Member and relating to such Member's ownership of the Interests or status as a member of the Company, challenging the validity or enforceability of this Agreement or seeking to enjoin or prohibit consummation of the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)There are no outstanding Governmental Orders and no unsatisfied judgments, penalties or awards against or affecting any Member and relating to such Member's ownership of the Interests or status as a member of the Company, challenging the validity or enforceability of this Agreement or seeking to enjoin or prohibit consummation of the transactions contemplated hereby.

**Section 3.4 <u>Ownership of Interests</u>**. Each Member is the sole legal and beneficial owner of the Interests in the Company as set forth on [Section 3.4](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure

19

------

Schedules, and such ownership is, and such delivery shall be made, free and clear of all Encumbrances. Each Member has been the sole legal and beneficial owner of the Interests since the formation of the Company and has not granted (and there do not exist) any subscriptions, options, rights, warrants, calls, voting agreements, commitments or arrangements of any kind with respect to the Interests. Pursuant to this Agreement, upon Closing, each Member will sell to Buyer all securities, voting rights, economic interests, profits interests and membership interests that such Member legally or beneficially owns or has any rights or interests in or with respect to the Company, and after such sale by the Members hereunder, each Member will have sold its entire membership interest in the Company to Buyer, and no Member will have any further ownership of or rights to (or rights to acquire any ownership of), and each Member will cease to be a member of, the Company.

**Section 3.5 <u>Brokers</u>**. No broker, finder or investment banker is entitled to any brokerage, finder's or other similar fee or commission in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of any Member.

**ARTICLE IV**

**REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND THE MEMBERS**

Except as set forth in the Disclosure Schedules, the Members and the Company, jointly and severally, represent and warrant to Buyer as follows:

**Section 4.1 <u>Organization and Qualification of the Company</u>**. The Company is a limited liability company duly organized, validly existing and in good standing under the Laws of the Delaware and has all necessary organizational power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as it is currently conducted. [Section 4.1](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules sets forth each jurisdiction in which the Company is licensed or qualified to do business, and the Company is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business as currently conducted makes such licensing or qualification necessary, except where the failure to be so licensed, qualified or in good standing would not have a Material Adverse Effect.

**Section 4.2 <u>Authority of the Company</u>**. The Company has all necessary organizational power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by the Company of this Agreement, the performance by the Company of its obligations hereunder and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all requisite organizational action on the part of the Company and the Members. This Agreement has been duly executed and delivered by the Company, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,

20

------

moratorium or similar Laws affecting creditors' rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

**Section 4.3 <u>Capitalization</u>**. The Interests owned by the Members in the Company are set forth on [Section 4.3](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedule constitute all of the issued and outstanding equity interests of the Company. The Interests have been duly authorized and validly issued and are fully paid and nonassessable, were issued in compliance with all applicable Laws, and were not issued in violation of, and are not subject to, any preemptive rights or any other agreement, arrangement or commitment to which the Members or the Company is party. There are no outstanding or authorized options, warrants, rights, subscriptions, claims of any character, agreements, obligations, convertible or exchangeable securities, or other commitments contingent or otherwise, relating to the capital stock of, or other equity or voting interest in, the Company, pursuant to which the Company or the Members is or may become obligated to issue, deliver or sell or cause to be issued, delivered or sold, shares of capital stock of or other equity or voting interests in, the Company or any securities convertible into, exchangeable for, or evidencing the right to subscribe for or acquire, any shares of the capital stock of or other equity or voting interests in, the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or similar rights with respect to the capital stock of, or other equity or voting interests in, the Company. There are no authorized or outstanding bonds, debentures, notes or other Indebtedness the holders of which have the right to vote (or convertible into, exchangeable for, or evidencing the right to subscribe for or acquire securities having the right to vote) with the equityholders of the Company on any matter. There are no proxies and no voting agreements or voting trusts or other voting arrangements with respect to any capital stock of, or other equity or voting interests in, the Company.

**Section 4.4 <u>No Subsidiaries</u>**. The Company does not own, or have any ownership interest in, any other Person.

**Section 4.5 <u>No Conflicts; Consents</u>**. The execution, delivery and performance by the Company of this Agreement, and the consummation of the transactions contemplated hereby do not and will not: (a) result in a violation or breach of any provision of the articles of formation of the Company or the Company Operating Agreement; (b) result in a violation or breach of any provision of any Law or Governmental Order applicable to the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;(c)require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of or the creation of any Encumbrance, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under or result in the acceleration or create in any party the right to accelerate, terminate, modify or cancel any Material Contract, except in the case of clause (c) as set forth in [Section 4.5](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules (the "<u>Consents</u>"). No consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to the Company in connection with the execution and delivery of this Agreement and the consummation of the

21

------

transactions contemplated hereby, except for such consents, approvals, Permits, Governmental Orders, declarations, filings or notices as are set for[th in Section 4.5](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules.

**Section 4.6&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)As of the date of this Agreement, the Company does not have any regularly prepared financial statements. As of the Schedule Delivery Date, the Company has made available to Buyer unaudited consolidated balance sheet and statements of income and cash flows for the Business as of and for the fiscal year ended on the Most Recent Financials Date (the "<u>Annual Financial Statements</u>"), and the unaudited consolidated balance sheet (the "<u>Most Recent Balance Sheet</u>") and statements of income and cash flows for the Business as of and for the period beginning on the Most Recent Financials Date and ending on the Most Recent Balance Sheet Date (the "<u>Interim Financial Statements</u>", and together with the Annual Financial Statements, the "<u>Financial Statements</u>"). Except as otherwise noted in the Financial Statements, the Financial Statements present fairly, in all material respects, the financial condition of the Business as of the dates thereof and the results of operations and cash flows for the periods then ended, except that the Interim Financial Statements do not contain footnotes and are subject to normal year-end adjustments that will not be material in amount or effect, either individually or in the aggregate. Except as may be indicated in the notes thereto, the Financial Statements have been prepared from, and are in accordance with, the books and records of the Company, which books and records are complete and correct in all material respects and have been regularly kept and maintained in accordance with the Company's normal and customary practices.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The accounts receivable and other receivables reflected on the Financial Statements, and those arising in the ordinary course of business after the date thereof, (i) have arisen from bona fide transactions in the ordinary course of business, and (ii) are not subject to valid counterclaims or setoffs other than adjustments and modifications in the ordinary course of business of the Company, consistent with past practice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)All inventory of the Business as of the Closing Date, whether or not reflected in the Most Recent Balance Sheet, consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All such inventory will be owned by the Company as of the Closing Date free and clear of all Encumbrances, and no inventory is held on a consignment basis. The quantities of each item of inventory (whether raw materials, work-in- process or finished goods) are not excessive, but are reasonable in the present circumstances of the Business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)[Section 4.6(d)](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules sets forth a full and complete list of all bank accounts and safe deposit boxes of the Company, the number of each such account or box, and the names of the Persons authorized to draw on such accounts or to access such boxes. All cash in such accounts is held in demand deposits and is not subject to any restriction as to withdrawal other than customary restrictions due to bank policies not specific to the Company.

**Section 4.7&nbsp;&nbsp;&nbsp;&nbsp;<u>Undisclosed Liabilities</u>**. As of the Closing Date, the Company and, with respect to the Business, the Members, and their respective Affiliates have no Liabilities,

22

------

except (i) those which are reflected or reserved against in the Most Recent Balance Sheet as of the Most Recent Balance Sheet Date; (ii) those which have been incurred in the ordinary course of business since the Most Recent Balance Sheet Date and which are not in the aggregate material in amount (to the extent such liabilities are included as Closing Indebtedness); and (iii) the Transaction Expenses.

**Section 4.8 <u>Absence of Certain Changes, Events and Conditions</u>**. Except as contemplated by this Agreement or as set forth on [Section 4.8](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules, from the Most Recent Balance Sheet Date until the Closing Date, the Business and the Company have operated in the ordinary course of business and there has not been, with respect to the Business or the Company, any:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)event, occurrence or development that has had or would reasonably be expected to have a Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)split, combination or reclassification of any Interests or other equity interests in the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)issuance, sale or other disposition of any Interests or other equity interests in the Company, or grant of any options, warrants or other rights to purchase or obtain (including upon conversion, exchange or exercise) any Interests or other equity interests in the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)declaration or payment of any dividends or distributions on or in respect of, or redemption, purchase or acquisition of, any Interests or other equity interests in the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)material change in any method of accounting or accounting practice, except as required by GAAP or as disclosed in the notes to the Financial Statements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)incurrence, assumption or guarantee of any indebtedness for borrowed money, except unsecured current obligations and liabilities incurred in the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)sale or other disposition of any of the assets shown or reflected on the Most Recent Balance Sheet, except in the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)transfer, assignment or grant of any license or sublicense of any material rights under or with respect to any Business IP;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)material damage, destruction or loss (whether or not covered by insurance)

to its property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)any material capital expenditures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)imposition of any Encumbrance upon any properties, capital stock or other

equity interests or assets, tangible or intangible;

23

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)acquisition by merger or consolidation with, or by purchase of a substantial portion of the assets or stock of, or by any other manner, any business or any Person or any division thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)adoption of any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)action by the Company to make, change or rescind any Tax election, amend any Tax Return or change any Tax accounting method, or take any action, omit to take any action or enter into any other transaction that would have the effect of increasing the Tax liability or reducing any Tax asset of Buyer; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)any agreement to do any of the foregoing, or any action or omission that would result in any of the foregoing.

**Section 4.9&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Contracts</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)[Section 4.9(a)](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules lists each of the following Contracts and other agreements of the Company Group to the extent related to the Business (together with all Leases listed in [Section 4.10(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules, collectively, the "<u>Material Contracts</u>"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)each agreement (A) involving aggregate consideration in excess of

$50,000 or (B) requiring performance by any party more than one year from the date hereof, which cannot be cancelled by the Company without penalty or without more than 90 days' notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)all agreements that relate to the sale of any of the assets related to the Business for consideration in excess of $50,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)all agreements that relate to the acquisition or disposition of any business, a material amount of stock or assets of any other Person or any real property (whether by merger, sale of stock, sale of assets or otherwise);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)all agreements that relate to any Business IP;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)all broker, distributor, dealer, manufacturer's representative, franchise, agency, sales promotion, market research, marketing consulting and advertising agreements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)all&nbsp;&nbsp;&nbsp;&nbsp;agreements&nbsp;&nbsp;&nbsp;&nbsp;with&nbsp;&nbsp;&nbsp;&nbsp;physicians,&nbsp;&nbsp;&nbsp;&nbsp;independent&nbsp;&nbsp;&nbsp;&nbsp;contractors&nbsp;&nbsp;&nbsp;&nbsp;or consultants (or similar arrangements);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)all agreements relating to indebtedness (including guarantees) of the Company or the Business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)all agreements with any Governmental Authority;

24

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)all agreements that would, upon assignment to the Company, limit or purport to limit the ability of the Company to compete in any line of business or with any Person or in any geographic area or during any period of time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)all agreements that would, upon assignment to the Company, require the Company to purchase its total requirements of any product or service from a third party or that contain "take or pay" provisions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)any agreements that would, upon assignment to the Company, provide for any joint venture, partnership or similar arrangement by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii)all agreements between or among the Company or the Members on the one hand and the Members or any member of the Company Group (other than the Company) on the other hand; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii)any agreement not otherwise disclosed in [Section 4.9](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules which is material to the Business and not entered into in the ordinary course of business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Company has made available to Buyer a correct and complete copy of each Material Contract, including all amendments, material waivers or modifications thereto. Each Material Contract is in full force and effect and (i) as of the date hereof, is the legal, valid and binding obligation of the respective member of the Company Group who is party to such Material Contract, (ii) as of the Closing Date, will be the legal, valid and binding obligation of the Company, and (iii) to the Knowledge of the Company, is the legal, valid and binding obligation of the other parties thereto, enforceable against each of them in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity). No member of the Company Group is in material default under, or in material breach or violation of, and an event has not occurred that (with or without notice, lapse of time or both) could reasonably be expected to constitute a material default by any member of the Company Group under any such Material Contract. To the Knowledge of the Company, no other party to any such Material Contract is in material default under any such Material Contract. No member of the Company Group has received any written notice or, to the Knowledge of the Company, oral notice from any counterparties in connection with any of the Material Contracts of (A) any material breach or default under any Material Contract, (B) the fact that any such party will terminate, not renew, cancel or substantially decrease its business with the Company, or (C) any claim for damages or indemnification with respect to the products or performance of services pursuant to any Material Contract.

**Section 4.10&nbsp;&nbsp;&nbsp;&nbsp;<u>Title to Assets; Sufficiency of Assets; Real Property</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)As of the date hereof, the Company Group has good and valid title to, or a valid leasehold interest in, all assets (tangible and intangible), rights and properties related to the Business. As of the Closing Date, the Company will have good and valid title to, or a valid leasehold interest in, all assets (tangible and intangible), rights and properties used to conduct the

25

------

Business, which will constitute all of the assets, rights and properties necessary for the conduct of the Business. All such properties and assets (including leasehold interests) are free and clear of Encumbrances except for the following (collectively referred to as "<u>Permitted Encumbrances</u>"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)liens for Taxes not yet due and payable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)liens associated with the Loan Documents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)mechanics, carriers', workmen's, repairmen's or other like liens arising or incurred in the ordinary course of business and securing obligations that are not delinquent and that will be paid and discharged in the ordinary course of business; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)easements, rights of way, zoning ordinances and other similar encumbrances affecting Real Property, that, singularly or in the aggregate, will not materially interfere with the ownership, use or operation of such Real Property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)[Section 4.10(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules lists the street address of each parcel of Real Property used in connection with the Business, and identifies all Real Property leases relating thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)All tangible assets that are necessary to conduct the Business, taken as a whole, are generally in operating condition in repair adequate for the purposes for which such assets are presently used, except for ordinary wear and tear or immaterial defects which do not materially adversely affect use and operation in the ordinary course of business, and have been maintained in accordance with normal industry practices.

**Section 4.11&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)As used herein, the term "<u>Intellectual Property</u>" means all intellectual property rights arising under the laws of the United States or any other jurisdiction, including the following: (i) trade names, trademarks and service marks (registered and unregistered), domain names, trade dress and similar rights and applications to register any of the foregoing (collectively, "<u>Marks</u>"); (ii) patents, patent applications, patentable inventions and rights in respect of utility models or industrial designs and invention disclosures (collectively, "<u>Patents</u>"); (iii) copyrights, copyrightable works, whether registered or unregistered, and registrations and applications therefor (collectively, "<u>Copyrights</u>"); and (iv) trade secrets, know-how, inventions, discoveries, methods, processes, technical data, specifications, research and development information, technology, data bases and other proprietary or confidential information, including customer lists, in each case that derives economic value (actual or potential) from not being generally known to other persons who can obtain economic value from its disclosure, but excluding any Copyrights or Patents that cover or protect any of the foregoing (collectively, "<u>Trade Secrets</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)[Section 4.11(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)(1) of the Disclosure Schedules sets forth an accurate and complete list of all Marks related to the Business owned by or licensed to the Company Group (collectively, "<u>Business Marks</u>"), [Section 4.11(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)(2) of the Disclosure Schedules sets forth an accurate and complete list of all Patents related to the Business owned by or licensed to the Company Group (collectively, "<u>Business Patents</u>"), and [Section 4.11(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)(3) of the Disclosure Schedules sets forth an accurate and complete list of all registered Copyrights and domain names

26

------

and URLs related to the Business, owned by or licensed to the Company Group (collectively, "<u>Business Copyrights</u>" and, together with the Business Marks and the Business Patents, the "<u>Business IP</u>"). All Business IP (excluding any pending applications included in the Business IP) is valid and enforceable and, except as set forth on [Section 4.11(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)(4) of the Disclosure Schedules, no adverse written notice or claim challenging the validity or enforceability or alleging the misuse of any Business IP has been received by any member of the Company Group. To the Knowledge of the Company, all applications for issuance of Business Patents and all applications to register Business Marks are in good standing and without challenge by any third party. The Company Group has the sole and exclusive right to bring actions for infringement or unauthorized use of the Business IP owned by the Company Group, and after the Closing Date, the Company will have, the sole and exclusive right to bring actions for infringement or unauthorized use of the Business IP owned by the Company as of the Closing Date. No member of the Company Group has taken any action (or failed to take any action) that would reasonably be expected to result in the abandonment, cancellation, forfeiture, relinquishment, invalidation or unenforceability of any Business IP, and all filing, examination, issuance, post registration and maintenance fees, annuities and the like that have come due and are required to maintain, preserve or renew any Business IP owned by the Company Group or, to Knowledge of the Company, licensed to the, the Company Group have been timely paid. Except as set forth on [Section 4.11(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)(5) of the Disclosure Schedules, with respect to all Business IP owned by the Company Group, and to the Knowledge of the Company with respect to all Business IP licensed to the Company Group, there are no filings, payments or other actions that were required to have been or are required to be made or taken on or prior to the date hereof that were not timely made or taken, including the payment of any registration, maintenance or renewal fees or the filing of any responses to office actions, documents, applications or certificates, for the purposes of complying with legal requirements to obtain, maintain, preserve or renew any material Business IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)All employees, agents, consultants or contractors of the Company Group who have contributed to or participated in the creation or development of any material patentable invention, Trade Secret, or copyrightable material, in each case relating to the Business either:

&nbsp;&nbsp;&nbsp;&nbsp;(i) is a party to an agreement (A) under which the applicable member of the Company Group is deemed to be the original owner/author of all property rights therein; and (B) which includes a provision assigning to the applicable member of the Company Group all right, title and interest in such work or whereby such employee, agent, consultant, or contractor agrees to assign all right, title and interest in such work; or (ii) has executed an assignment or an agreement to assign in favor of such member of the Company Group all right, title and interest in such work.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)The Company Group has taken such steps to protect its rights in the Intellectual Property related to the Business and owned by the Company Group and maintain the confidentiality of all of the Trade Secrets related to the Business as are consistent with reasonably prudent business practices employed by similarly situated businesses operating in the same industry as the Company Group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)The Company Group owns or possesses adequate licenses or other valid rights to use, and as of the Closing Date the Company will own or possess adequate licenses or other valid rights to use, all of the Intellectual Property that is necessary for the conduct of the Business. None of such owned Intellectual Property or, to the Knowledge of the Company, such

27

------

licensed Intellectual Property is subject to any material outstanding order, judgment, or stipulation restricting the use or exploitation thereof by the Company Group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)Except as set forth on [Section 4.11(f)](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules, the Company Group has not granted to any third party any rights under any Intellectual Property related to the Business and owned by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)The Company Group owns, and as of the Closing Date the Company will own, exclusively all right, title and interest to the Business IP (other than the Business IP licensed to the Company Group or, as of the Closing Date, licensed to the Company), free and clear of all Encumbrances other than Permitted Encumbrances, and no member of the Company Group has received any written or, to the Knowledge of the Company, oral notice or claim challenging such member's ownership of any of such Intellectual Property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)The conduct of the Business, including the use or other exploitation of the Intellectual Property owned by the Company Group, has not infringed, misappropriated, diluted or violated, and does not infringe, misappropriate, dilute or violate any Intellectual Property of any third party, and the Company Group has not received any written or, to the Knowledge of the Company, oral notice or claim asserting or suggesting that any such infringement, misappropriation, violation, or dilution has occurred. To the Knowledge of the Company, no third party is misappropriating or infringing any Intellectual Property owned by or licensed to the Company Group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)To the Knowledge of the Company, at no time during the conception of or reduction to practice of any Intellectual Property related to the Business and owned by the Company Group was any developer, inventor or other contributor to such Intellectual Property operating under any grants from any Governmental Authority or other third party, performing research sponsored by any Governmental Authority or other third party or subject to any employment agreement or invention assignment or nondisclosure agreement or other obligation with any Governmental Authority or other third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)No member of the Company Group is subject to any agreement with any standards body or other similar entity that would obligate such member of the Company Group to grant licenses to any Person with respect to, or otherwise impair or limit such member's control of, any Business IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)[Section 4.11(k)](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules contains a complete and accurate list of any Open Source that is incorporated into, integrated or bundled with, or otherwise used in or with any software used in the Business, identification of the applicable Open Source license and a description of the manner in which such Open Source has been used in software used in the Company Products. No software used in the Company Products is, has become or will become, upon commercialization of any product, subject to Open Source disclosure obligations that would obligate the Company Group, or after the Closing Date, the Company, to disclose, make available, offer or deliver any portion of the source code of any such software used in the Company Products to any third party.

28

------

**Section 4.12 <u>Insurance</u>**. [Section 4.12](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules sets forth a list, as of the date hereof, of all insurance policies related to the Business that are maintained by the Company Group or with respect to which any member of the Company Group is a named insured or otherwise the beneficiary of coverage (collectively, the "<u>Insurance Policies</u>") and true and complete copies of such Insurance Policies have been made available to Buyer. Such Insurance Policies are in full force and effect on the date of this Agreement and all premiums due on such Insurance Policies have been timely paid and the Company Group is otherwise in compliance in all material respects with the terms of such policies. No member of the Company Group has received any written notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of such Insurance Policies. There are no material disputes with the underwriters of any such policies or any material claims pending under such policies as to which coverage has been questioned, denied or disputed by the underwriters of such policies.

**Section 4.13&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Proceedings; Governmental Orders</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)There are no actions, suits, claims, investigations or other legal proceedings pending or, to the Knowledge of the Company, threatened against or by the Company Group affecting any of the properties or assets related to the Business or challenging the enforceability of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)There are no outstanding Governmental Orders and no unsatisfied judgments, penalties or awards against or affecting the Company or any of the properties or assets related to the Business.

**Section 4.14&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Laws; Permits</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Company Group is and has been in compliance in all material respects with all Laws applicable to the Business or the properties or assets related to the Business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)All material Permits required for the Company Group to conduct the Business have been obtained by it, are valid and in full force and effect and are being complied with in all material respects. As of the Closing Date, all such Permits will be held by the Company. A true, correct and complete list of all such material Permits is set forth in [Section 4.14(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules.

**Section 4.15&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory Matters</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)There is no false information or significant omission in any product application or product-related submission to the U.S. Food and Drug Administration ("<u>FDA</u>") or comparable foreign Governmental Authority with respect to the Company Products.[Section 4.15(a)](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedule lists each jurisdiction for which the Company has received regulatory approval to engage in clinical trials, manufacture, distribute and/or sell the Company Products and the nature of such approval.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Neither the Company nor any of its Affiliates has received any warning letter from the FDA or any other Governmental Authority related to the Company Products or the Business. Neither the Company nor any of its Affiliates has received any verbal or written notification from the FDA or any other Governmental Authority related to the Business or the

29

------

Company Products (i) that any product approval is withdrawn or modified or that such an action is under consideration, (ii) contesting the uses of or the labeling and promotion of any such products, (iii) with respect to any other enforcement actions under any Health Care Legal Requirement, or (iv) otherwise alleging or asserting material noncompliance with any Health Care Legal Requirement. Without limiting the foregoing, with respect to the Business, the Company is in compliance, in all material respects, with all current applicable statutes, rules, regulations, guidelines, policies or orders administered or issued by the FDA and comparable foreign Governmental Authorities in connection with the Business, including (i) the FDA's Quality System Regulation, 21 C.F.R. Part 820, (ii) the Laws and regulations promulgated under the Medical Device Directive in the European Union and (iii) any other foreign Laws pertaining to medical device products. To the Company's Knowledge, there are no facts which furnish any reasonable basis for any Form FDA-483 observations or regulatory or warning letters from the FDA, Section 305 notices, or other similar communications from the FDA or any other Governmental Authority, in each case related to or arising from the operation of the Business. There have been no recalls, corrections, repairs, replacements, refunds, safety alerts (or other notice relating to an alleged lack of safety, efficacy or regulatory compliance of any of the Company Products), detentions, withdrawals, seizures, termination or suspension of manufacturing, or other adverse regulatory actions requested or threatened relating to any of the Company Products, and no field notifications, field corrections or alerts, or, to the Knowledge of the Company, any facilities where any such products are produced, processed, packaged or stored, and the Company has not within the last five (5) years, either voluntarily or at the request of any Governmental Authority, initiated or participated in a recall, correction, repair, replacement, refund, safety alert (or other notice relating to an alleged lack of safety, efficacy or regulatory compliance of any of the Company's products), detention, withdrawal, seizure, termination or suspension of manufacturing or provided post-sale warnings regarding any of the Company Products. With respect to the Business, the Company is and has been in material compliance with FDA's registration and listing requirements to the extent required by applicable Health Care Legal Requirements, and the Company Products, if so required, are in conformance in all material respects with applicable Health Care Legal Requirements. To the Company's Knowledge, there are no facts which are reasonably likely to cause (1) the recall, market withdrawal or replacement of any of the Company Products sold or intended to be sold; (2) a change in the marketing classification or a material change in the labeling of any such product, or (3) a termination or suspension of the marketing of such product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)The Company maintains documentation showing that components supplied to the Company with respect to the Company Products are manufactured in accordance with the Company's specifications therefor. The processes used to produce the Company Products are accurately described in documents maintained by the Company, and such documents have been made available to Buyer. Such processes are adequate to ensure that commercial quantities of the Company Products conform to the specifications established therefor and are (i) of merchantable quality, (ii) salable in the ordinary course of business at prevailing market prices, (iii) free from defects in design, material and workmanship, and (iv) suitable for their intended purposes and efficacy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)The Company Group is in compliance with all applicable Health Care Legal Requirements applicable to the Business. All documentation, correspondence, reports, data, analyses and certifications relating to or regarding any of the Company Products filed or delivered

30

------

by or on behalf of the Company Group to any Governmental Authority were true and accurate on the date filed or furnished (or were corrected in or supplemented by a subsequent filing) and remains true and accurate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)All billing practices of the Company with respect to the Business to all third party payor programs (whether private, commercial or governmental) have been conducted in compliance in all material respects with all Health Care Legal Requirements and the billing guidelines of such programs. To the Knowledge of the Company, with respect to the Business, the Company has in all material respects timely and accurately filed all claims and other reports required to be filed prior to the date hereof with respect to all Programs, all fiscal intermediaries and/or carriers, and other insurance carriers ("<u>Payor Claims</u>"). All such Payor Claims and reports are true and correct in all material respects. The Company has paid or caused to be paid all known and undisputed refunds, overpayments, discounts or adjustments that have become due pursuant to such Payor Claims.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)The Company and, with respect to the Business, the Members, and each of their respective Affiliates are complying with all Health Care Legal Requirements, including Health Care Legal Requirements applicable to privacy or security of individually identifiable health information. The Company Group has not suffered any unauthorized acquisition, access, use or disclosure of any individually identifiable health information that, individually or in the aggregate, compromises the security or privacy of such individually identifiable health information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)Neither the Company Group nor any employee of the Company Group has been excluded, suspended or debarred from participating in any federal health care program (as defined in 42 U.S.C. §1320a-7b(f)) or been subject to sanction pursuant to 42 U.S.C. §1320a-7a or 1320a-8 or been convicted of a crime described at 42 U.S.C. §1320a-7b. To the Knowledge of the Company, no such exclusions are threatened nor is there any basis for such exclusions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)The Company's operation of the Business is and has been in compliance in all material respects with all Laws relating to export control and trade sanctions or embargoes and the Company, with respect to the Business, (i) have no pending voluntary self-disclosures with respect to applicable export or reexport control or sanctions Laws of any and all applicable jurisdictions, including the Export Administration Regulations with the Bureau of Industry and Security of the U.S. Department of Commerce, sanctions and embargo executive orders and regulations administered by the Office of Foreign Assets Control of the U.S. Treasury Department, and the respective executive orders and the regulations promulgated thereunder, all as amended from time to time, (ii) have not received written notice from any Governmental Authority that the Company is under criminal or civil investigation concerning any of such export control laws, and

&nbsp;&nbsp;&nbsp;&nbsp;(iii)have at all times acted without material violation and in material compliance with the Export Administration Regulations with the Bureau of Industry and Security of the U.S. Department of Commerce.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The Company Group is and has been, in compliance with all Privacy and Security Laws and privacy policies applicable to it or the operation, use, occupancy or ownership of its assets or properties or the conduct of the Business. No written notice has been received by the Company Group from any Governmental Authority alleging a violation of or liability under

31

------

any Privacy and Security Law. The Company Group has in place compliance programs reasonably designed to cause the Company Group to be in compliance with all applicable Privacy and Security Laws. The Company Group has not made or suffered any unauthorized access, use or disclosure of any Personally Identifiable Information that, individually or in the aggregate, compromises the security or privacy of such Personally Identifiable Information or required notification to any Person. The Company has not notified, either voluntarily or as required by Law, any affected Person, any Governmental Authority or the media of any breach of Personally Identifiable Information. The Company Group is not currently conducting or planning to conduct any investigation as to whether any such notification is required. The Company Group has not been notified by any third party vendor or service provider that the third party vendor or service provider has suffered an unauthorized acquisition, access, use or disclosure of any Personally Identifiable Information that is owned or licensed by the Company Group.

**Section 4.16&nbsp;&nbsp;&nbsp;&nbsp;<u>Environmental Matters</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Company is, and in the past 6 years has been, in compliance in all material respects with all applicable Environmental Laws. The Company has not received notice of, and is not the subject of, any actions, demands, or notices by any person (i) alleging liability under or non-compliance with any Environmental Law or (ii) relating to the Release, alleged Release, presence or alleged presence of Hazardous Materials in, under or upon the real property leased by the Company or any offsite disposal facility or location.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Company has no material liability under any Environmental Law nor is it responsible for any material liability of any other Person under any Environmental Law.

**Section 4.17&nbsp;&nbsp;&nbsp;&nbsp;<u>Employee Benefit Matters</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Set forth on [Section 4.17(a)](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules is a list of all Employee Benefit Plans established, maintained or contributed to by the Company Group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Company Group has delivered or caused to be delivered or made available to Buyer copies of (i) each current Employee Benefit Plan, together with the most recent amendments thereto, and related trust agreement or other funding instrument, as well as the most recent Internal Revenue Service determination letter, opinion or advisory related to each Employee Benefit Plan qualified under Section 401(a) or 501 of the Code, (ii) IRS Form 5500 for the three most recently completed plan years for each Employee Benefit Plan required to file such Form and any related audited financial statements and opinions; (iii) the most recent Summary Plan Description (plus all subsequent Summaries of Material Modification) for each Employee Benefit Plan subject to the Summary Plan Description requirements of Section 104(b) of ERISA, (iv) all material communications to or from any governmental authority (including the Internal Revenue Service and Department of Labor) concerning any Employee Benefit Plan within the past three

&nbsp;&nbsp;&nbsp;&nbsp;(3) years, and (v) with respect to each Employee Benefit Plan qualified under Section 401(a) of the Code, test results for the prior plan year demonstrating such Employee Benefit Plan's compliance with the applicable coverage, annual additions and discrimination rules under the Code.

32

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)The Company Group (including all employers, whether or not incorporated, that are treated together with the Company Group as a single employer within the meaning of Section 414 of the Code) does not maintain or contribute to, and has not maintained or contributed to in the six (6) years prior to Closing, an Employee Benefit Plan that is either (i) subject to Title IV of ERISA, (ii) a "multiemployer plan" within the meaning of Section 3(37) of ERISA or

&nbsp;&nbsp;&nbsp;&nbsp;(iii) subject to the minimum funding standards of Section 412 of the Code or Section 302 of ERISA. No Employee Benefit Plan is a multiple employer plan within the meaning of Section 413(c) of the Code. No Employee Benefit Plan is a "multiple employer welfare arrangement" as defined in Section 3(40) of ERISA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Each Employee Benefit Plan conforms to and has been operated and administered in material compliance with the requirements of ERISA, the Code and all other applicable Laws. To the Knowledge of the Company, there are no facts relating to any Employee Benefit Plan that (i) have resulted in a "prohibited transaction" (within the meaning of Section 4975 of the Code or Section 406 of ERISA) or otherwise have resulted in or could reasonably result in the imposition of an excise tax, penalty or similar liability under ERISA or the Code; (ii) have resulted in a breach of fiduciary duty or violation of Part 4 of Title I of ERISA; or

&nbsp;&nbsp;&nbsp;&nbsp;(iii) could reasonably result in any material liability (whether or not asserted as of the date hereof) under ERISA, the Code, any other applicable Laws or otherwise, other than liability for benefit claims and funding obligations in the ordinary course to Buyer. There are no pending or, to the Knowledge of the Company, threatened, claims (other than routine claims for benefits) or lawsuits against or with respect to any Employee Benefit Plans. The Knowledge of the Company no governmental audit or examination of any Employee Benefit Plan is pending or threatened nor are do any facts exist which would reasonably lead to any such audit or examination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Each Employee Benefit Plan intended to qualify under Section 401(a) of the Code and each related trust intended to be exempt under Section 501 of the Code has been and is so qualified or exempt as of the date hereof, and the Company Group has received a current favorable determination letter to such effect from the Internal Revenue Service or is properly relying on the Internal Revenue Service opinion or advisory letter issued with respect to the qualification of a prototype plan document that Company Group has duly adopted. To the Knowledge of the Company, the amendments to and operation of any Employee Benefit Plan or related trust since receipt of such letter do not materially adversely affect the qualified or exempt status of any such Employee Benefit Plan or related trust.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)All amounts required to have been paid as contributions to any Employee Benefit Plan have been paid within the time prescribed by applicable Laws and the applicable plan documents. The Company Group has not been delinquent as to premiums, reimbursements, accruals, contributions or payments to or in respect of any Employee Benefit Plan. With respect to each Employee Benefit Plan, there are no funded benefit obligations for which contributions have not been made or properly accrued and there are no unfunded benefit obligations that have not been accounted for by reserves, or otherwise properly footnoted on the Financial Statements. The Company has furnished or made available to Buyer complete financial information regarding the funding and present and future liabilities of any and all deferred compensation, salary continuation, or other Employee Benefit Plans which are not intended to be qualified under Section 401(a) of the Code. No assets of Business are allocated to or held in a "rabbi trust" or similar funding vehicle.

33

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)No member of the Company Group has made any promises or incurred any liability under any Employee Benefit Plan or otherwise to provide health or other welfare benefits to Business Employees (or to their spouses or dependents) or to anyone else, except as specifically required by applicable Laws.

**Section 4.18&nbsp;&nbsp;&nbsp;&nbsp;<u>Employment Matters</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)[Section 4.18](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules sets forth a true, correct and complete listing of the employees of the Business (collectively, the "<u>Business Employees</u>"). The Company Group is in compliance in all material respects with all applicable Laws pertaining to employment and employment practices related to the Business Employees and there are no actions, suits, claims, investigations or other legal proceedings against the Company Group pending, or to the Knowledge of the Company, threatened to be brought or filed, by or with any Governmental Authority or arbitrator in connection with any alleged employment of any Business Employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Except as set forth on [Section 4.18](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules and other than for customary "at will" oral employment arrangements, the Company Group does not have any written, oral or implied employment contracts with any of the Business Employees. As of the date hereof: (a) the Company Group is not delinquent in the payment (i) to or on behalf of its past or present Business Employees of any wages, salaries, commissions, bonuses, benefit plan contributions or other compensation for all periods prior to the date hereof, or (ii) of any amount which is due and payable to any state or state fund pursuant to any workers' compensation statute, rule or regulation or any amount which is due and payable to any workers' compensation claimant;

&nbsp;&nbsp;&nbsp;&nbsp;(b)there are no collective bargaining agreements currently in effect between the Company Group and labor unions or organizations representing any Business Employees; (c) no such collective bargaining agreement is currently being negotiated by Company Group; (d) to the Knowledge of the Company, there are no union organizational drives in progress and there has been no formal or informal request to Company Group for such collective bargaining or for an employee election from any union or from the National Labor Relations Board; and (e) no dispute exists between Company Group and any of its sales representatives related to the Business or, to the Knowledge of the Company, between any such sales representatives with respect to territory, commissions, products or any other terms of their representation. Except set forth on [Section 4.18](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules, no Business Employees will be entitled to any severance or other payment in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby. The Company Group has not extended to any of its Business Employees any loans or credit.

**Section 4.19&nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes</u>**.&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in [Section 4.19](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure

Schedules:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Each of the Company and, with respect to the Business, the Members, and

each of their respective Affiliates has filed (taking into account any valid extensions) all Tax Returns required to be filed by the Company Group. Such Tax Returns are true, complete and correct in all material respects. Neither the Company nor, with respect to the Business, the Members, and each of their respective Affiliates is currently the beneficiary of any extension of time within which to file any such Tax Return. All Taxes due and owing by the Company or, with

34

------

respect to the Company or the Business, the Members, and each of their respective Affiliates, whether or not shown on such Tax Returns, have been timely paid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Each of the Company and, with respect to the Company or the Business, the Members, and each of their respective Affiliates has withheld and paid all Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, customer, shareholder or other party, and has complied with all information reporting and backup withholding required by applicable Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)No claim has been made by any taxing authority in any jurisdiction where the Company and, with respect to the Company or the Business, the Members, and each of their respective Affiliates does not file Tax Returns that it or they are, or may be, subject to Tax by that jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of the Company or, with respect to the Company or the Business, the Members, or any of their respective Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)All deficiencies asserted, or assessments made, against the Company or, with respect to the Company or the Business, Members, or each of their respective Affiliates as a result of any examinations by any taxing authority have been fully paid or resolved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)Neither the Company nor, with respect to the Company or the Business, the Members, or any of their respective Affiliates is a party to any audit or court or administrative proceeding by any taxing authority. There are no such pending or threatened audits or court or administrative proceedings by any taxing authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)There are no Encumbrances for Taxes (other than Permitted Encumbrances) upon the assets of the Business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)Neither the Company nor, with respect to the Company or the Business, the Members, or any of their respective Affiliates has any liability for Taxes of any Person (other than the Company Group) as transferee or successor, by contract or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The Company is, and has been at all times since its formation, a partnership for U.S. federal income tax purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)Neither the Company nor, with respect to the Company or the Business, the Members, or any of their respective Affiliates is a party to, or bound by, any Tax indemnity, Tax sharing or Tax allocation agreement other than commercial agreements entered into in the ordinary course of business, the primary purpose of which is not related to Taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)The Company has not participated in any "reportable transaction" or "listed transaction" within the meaning of Treasury Regulation Section 1.6011-4 or 301.6112-1 or any similar provision of state, local or non-U.S. Tax Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)The Company is not liable with respect to any Indebtedness the interest of which is not deductible for applicable U.S. federal, state or local or non-U.S. income tax purposes.

35

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)The Company does not have permanent establishment in any country other than the country of its organization, as defined in any applicable Tax treaty between the United States and such other country.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)No power of attorney currently in force has been granted with respect to any matter relating to the Taxes of the Company that will be in force for any taxable period beginning after the Closing Date.

**Section 4.20&nbsp;&nbsp;&nbsp;&nbsp;<u>Questionable Payments</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)No member of the Company Group (nor any of their respective officers and directors and, to the Knowledge of the Company, any employees, representatives, agents, consultants, or distributors), directly or indirectly: (i) has used or is using any funds for any illegal contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) has used or is using any funds for any direct or indirect unlawful payment to any foreign or domestic Governmental Authority, government official or employee; (iii) has violated or is violating any provision of, or any rule or regulation issued under, (A) the US Foreign Corrupt Practices Act of 1977, 15 U.S.C. §§ 78dd-1, et seq., (B) the US Travel Act, 18 U.S.C. § 1952, (C) any applicable Law enacted in any applicable jurisdiction in connection with, or arising under, the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or (D) any other Law, rule, regulation, or other legally binding measure of any foreign or domestic jurisdiction of similar effect or that relates to bribery or corruption (collectively, "<u>Anti-Bribery Laws</u>"); (iv) has failed to maintain in all material respects complete and accurate books and records as required by applicable Anti-Bribery Laws; (v) has established or maintained, or is maintaining, any unlawful fund of corporate monies or other properties;

&nbsp;&nbsp;&nbsp;&nbsp;(vi) has made, offered to make, promised to make, ratified or authorized the payment or giving, directly or indirectly, of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment, gift or anything of value to a foreign or domestic government official or employee to secure or attempt to secure any improper business advantage (within the meaning of such term under any applicable Anti-Bribery Law) or to obtain or retain business; or (vii) has otherwise taken any action that has caused, or would reasonably be expected to cause the Company Group to be in violation of any applicable Anti-Bribery Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)There is no proceeding (i) excluding any sealed proceeding, pending or received, (ii) in the case of a sealed proceeding, to the Knowledge of the Company, pending or received, or (iii) in the case of any proceeding, to the Knowledge of the Company, threatened, in each case against any member of the Company Group, that could reasonably be expected to result in any liability on the part of the Company Group under any Anti-Bribery Laws to which any member of the Company Group is subject. No member of the Company Group (nor any of their respective directors, officers, executives, employees, agents, distributors, consultants or other representatives), is party to or otherwise subject to the terms of any Corporate Integrity Agreement, Non-prosecution Agreement, Deferred Prosecution Agreement or any other arrangement similar to any of the foregoing arising from or otherwise relating to any such proceeding.

**Section 4.21 <u>Brokers</u>.** Except as set forth in [Section 4.21](#iad153e23c3af4c5d94fd367f56a26c38_40) of the Disclosure Schedules, no broker, finder or investment banker is entitled to any brokerage, finder's or other similar fee or commission in connection with the transactions contemplated by this Agreement or

36

------

any other Transaction Document based upon arrangements made by or on behalf of the Company or the Members.

**Section 4.22 <u>Solvency</u>.** The Company is, and after giving effect to the transactions contemplated by this Agreement, will be, on either an unconsolidated basis or a consolidated basis, Solvent, and the Company has and will have assets which, fairly valued, exceed its indebtedness, liabilities or obligations. "<u>Solvent</u>" means, with respect to any Person on a particular date, that on such date (a) the present fair salable value of the property and assets of such Person exceeds the debts and liabilities, including contingent liabilities, of such Person, (b) the present fair salable value of the property and assets of the such Person is greater than the amount that will be required to pay the probable liability of such Person on its debts and other liabilities, including contingent liabilities, as such debts and other liabilities become absolute and matured,

&nbsp;&nbsp;&nbsp;&nbsp;(c)such Person does not intend to incur, or believe (nor should it reasonably believe) that it will incur, debts and liabilities, including contingent liabilities, beyond its ability to pay such debts and liabilities as they become absolute and matured, and (d) such Person does not have unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted; provided, that the amount of contingent liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.

**Section 4.23 <u>Full Disclosure</u>.** No representation or warranty in this Agreement and no statement contained in the Disclosure Schedule or any certificate or other document furnished or to be furnished to Buyer pursuant to this Agreement contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading.

**ARTICLE V REPRESENTATIONS AND WARRANTIES OF BUYER**

Buyer represents and warrants to the Members and the Company as follows:

**Section 5.1 <u>Organization and Authority of Buyer</u>**. Buyer is a corporation duly organized, validly existing and in good standing under the Laws of Delaware. Buyer has all necessary organizational power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by Buyer of this Agreement, the performance by Buyer of its obligations hereunder and the consummation by Buyer of the transactions contemplated hereby have been duly authorized by all requisite organizational action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by the Company and the Members) this Agreement constitutes a legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting

37

------

creditors' rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

**Section 5.2 <u>No Conflicts; Consents</u>**. The execution, delivery and performance by Buyer of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (a) result in a violation or breach of any provision of any of the articles of incorporation, bylaws or other similar charter documents of Buyer; (b) result in a violation or breach of any provision of any Law or Governmental Order applicable to Buyer; or (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default under or result in the acceleration of any material agreement to which Buyer is a party, except in the case of clauses (a) or (c) for any such violations, breaches, conflicts, defaults, or accelerations that, individually, or in the aggregate, are not reasonably expected to have a material adverse effect on the ability of Buyer to consummate the transactions contemplated hereby. No consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Buyer in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby.

**Section 5.3 <u>Investment Purpose</u>**. Buyer is acquiring the Interests solely for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof. Buyer acknowledges that the Interests are not registered under the Securities Act, as amended, or any state securities laws, and that the Interests may not be transferred or sold except pursuant to the registration provisions of the Securities Act, as amended or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable. Buyer is able to bear the economic risk of holding the Interests for an indefinite period (including total loss of its investment), and has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risk of its investment.

**Section 5.4 <u>Brokers</u>**. No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer.

**Section 5.5 <u>Legal Proceedings</u>**. There are no actions, suits, claims, investigations or other legal proceedings pending or, to Buyer's knowledge, threatened against or by Buyer or any Affiliate of Buyer that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.

**ARTICLE VI**

**CONDUCT BY THE COMPANY AND THE MEMBERS PRIOR TO THE CLOSING DATE**

**Section 6.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Conduct of Business</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)***Conduct of Business*** . During the period from the date hereof continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date, the Company and, with respect to the Company or the Business, the Members shall, and the Members

38

------

shall cause each of their respective Affiliates to, except as otherwise expressly contemplated by this Agreement or to the extent that Buyer shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), (i) carry on the Business in the usual, regular and ordinary course, in substantially the same manner as previously conducted and in compliance in all material respects with all applicable laws and regulations, (ii) pay its debts and Taxes prior to delinquency and pay or perform other material obligations when due, and (iii) use commercially reasonable efforts to preserve intact the Company's present business organization and retain the Business Employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Required Consent From the Date Hereof***. In addition, without limiting the generality of [Section 6.1(a),](#iad153e23c3af4c5d94fd367f56a26c38_40)except as permitted or contemplated by the terms of this Agreement, and except as provided in [Section 6.1(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules, without the prior written consent of Buyer (which consent shall not be unreasonably withheld, delayed or conditioned), during the period from the date hereof and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date, the Company and, with respect to the Company or the Business, the Members shall not do any of the following, and, with respect to the Business, the Members shall not permit any of their respective Affiliates to do any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Cause, permit or propose any amendments to the Company Operating Agreement or other organizational documents of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Adopt a voluntary plan of complete or partial liquidation or

dissolution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)Cause the Company to declare, set aside or pay any dividends on or

make any other distributions (whether in cash, Interests, equity securities or property) in respect of any Interests of the Company or split, combine or reclassify any such Interests or issue or authorize the issuance of any other securities of the Company in respect of, in lieu of or in substitution for any Interests;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)Cause the Company to issue, deliver, sell, authorize, pledge or otherwise encumber any Interests, or any securities convertible into Interests, or subscriptions, rights, warrants or options to acquire any Interests or any securities convertible into Interests, or enter into other agreements or commitments of any character obligating it to issue any such securities or rights, excluding the issuance of Incentive Units to employees of the Company or its Affiliates in accordance with the Equity Incentive Plan and subject to <u>[Section 7.13](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)Cause the Company to acquire or agree to acquire by merging or consolidating with, or by purchasing any material equity or voting interest in or a material portion of the assets of, or by any other manner, any business or any Person or division thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)Sell, lease, license, encumber or otherwise dispose of any material properties or assets of the Company or the Business or enter into any written or oral agreement with a third party with respect to the distribution or sale of any Company Products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)Enter into any written or oral agreement pursuant to which any member of the Company Group is licensing, sublicensing or otherwise granting rights to a third party with respect to the Business IP owned by the Company Group;

39

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)Cause the Company to (A) incur any indebtedness for borrowed money or guarantee any such indebtedness of another Person, (B) issue or sell any debt securities or options, warrants, calls or other rights to acquire any debt securities of the Company, guarantee any debt securities of another Person, or (C) enter into any "keep well" or other agreement to maintain any financial statement condition of any other Person (other than any wholly-owned subsidiary of it);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)Enter into or renew any Contracts containing any non-competition, exclusivity or other similar material restrictions on the Company or the Business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)Enter into any Material Contract that would require consent of the counter party thereto with respect to the consummation of the transactions contemplated by this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi)Amend any agreement between the Company and the Members or any Affiliates of the Members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii)Amend the Equity Incentive Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii)Cause the Company to purchase, redeem or otherwise acquire, directly or indirectly, any shares of its capital stock or other equity interests, except repurchases of unvested shares in connection with the termination of the employment or consulting relationship with any employee or consultant pursuant to stock option or purchase agreements or other similar agreements; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv)Make any material Tax election, including but not limited to an entity classification election with respect to the Company or a Tax accounting method change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)***Required Consent Following the Acquisition Notice***. In addition, without limiting the generality of [Section 6.1(a),](#iad153e23c3af4c5d94fd367f56a26c38_40)except as permitted or contemplated by the terms of this Agreement, and except as provided in [Section 6.1(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)or [Section 6.1(c)](#iad153e23c3af4c5d94fd367f56a26c38_40)of the Disclosure Schedules, without the prior written consent of Buyer (which consent shall not be unreasonably withheld, delayed or conditioned), during the period from the date of the Acquisition Notice and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date, the Company and, with respect to the Company or the Business, the Members shall not do any of the following, and, with respect to the Business, the Members shall not permit any of their respective Affiliates to do any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Cause the Company to make any material loans, advances or capital contributions to, or investments in, any other Person, other than employee advances made in the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Except as required by GAAP, make any material change in its methods or principles of accounting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)Settle or compromise any Tax liability or consent to any extension or waiver of any limitation period with respect to any Tax;

40

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)Other than in the ordinary course of business and consistent with past practice, or pursuant to agreements, policies, or arrangements outstanding or existing on the date hereof, or as may be required by applicable Legal Requirements (including amending arrangements as necessary or desirable to comply with Section 409A of the Code), adopt or materially amend any Employee Benefit Plan, or enter into any collective bargaining agreement, or pay any special bonus or special remuneration (cash, equity or otherwise) to any Business Employee (including rights to severance or indemnification of its directors, officers, employees or consultants);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)Other than in the ordinary course of business and consistent with past practice, or pursuant to agreements, policies, or arrangements outstanding or existing on the date hereof, or as may be required by applicable Legal Requirements (including amending arrangements as necessary or desirable to comply with Section 409A of the Code), grant any severance or termination pay (cash, equity or otherwise) to any officer of the Company, or adopt any new severance plan, or amend or modify or alter in any respect any severance plan, agreement or arrangement existing on the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)Accelerate, beyond the normal collection cycle, the collection of accounts receivable or the purchase of inventory;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)Make, accelerate or defer any capital expenditures other than any such expenditures as are necessary to prevent the destruction, removal, wasting, deterioration or impairment of its assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)(A) conclude or agree to any corrective action plans, consents, decrees, actions or orders, or (B) cancel, compromise or settle any claim that is related to or affects the Company or the Business, or waive or release any material rights of the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix)Cancel or terminate any insurance policies or cause any of the coverage thereby to lapse, unless simultaneously with such termination, cancellation or lapse, replacement policies providing, to the extent reasonably available, coverage equal to or greater than the coverage under the canceled, terminated or lapsed policies for substantially similar premiums are in full force and effect.

**Section 6.2 <u>Certain Notifications</u>.** Until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date, (a) the Company and the Members shall promptly notify Buyer in writing of the occurrence of any event that will or could reasonably be expected to result in the failure by the Company Group to satisfy any of the conditions specified in [Section 8.1](#iad153e23c3af4c5d94fd367f56a26c38_40)or [Section 8.2](#iad153e23c3af4c5d94fd367f56a26c38_40)and (b) Buyer shall promptly notify the Company in writing of the

41

------

occurrence of any event that will or could reasonably be expected to result in the failure by Buyer or its Affiliates to satisfy any of the conditions specifie[d in Section 8.1](#iad153e23c3af4c5d94fd367f56a26c38_40) or [Section 8.3.](#iad153e23c3af4c5d94fd367f56a26c38_40)

**ARTICLE VII ADDITIONAL AGREEMENTS**

**Section 7.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Acquisition Proposals; No Solicitation</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)During the period from the date hereof and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date, the Company and each Member each agrees that neither it nor any of its Affiliates nor any of the officers and directors of it or its Affiliates shall, and that it shall not authorize or permit its and its Affiliates' employees, stockholders, agents and representatives (including any investment banker, attorney or accountant retained by it or any of its Affiliates) to, directly or indirectly: (i) solicit, initiate, knowingly encourage or knowingly facilitate any inquiries with respect to, or the making, submission or announcement of, any offer or proposal for an Acquisition Proposal; (ii) participate in any discussions or negotiations regarding, or furnish to any Person any nonpublic information with respect to, any Acquisition Proposal; (iii) engage in discussions with any Person with respect to any Acquisition Proposal, except as to the existence of these provisions; (iv) approve, endorse or recommend any Acquisition Proposal; or (v) enter into any letter of intent or similar document or any Contract, agreement or commitment contemplating any Acquisition Proposal or transaction contemplated thereby. The Company and its Affiliates will immediately cease any and all existing activities, discussions or negotiations with any third parties conducted heretofore with respect to any Acquisition Proposal. For purposes of this Agreement, "<u>Acquisition Proposal</u>" means any inquiry, proposal or offer from any Person relating to any direct or indirect acquisition or purchase of any assets related to the Business, or any equity interests of the Company, any tender offer or exchange offer of equity interests of the Company, or any merger, consolidation, business combination, recapitalization, liquidation, dissolution or similar transaction involving the acquisition of equity interests or assets of the Company, other than the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Notification of Unsolicited Acquisition Proposals***. During the period from the date hereof and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date, as promptly as practicable after receipt of any Acquisition Proposal or any request for nonpublic information or inquiry which the Company or the Members reasonably believes would lead to an Acquisition Proposal, the Company or the Members shall provide Buyer with oral and written notice of its receipt of such Acquisition Proposal request or inquiry, and a summary of the material terms and conditions of such Acquisition Proposal, request or inquiry or the identity of the Person or group making such Acquisition Proposal, request or inquiry.

**Section 7.2&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidentiality; Access to Information</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)***Confidentiality***. The parties acknowledge that the Company and Buyer have previously executed a certain Mutual Non-Disclosure Agreement, dated August 21, 2020 (the "<u>Confidentiality Agreement</u>"), which Confidentiality Agreement will continue in full force and effect in accordance with the its terms and each of Buyer and the Company will hold, and will cause its respective directors, officers, employees, agents and advisors (including attorneys,

42

------

accountants, consultants, bankers and financial advisors) to hold, any Confidential Information (as defined in the Confidentiality Agreement) confidential in accordance with the terms of the Confidentiality Agreement. Members hereby agree to be bound by the confidentiality restrictions in the Confidentiality Agreement on the same terms as the Company as if each Member were an original party to such Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Access to Information***. During the period from the date hereof and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing Date, the Company and the Members will afford Buyer and Buyer's accountants, counsel and other representatives reasonable access during normal business hours to its properties, books, records and personnel to obtain all information concerning the Business, including the status of development efforts related to the Company Products, properties, results of operations and personnel, in each case solely for purposes of this Agreement, as Buyer may reasonably request; *provided, however,* that the Company and the Members may restrict the foregoing access to the extent that (i) any law, treaty, rule or regulation of any Governmental Authority applicable to the Company or the Business requires the Company or the Members to restrict or prohibit access to any such properties or information, or (ii) such access would, in the reasonable judgment of the Company compromise or constitute a waiver of any attorney-client privilege. In addition, any information obtained from the Company or the Members pursuant to the access contemplated by this [Section 7.2(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)shall be subject to the confidentiality provisions contained in Confidentiality Agreement.

**Section 7.3 <u>Public Announcements</u>**. Unless otherwise required by applicable Law or stock exchange requirements (based upon the reasonable advice of counsel), none of Buyer or the Company or the Members shall make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of the other party (which consent shall not be unreasonably withheld or delayed), and the parties shall cooperate as to the timing and contents of any such announcement. Notwithstanding the foregoing, (a) Buyer shall be entitled to make any public disclosure required by applicable Laws and any rules or regulations of any supervisory, regulatory or other Governmental Authority having jurisdiction over it or any of its Affiliates (including the Securities and Exchange Commission and the New York Stock Exchange), including disclosure of this Agreement as a material contract in its filings with the Securities and Exchange Commission and any subsequent disclosures and press releases related thereto and (b) nothing contained in this Agreement will limit Buyer's (or its Affiliates') rights to disclose the existence of this Agreement and the general nature of the transaction described herein on any earnings call or in similar discussions with financial media or analysts, stockholders and other members of the investment community.

**Section 7.4 <u>Third Party Consents</u>**. Each of the Company and each Member shall use its commercially reasonable efforts to obtain all Consents prior to the prior to the Closing Date.

**Section 7.5 <u>Further Assurances</u>**. Following the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances, and take such further actions as may be

43

------

reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement.

**Section 7.6 <u>Transition Services Agreement</u>**. Prior to the Closing, Buyer, on the one hand, and Phillippe Marco and any other key individuals identified by Buyer (the "<u>Key</u> <u>Individuals</u>"), on the other hand, shall negotiate in good faith an agreement to provide certain post- Closing services to be identified by Buyer as necessary to support activities relating to the IDE Approvals (the "<u>Transition Services Agreements</u>"). The Transition Services Agreement may be entered into directly between Buyer and the Key Individuals or between Buyer and an entity that engages the Key Individuals. The fees related to the services to be provided under the Transition Services Agreement will be an amount to be agreed by Buyer and the Key Individuals and will be payable from the remaining proceeds of the loan issued to the Company in accordance with the Loan Documents.

**Section 7.7 <u>Transfer Taxes</u>**. All transfer, documentary, sales, use, stamp, registration, value added and other similar Taxes and fees (including any penalties and interest) incurred in connection with this Agreement shall be borne and paid by the Members when due. The Members shall, at their own expense, timely prepare and file any Tax Return or other document required by law with respect to such Taxes or fees (and Buyer shall cooperate with respect thereto as reasonably necessary).

**Section 7.8&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Treatment</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The parties shall allocate the Closing Date Consideration among the assets of the Company in accordance with Section 1060 of the Code. A statement setting forth such proposed allocation (the "<u>Tax Allocation Schedule</u>") shall be prepared in good faith by Buyer and delivered to the Members within ninety (90) days following the Closing Date. Within 30 days following Buyer's delivery of the proposed Tax Allocation Schedule to the Members, the Members may give Buyer a written notice stating the Members' objections to the proposed Tax Allocation Schedule (an "<u>Allocation Objection Notice</u>"). If the Members do not give Buyer an Allocation Objection Notice within such 30 day period, then the proposed Tax Allocation Schedule will be conclusive and binding upon the parties. If the Members do give Buyer an Allocation Objection Notice, and in the event that Buyer and the Members fail to resolve all of the issues set forth in the Allocation Objection Notice within 30 days after Buyer receives the Allocation Objection Notice (the "<u>Allocation Agreement Period</u>"), (i) Buyer and the Members will retain a firm of certified public accountants designated by the Members and reasonably acceptable to the Buyer (the "<u>CPAs</u>") to make the determination of the purchase price allocation within the 30 day period immediately following the Allocation Agreement Period, and (ii) Buyer and the Members will each provide the CPAs with their respective determinations of the purchase price allocation. The CPAs will consider only those items and amounts in Buyer's and the Members' respective determinations of proposed purchase price allocation that are identified as being items and amounts to which Buyer and the Members have been unable to agree. In resolving any such disputed item or amount, the CPAs may not assign a value to any item or amount that is higher than the highest value for such item or amount claimed by either party or lower than the lowest value for such item or amount claimed by either party. The determination of the purchase price allocation by the CPAs will be conclusive and binding upon the parties. The fees, costs and expenses of the CPAs shall be paid shall be allocated between the Members, on the one hand, and Buyer, on the other hand,

44

------

in inverse proportion as the Members and Buyer may prevail on matters resolved by the Independent Auditors, which proportionate allocations shall be determined by the Independent Auditors. The parties shall report, act and file all Tax Returns in all respects and for all purposes consistent with the Tax Allocation Schedule and this [Section 7.8](#iad153e23c3af4c5d94fd367f56a26c38_40), and no party shall take any position (whether in audits, Tax Returns or otherwise) that is inconsistent with the Tax Allocation Schedule or this [Section 7.8](#iad153e23c3af4c5d94fd367f56a26c38_40) unless required to do so by applicable Law. If the Closing Date Consideration is adjusted in any manner as provided in this Agreement, the Tax Allocation Schedule shall be adjusted as mutually agreed by the parties to reflect such adjustments to the consideration paid pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Members shall, at the Members' expense, prepare or cause to be prepared and file or cause to be filed (taking into account all applicable extensions) with the applicable Tax authority any income Tax Returns required to be filed by or with respect to Company for taxable years ending on or before the Closing Date, which for avoidance of doubt shall include the final partnership income Tax Returns of the Company for the tax period ending on the Closing Date. Such income Tax Returns shall be prepared in a manner consistent with the Company's past practice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Except for the Tax Returns prepared by the Members pursuant to[Section 7.8(b),](#iad153e23c3af4c5d94fd367f56a26c38_40)Buyer shall file or cause to be filed when due all Tax Returns of the Company that are required to be filed by or with respect to Company after the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)The Buyer and the Members shall reasonably cooperate, and shall cause their respective Affiliates (including the Company), officers, employees, agents, auditors and representatives reasonably to cooperate, with each other in preparing and filing all Tax Returns of the Company, resolving all disputes relating to Taxes of the Company, and handling all proceedings, examinations, and audits relating to Tax matters of the Company, including maintaining and making available all records necessary in connection with such Tax Returns, disputes and Tax matters.

**Section 7.9 <u>Release and Waiver</u>**. Effective as of and subject to the Closing, each Member, for itself and on behalf of its Affiliates, agents, representatives, attorneys, assigns, dependents, heirs, executors, and administrators, hereby irrevocably and unconditionally releases, acquits and forever discharges the Company from any and all claims, rights, demands, actions, suits, damages, losses, expenses, liabilities, indebtedness, and causes of action, of whatever kind or nature that existed or arose from the beginning of time through the Closing, regardless of whether known or unknown, and regardless of whether asserted by such Member to date, other than claims arising under or in connection with this Agreement or the transactions contemplated hereby or which may not otherwise be released as a matter of applicable Law (the "<u>Released</u> <u>Member Claims</u>"). Each Member further agrees and covenants not to participate in any action or proceeding against the Company based upon any of the Released Member Claims. Each Member

&nbsp;&nbsp;&nbsp;&nbsp;(a)understands that the release contained in this [Section 7.9](#iad153e23c3af4c5d94fd367f56a26c38_40)is binding on such Member and its Affiliates, agents, representatives, attorneys, assigns, dependents, heirs, executors, and administrators and (b) represents and warrants that (i) it has had the opportunity to consult with

45

------

counsel of its choice, (ii) it is fully informed of the nature and contents of this release and (iii) it has entered into this release freely and without any threat or coercion whatsoever.

**Section 7.10&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Competition; Non-Solicitation</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)For a period of 2 years commencing on the Closing Date (the "<u>Restricted Period</u>"), each Member holding 10% or more of the Interests as of the Closing Date (each a "<u>Restricted Member</u>") shall not, and shall cause its Affiliates not to, directly or indirectly,

&nbsp;&nbsp;&nbsp;&nbsp;(i) engage in or assist others in engaging in the Business or any business that is competitive with the Business in the Territory; (ii) have an interest in any Person that engages directly or indirectly in the Business or any business that is competitive with the Business in the Territory in any capacity, including as a partner, shareholder, member, employee, principal, agent, trustee or consultant; or (iii) intentionally interfere in any material respect with the business relationships (whether formed prior to or after the date of this Agreement) between the Company and clients, customers or suppliers of the Company. Notwithstanding the foregoing, nothing in this[Section 7.10](#iad153e23c3af4c5d94fd367f56a26c38_40)shall prohibit any Restricted Member from (x) performing its obligations under the Transition Services Agreement or (y) owning, directly or indirectly, solely as an investment, securities of any Person traded on any national securities exchange if such Restricted Member is not a controlling Person of, or a member of a group which controls, such Restricted Member and does not, directly or indirectly, own 2% or more of any class of securities of such Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)During the Restricted Period, each Restricted Member shall not, directly or indirectly, hire or solicit any employee or independent contractor of the Company or encourage any such employee or independent contractor to leave such employment or relationship with the Company or hire any such employee or independent contractor who has left such employment or relationship with the Company, except pursuant to a general solicitation which is not directed specifically to any such employees or contractors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)During the Restricted Period, each Restricted Member shall not, directly or indirectly, solicit or entice, or attempt to solicit or entice, any vendor, suppliers, clients or customers of the Company or the Business or potential clients or customers of the Company or the Business for purposes of diverting their business or services from the Company or the Business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Each Restricted Member acknowledges that a breach or threatened breach of this would give rise to irreparable harm to Buyer, for which monetary damages would not be an adequate remedy, and hereby agrees that in the event of a breach or a threatened breach by such Restricted Member of any such obligations, Buyer shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief that may be available from a court of competent jurisdiction (without any requirement to post bond).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Each Restricted Member acknowledges that the restrictions contained in this Section 7.10 are reasonable and necessary to protect the legitimate interests of Buyer and constitute a material inducement to Buyer to enter into this Agreement and consummate the transactions contemplated by this Agreement. In the event that any covenant contained in this Section 7.10 should ever be adjudicated to exceed the time, geographic, product or service, or other

46

------

limitations permitted by applicable Law in any jurisdiction, then any court is expressly empowered to reform such covenant, and such covenant shall be deemed reformed, in such jurisdiction to the maximum time, geographic, product or service, or other limitations permitted by applicable Law. The covenants contained in this Section 7.10 and each provision hereof are severable and distinct covenants and provisions. The invalidity or unenforceability of any such covenant or provision as written shall not invalidate or render unenforceable the remaining covenants or provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such covenant or provision in any other jurisdiction.

**Section 7.11 <u>Updated Disclosure Schedules</u>**. Within ten (10) Business Days following the later of the date of Second FIH Study Milestone and January 1, 2024, the Company shall deliver updated Disclosure Schedules (including new Disclosure Schedules, if any, where, as of the date hereof, no Disclosure Schedules are yet provided) to reflect any matters arising from circumstances first occurring after the date of this Agreement (the "<u>Updated Disclosure</u> <u>Schedules</u>"), which will be certified as complete and final as of the date of delivery by an officer of the Company; <u>provided</u>, that any new disclosures set forth in the Updated Schedules shall not be deemed to have cured any breach of any representation or warranty made by the Company for the purposes of this Agreement, including the closing conditions set forth in Article VIII and indemnification pursuant to Article IX, other than disclosure of any actions taken by the Company with Buyer's written consent or that do not require Buyer's consent pursuant to this Agreement, including Section 6.1.

**Section 7.12 <u>Lease Assignment</u>**. At or prior to the Closing, the Company shall assign the Lease to Nextgen Vascular Technologies, LLC, or any other third party (excluding any controlled Affiliate of the Company), which assignment shall include a full release of the Company from all of its obligations under the Lease.

**Section 7.13 <u>Incentive Units</u>**. Promptly following the grant of any Incentive Units, the Company shall cause each Incentive Unit Holder to execute a joinder to this Agreement in the form attached hereto as <u>Exhibit B</u> (the "<u>Joinder Agreement</u>"), pursuant to which the Incentive Unit Holder will agree to be subject to the terms of <u>[Article II](#iad153e23c3af4c5d94fd367f56a26c38_31)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_31)<u>[Article III](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>[,](#iad153e23c3af4c5d94fd367f56a26c38_40)<u>[Section 4.3](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>and <u>[Article XI](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>and the related definitions as a "Member".

**ARTICLE VIII CONDITIONS TO CLOSING**

**Section 8.1 <u>Conditions to the Obligations of Each Party</u>**. The respective obligations of each party to this Agreement to close the Acquisition shall be subject to no action or proceeding having been instituted or threatened before any Governmental Authority to restrain or prohibit, or to obtain substantial damages in respect of this Agreement or the consummation of

47

------

the transactions contemplated herein which, in the reasonable opinion of such party, makes it inadvisable to consummate such transactions.

**Section 8.2 <u>Additional Conditions to the Obligations of Buyer</u>**. The obligations of Buyer to close the Acquisition shall be subject to the satisfaction at or prior to the Closing Date of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)***Representations and Warranties True at Closing***. The representations and warranties of the Company and the Members contained in this Agreement shall be true and correct in all material respects as of the date hereof and as of the Closing Date (except that the representations and warranties made as of a specified date shall be true and correct only as of such date and it being understood that, for purposes of determining the effect of such exceptions, all Material Adverse Effect and materiality qualifications shall be disregarded). Notwithstanding the foregoing, the Seller Fundamental Representations shall be true and correct in all respects as of the date hereof and as of the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Compliance with Agreement***. Each of the covenants, agreements and obligations required by this Agreement to be performed or complied with by the Members or the Company on or before the Closing Date pursuant to the terms hereof shall have been duly performed or complied with in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)***No Material Adverse Effect***. Between the date hereof and the Closing Date, there shall have been no Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)***Closing Deliverables***. Buyer shall have received the closing deliverables required to be delivered by the Members and/or the Company, as applicable, pursuant to[Section 2.4(b)](#iad153e23c3af4c5d94fd367f56a26c38_34)and [Section 2.4(c).](#iad153e23c3af4c5d94fd367f56a26c38_34)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)***Closing Certificate***. Buyer shall have received a certificate signed by the Company and the Members and dated as of the Closing Date certifying as to the satisfaction of the conditions set for[th in Section 8.2(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)and [Section 8.2(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)***Required Consents***. The Company and the Members shall have obtained the Consents designated by Buyer as required to be delivered prior to the Closing (the "<u>Required Consents</u>") and provided Buyer a copy of each such Required Consent in a form reasonably acceptable to Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)***Event of Default***. No Event of Default shall have occurred and not be cured in accordance with the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)***Joinder Agreements***. Each of the Incentive Unit Holders shall have executed a Joinder Agreement.

48

------

**Section 8.3 <u>Additional Conditions to the Obligations of the Members and</u> <u>the Company</u>**. The respective obligations of the Members and the Company to close shall be subject to the satisfaction at or prior to the Closing Date of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)***Representations and Warranties True at Closing***. The representations and warranties of Buyer contained in this Agreement shall be true and correct in all material respects as of the date hereof and as of the Closing Date, or in case of representations and warranties made as of a specified date earlier than the Closing Date, on and as of such earlier date, subject to such exceptions as would not (individually or in the aggregate) have a material adverse effect on Buyer's ability to consummate the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Compliance with Agreement***. Each of the covenants, agreements and obligations required by this Agreement to be performed or complied with by Buyer on or before the Closing Date pursuant to the terms hereof shall have been duly performed or complied with in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)***Closing Deliverables***. The Members shall have received the closing deliverables required to be delivered by Buyer pursua[nt to Section 2.4(d).](#iad153e23c3af4c5d94fd367f56a26c38_34)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)***Closing Certificate***. The Members shall have received a certificate signed by Buyer and dated as of the Closing Date certifying as to the satisfaction of the conditions set for[th in Section 8.3(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)and [Section 8.3(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)hereof.

**ARTICLE IX INDEMNIFICATION**

**Section 9.1 <u>Survival</u>**. Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the eighteen (18) month anniversary of the Closing Date; *provided, however,* that for purposes of claims for indemnification pursuant to [Section 9.2(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)or [Section 9.3(a](#iad153e23c3af4c5d94fd367f56a26c38_40)**[)](#iad153e23c3af4c5d94fd367f56a26c38_40)**: (a) the Seller Fundamental Representations and the Buyer Fundamental Representations (collectively, the "<u>Fundamental Representations</u>") shall survive the Closing indefinitely, and (b) [Section 4.11](#iad153e23c3af4c5d94fd367f56a26c38_40) (Intellectual Property), [Section 4.15](#iad153e23c3af4c5d94fd367f56a26c38_40) (Regulatory Matters), [Section 4.17](#iad153e23c3af4c5d94fd367f56a26c38_40) (Employee Benefit Matters) and [Section 4.19](#iad153e23c3af4c5d94fd367f56a26c38_40) (Taxes) (collectively, the "<u>SOL</u> <u>Representations</u>") shall survive until the sixtieth (60th) day following the expiration of the applicable statute of limitations. Each covenant and agreement shall survive the Closing for the period as contemplated by its terms. Notwithstanding the foregoing, any claims asserted in good faith with reasonable specificity and in writing by notice from the non-breaching party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of such survival period and such claims shall survive until finally resolved.

**Section 9.2 <u>Indemnification by the Members</u>**. Subject to the other terms and conditions of this [Article IX,](#iad153e23c3af4c5d94fd367f56a26c38_40)the Members shall jointly and severally indemnify each of Buyer and its Affiliates and its and their respective directors, officers, members, managers, partners and employees (collectively, the "<u>Buyer Indemnified Parties</u>") against, and hold the Buyer Indemnified

49

------

Parties harmless from and against, any and all Losses incurred or sustained by, or imposed upon, the Buyer Indemnified Parties based upon, arising out of, with respect to or by reason of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)any breach of any of the representations or warranties of the Members or the Company contained in [Article III](#iad153e23c3af4c5d94fd367f56a26c38_40) or [Article IV](#iad153e23c3af4c5d94fd367f56a26c38_40) of this Agreement or in any certificate or instrument delivered by or on behalf of the Members or the Company pursuant to this Agreement, in all cases without giving effect to any qualifications as to materiality, material adverse effect or similar qualifications contained in such representations and warranties; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any breach or non-fulfillment of any covenant, agreement or obligation to be performed by the Members at any time pursuant to the Transaction Documents or by the Company prior to the Closing pursuant to the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)any Losses attributable to Taxes (or the non-payment thereof) of, or attributable to, (A) the Company for all taxable periods or portions thereof ending on or prior to the Closing Date, and (B) any Person (other than the Company) for which the Company may be liable as a transferee or successor, by contract or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)any Closing Indebtedness and Transaction Expenses, to the extent not included in the calculation of Estimated Closing Date Consideration provided by the Company pursua[nt to Section 2.3(b)](#iad153e23c3af4c5d94fd367f56a26c38_34);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)any claims of personal injury, bodily injury or property damage arising from or related to the Company Products, whether made before or after the Closing, in connection with any device or other product manufactured or sold by the Business prior to the Closing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)any amounts set forth in the Allocation Schedule (as may be updated pursuant to this Agreement), including any claim by any Member for any amounts in excess of what is set forth in the Allocation Schedule; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)the termination of any employees of the Company on or before the Closing

Date.

**Section 9.3&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by Buyer</u>**.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the other terms and

conditions of this [Article IX,](#iad153e23c3af4c5d94fd367f56a26c38_40) Buyer shall indemnify each of the Members and the Member's Affiliates and its and their respective directors, officers, members, managers, partners and employees, heirs, executors and administrators (collectively, the "<u>Member Indemnified Parties</u>") against, and hold the Member Indemnified Parties harmless from and against, any and all Losses incurred or sustained by, or imposed upon, the Member Indemnified Parties based upon, arising out of, with respect to or by reason of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)any breach of any of the representations or warranties of Buyer contained in this Agreement or in any certificate or instrument delivered by or on behalf of Buyer pursuant to this Agreement, in all cases without giving effect to any qualifications as to materiality, material adverse effect or similar qualifications contained in such representations and warranties; and

50

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any breach or non-fulfillment of any covenant, agreement or obligation to be performed by (i) Buyer at any time pursuant to this Agreement or (ii) the Company from and after the Closing pursuant to this Agreement.

**Section 9.4 <u>Certain Limitations</u>**. The party making a claim for indemnification under this [Article IX](#iad153e23c3af4c5d94fd367f56a26c38_40) is referred to as the "<u>Indemnified Party</u>" and the party against whom such claims are asserted under this [Article IX](#iad153e23c3af4c5d94fd367f56a26c38_40) is referred to as the "<u>Indemnifying Party</u>". The indemnification provided for in [Section 9.2](#iad153e23c3af4c5d94fd367f56a26c38_40) and [Section 9.3](#iad153e23c3af4c5d94fd367f56a26c38_40) shall be subject to the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Members shall not be liable to the Buyer Indemnified Parties for indemnification under Section 9.2(a) until the aggregate amount of all Losses in respect of indemnification under such section exceeds $225,000 (the "Basket"), in which event the Members shall be liable for the full amount of all such Losses (i.e. from and including the first dollar of such Losses); provided, however, that notwithstanding the foregoing in this Section 9.4(a), the Basket shall not apply to (i) any claims arising from fraud on the part of the Members in connection with the transactions contemplated by this Agreement or (ii) any claim as to which the Buyer Indemnified Parties may be entitled to indemnification under Section 9.2(a) in respect of claims arising out of any breach of any of the Seller Fundamental Representations or SOL Representations made by the Members or the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The amount of all Losses for which the Members shall be liable pursuant to[Section 9.2(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)shall be capped at an aggregate amount equal to twenty-five percent (25%) of the Aggregate Consideration (the "<u>Cap</u>"); *provided*, *however*, that the Cap shall not apply to any

&nbsp;&nbsp;&nbsp;&nbsp;(i) any claims arising from fraud on the part of the Members in connection with the transactions contemplated by this Agreement or (ii) Losses for which indemnification is sought under[Section 9.2(a)](#iad153e23c3af4c5d94fd367f56a26c38_40) in respect of claims arising out of any breach of any of the Fundamental Representations or SOL Representations made by the Members or the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Buyer shall not be liable to the Member Indemnified Parties for indemnification under [Section 9.3(a)](#iad153e23c3af4c5d94fd367f56a26c38_40) until the aggregate amount of all Losses in respect of indemnification under such section exceeds an amount equal to the Basket, in which event Buyer shall be liable for the full amount of all such Losses (i.e. from and including the first dollar of such Losses); *provided, however*, that notwithstanding the foregoing in this [Section 9.4(c),](#iad153e23c3af4c5d94fd367f56a26c38_40)the Basket shall not apply to (i) any claims arising from fraud on the part of Buyer in connection with the transactions contemplated by this Agreement or (ii) any claim as to which the Member Indemnified Parties may be entitled to indemnification under [Section 9.3(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)in respect of claims arising out of any breach of any of the Fundamental Representations of Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)The amount of all Losses for which Buyer shall be liable pursuant to[Section 9.3(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)shall be limited to the Cap; *provided*, *however*, that the Cap shall not apply to (i) any claims arising from fraud on the part of Buyer in connection with the transactions contemplated by this Agreement or (ii) any Losses for which indemnification is sought under [Section 9.3(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)in respect of claims arising out of any breach of any of the Fundamental Representations of Buyer; *provided further*, that in no event shall Buyer be liable to the Member Indemnified Parties for indemnification under [Section 9.3(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)in an aggregate amount in excess of the Upfront Amount.

51

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Payments by an Indemnifying Party pursuant to [Section 9.2](#iad153e23c3af4c5d94fd367f56a26c38_40)or [Section 9.3](#iad153e23c3af4c5d94fd367f56a26c38_40) in respect of any Loss shall be limited to the amount of any liability or damage that remains after deducting therefrom any insurance proceeds and any indemnity, contribution or other similar payment actually received by the Indemnified Party (or the Company) in respect of any such claim after deducting all related reasonable and out-of-pocket attorneys' fees, expenses and other costs of recovery (including any deductible amount) and any resultant increase in insurance premiums. The Indemnified Party shall use its commercially reasonable efforts to recover under insurance policies or indemnity, contribution or other similar agreements for any Losses prior to seeking indemnification under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)In no event shall any Indemnifying Party be liable to any Indemnified Party for any punitive or special damages relating to the breach or alleged breach of this Agreement except to the extent awarded to a third party; *provided*, that the foregoing shall not limit any Indemnifying Party's liability for damages that were probable or reasonably foreseeable and were a direct result of a breach or alleged breach of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)Each Indemnified Party shall take, and cause its Affiliates to take, all commercially reasonable steps to mitigate any Loss upon becoming aware of any event or circumstance that would be reasonably expected to, or does, give rise thereto; *provided*, *however*, that this subsection (h) shall neither expand nor limit the obligations of the parties to so mitigate under applicable Law.

**Section 9.5&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification Procedures</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)***Third-Party Claims***. If any Indemnified Party receives notice of the assertion or commencement of any action, suit, claim or other legal proceeding made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a "<u>Third-Party Claim</u>") against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party prompt written notice thereof. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Third-Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party within thirty (30) days of receipt of notice of such Third-Party Claim, to assume the defense of any Third-Party Claim at the Indemnifying Party's expense and by the Indemnifying Party's own counsel, and the Indemnified Party shall cooperate in good faith in such defense. In the event that the Indemnifying Party assumes the defense of any Third-Party Claim, subject to [Section 9.5(b)](#iad153e23c3af4c5d94fd367f56a26c38_40), it shall have the right to take such action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third-Party Claim in the name and on behalf of the Indemnified Party; *provided*, *however*, that if (i) the Indemnifying Party elects not to compromise or defend such Third-Party Claim, (ii) the Indemnifying Party fails to notify the Indemnified Party in writing within thirty (30) days of its receipt of notice of such Third-Party Claim of its election to defend as provided in this Agreement, (iii) the Indemnifying Party fails to use reasonable best efforts to

52

------

actively and diligently, with legal counsel reasonably acceptable to the Indemnified Party, conduct the defense of the action, (iv) such Third-Party Claim seeks an injunction or other equitable remedies in respect of the Indemnified Party or its business; (v) such Third-Party Claim is reasonably likely to result in liabilities that, taken with other then existing claims under this[Article IX](#iad153e23c3af4c5d94fd367f56a26c38_40)would not be fully indemnified hereunder; (vi) the Indemnified Party has been advised by counsel that an actual or potential conflict exists between the Indemnified Party and the Indemnifying Party in connection with the defense of such Third-Party Claim; (vii) such Third- Party Claim seeks a finding or admission of a violation of Law or violation of the rights of any Person by the Indemnified Party; or (viii) such Third-Party Claim relates to Intellectual Property, the Indemnified Party may, but shall not be obligated to, subject to [Section 9.5(b),](#iad153e23c3af4c5d94fd367f56a26c38_40)retain separate counsel of its choosing, defend such Third-Party Claim and have the sole power to direct and control such defense (all at the cost and expense of the Indemnifying Parties) and seek indemnification for any and all Losses based upon, arising from or relating to such Third-Party Claim. In the event that the Indemnifying Party defends against a Third-Party Claim, the Indemnified Party shall have the right, at its own cost and expense, to participate in the defense of such Third-Party Claim with counsel selected by it subject to the Indemnifying Party's right to control the defense thereof; *provided*, *however*, that if such Indemnified Party shall have reasonably concluded that a conflict or potential conflict exists between the Indemnified Party and the Indemnifying Party or there may be defenses available to the Indemnified Party that are contrary to, or inconsistent with, those available to the Indemnifying Party, then, in each such event, the fees and expenses of not more than one additional counsel for the Indemnified Party shall be borne by the Indemnifying Party. The Members and Buyer shall cooperate with each other in all reasonable respects in connection with the defense of any Third-Party Claim, including making available (subject to the provisions of [Section 7.2](#iad153e23c3af4c5d94fd367f56a26c38_40)) records relating to such Third-Party Claim and furnishing, without expense (other than reimbursement of actual out-of-pocket expenses) to the defending party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third-Party Claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)***Settlement of Third-Party Claims***. Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third-Party Claim without the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld or delayed), except as provided in this [Section 9.5(b).](#iad153e23c3af4c5d94fd367f56a26c38_40) If a firm offer is made to settle a Third-Party Claim without leading to liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all liabilities and obligations in connection with such Third-Party Claim and the Indemnifying Party desires to accept and agree to such offer, the Indemnifying Party shall give written notice to that effect to the Indemnified Party. If the Indemnified Party fails to consent to such firm offer within ten (10) calendar days after its receipt of such notice, the Indemnified Party may continue to contest or defend such Third-Party Claim and in such event, the maximum liability of the Indemnifying Party as to such Third-Party Claim shall not exceed the amount of such settlement offer. If the Indemnified Party fails to consent to such firm offer and also fails to assume defense of such Third-Party Claim, the Indemnifying Party may settle the Third-Party Claim upon the terms set forth in such firm offer to settle such Third- Party Claim. If the Indemnified Party has assumed the defense pursuant to [Section 9.5(a),](#iad153e23c3af4c5d94fd367f56a26c38_40) it shall not agree to any settlement without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed), except with respect to Third-Party Claims related to Intellectual Property.

53

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)***Direct Claims*.** Any claim by an Indemnified Party on account of a Loss which does not result from a Third-Party Claim (a "<u>Direct Claim</u>") shall be asserted by the Indemnified Party giving the Indemnifying Party prompt written notice thereof. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have thirty (30) calendar days after its receipt of such notice to respond in writing to such Direct Claim. During such thirty

&nbsp;&nbsp;&nbsp;&nbsp;(30)calendar day period, the Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying Party's investigation by giving such information and assistance (including access to the Company's premises and personnel and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its professional advisors may reasonably request. If the Indemnifying Party does not so respond within such thirty (30)-calendar day period, the Losses identified in the notice of Direct Claim will be conclusively deemed a liability of the Members under [Section 9.2](#iad153e23c3af4c5d94fd367f56a26c38_40).

**Section 9.6 <u>Tax Treatment of Indemnification Payments</u>**. All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Closing Date Consideration for Tax purposes, unless otherwise required by Law.

**Section 9.7 <u>Exclusive Remedies</u>**. Subject to [Section 11.12,](#iad153e23c3af4c5d94fd367f56a26c38_46) the parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than claims arising from fraud on the part of a party hereto in connection with the transactions contemplated by this Agreement) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this [Article IX.](#iad153e23c3af4c5d94fd367f56a26c38_40) In furtherance of the foregoing, each party hereby waives, to the fullest extent permitted under Law, any and all rights, claims and causes of action for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement it may have against the other parties hereto and their Affiliates and each of their respective Representatives arising under or based upon any Law, except pursuant to the indemnification provisions set forth in this [Article IX.](#iad153e23c3af4c5d94fd367f56a26c38_40) Nothing in this [Section 9.7](#iad153e23c3af4c5d94fd367f56a26c38_40)shall limit any Person's right to seek and obtain any equitable relief to which any Person shall be entitled pursuant to [Section 11.12](#iad153e23c3af4c5d94fd367f56a26c38_46) or to seek any remedy on account of fraud by any party hereto.

**Section 9.8&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments; Escrow Release</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)In the event that Buyer has a claim for indemnification against the Members pursuant to this [Article IX,](#iad153e23c3af4c5d94fd367f56a26c38_40)Buyer shall be entitled to recover the amount of such claim and/or payment (i) first from the Escrow Fund, (ii) then, to the extent the Escrow Fund is insufficient, by set off against the First Contingent Payment or the Second Contingent Payment, if payable, and

&nbsp;&nbsp;&nbsp;&nbsp;(iii) finally, to the extent the amount of such claim and/or payment exceeds the amount of the

54

------

Escrow Fund and the amounts payable under the First Contingent Payment or the Second Contingent Payment, as applicable, from the Members directly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)On the date that is eighteen (18) months after the Closing Date, subject to the terms and conditions of the Escrow Agreement, the Escrow Agent shall distribute to the Members from the Escrow Fund (based on the updated Allocation Schedule delivered pursuant to Section 9.8(c)) an amount, if any, equal to the remaining balance of the Escrow Fund less the sum of (a) the amounts of the Second Escrow Deposit and the Third Escrow Deposit, if any, (b) any amounts with respect to which Buyer is entitled to, but has not yet received, indemnification, pursuant to Section 9.2, and (c) the amount of any unresolved claims for indemnification as of such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)On the date that is twelve (12) months after the Second Escrow Deposit, subject to the terms and conditions of the Escrow Agreement, the Escrow Agent shall distribute to the Members from the Escrow Fund (based on the updated Allocation Schedule delivered pursuant to Section 9.8(c)) an amount, if any, equal to the remaining balance of the Escrow Fund less the sum of (a) the amount of the Third Escrow Deposit, if any, (b) any amounts with respect to which Buyer is entitled to, but has not yet received, indemnification, pursuant to Section 9.2, and (c) the amount of any unresolved claims for indemnification as of such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)On the date that is twelve (12) months after the Third Escrow Deposit, subject to the terms and conditions of the Escrow Agreement, the Escrow Agent shall distribute to the Members from the Escrow Fund (based on the updated Allocation Schedule delivered pursuant to Section 9.8(c)) an amount, if any, equal to the remaining balance of the Escrow Fund, less the sum of (a) any amounts with respect to which Buyer is entitled to, but has not yet received, indemnification, pursuant to Section 9.2, and (b) the amount of any unresolved claims for indemnification as of such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Notwithstanding the foregoing, at least five (5) Business Days prior to any distribution of the Escrow Fund to the Members pursuant to this <u>[Section 9.8](#iad153e23c3af4c5d94fd367f56a26c38_40)</u>, the Members shall deliver to Buyer and the Escrow Agent an updated Allocation Schedule setting forth the portion of such distribution payable to each Member in accordance with the Company Operating Agreement as of immediately prior to the Closing.

**Section 9.9 <u>Effect of Investigation</u>**. The representations, warranties and covenants of the Indemnifying Party, and the Indemnified Party's right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of the Indemnified Party (including by any of its Representatives) or by reason of the fact that the Indemnified Party or any of its Representatives knew or should have known that any such representation or warranty is, was or might be inaccurate.

**ARTICLE X TERMINATION**

**Section 10.1&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>**. This Agreement may be terminated at any time prior

to the Closing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)by the mutual written consent of Buyer and the Members;

55

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)if an Event of Default has occurred and remains uncured for the respective cure periods set forth in the Loan Documents, by Buyer, for any reason, in its sole discretion, at any time during the Buyer Acquisition Option Term but prior to delivery of the Buyer Acquisition Notice;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)by Buyer, if (i) there shall have been a breach in any material respect of any representation and warranty in this Agreement of the Company or the Members, or (ii) the Company or the Members shall not have performed or complied in any material respect with any material covenant or material agreement of the Company or the Members contained in this Agreement, such that the conditions set forth in [Section 8.2(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)and [Section 8.2(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)(as applicable) would be incapable of being satisfied by the Termination Date (as defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)by the Members, if (i) there shall have been a breach in any material respect of any representation and warranty in this Agreement of Buyer, or (ii) Buyer shall not have performed or complied in any material respect with any material covenant or material agreement of Buyer, such that the conditions set forth in [Section 8.3(a)](#iad153e23c3af4c5d94fd367f56a26c38_40)and [Section 8.3(b)](#iad153e23c3af4c5d94fd367f56a26c38_40)(as applicable) would be incapable of being satisfied by the Termination Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)by Buyer if the Closing shall not have occurred before the date that is one hundred eighty (180) days after the delivery of an Acquisition Notice pursuant to Section 2.1 (or such later date as may be mutually agreed to be writing by the parties) (the "<u>Termination Date</u>"); *provided, however*, that the right to terminate this Agreement under this [Section 10.1(e)](#iad153e23c3af4c5d94fd367f56a26c38_40): (i) shall not be available to Buyer if its willful action or willful failure to act has been a principal cause of or resulted in the failure of the Closing to occur on or before such date and such action or failure to act constitutes a breach of this Agreement or (ii) shall be extended for an additional sixty

&nbsp;&nbsp;&nbsp;&nbsp;(60) days if the only condition(s) to Closing that remain unsatisfied at such time are as set forth in[Section 8.1](#iad153e23c3af4c5d94fd367f56a26c38_40);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)by the Members if the Closing shall not have been consummated before the Termination Date; *provided, however*, that the right to terminate this Agreement under this[Section 10.1(f)](#iad153e23c3af4c5d94fd367f56a26c38_40): (i) shall not be available to the Members if the willful action or willful failure to act of the Company or either Member has been a principal cause of or resulted in the failure of the Closing to occur on or before such date and such action or failure to act constitutes a breach of this Agreement or (ii) shall be extended for an additional sixty (60) days if the only condition(s) to Closing that remain unsatisfied at such time are as set forth in [Section 8.1](#iad153e23c3af4c5d94fd367f56a26c38_40);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)by the Members or Buyer if a Governmental Authority shall have issued an order, decree or ruling or taken any other action (including the failure to have taken an action), in any case having the effect of permanently restraining, enjoining or otherwise prohibiting the Closing, which order, decree, ruling or other action is final and nonappealable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)by the Members or Buyer if the Buyer Acquisition Option Term has expired and no Acquisition Notice has been delivered in accordance w[ith Section 2.1(a)](#iad153e23c3af4c5d94fd367f56a26c38_31);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)by Buyer if the Second FIH Study Milestone has not occurred on or before the Target Date; or

56

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)by Buyer upon the occurrence of an Event of Default (and subject to any applicable cure periods provided for in the Loan Documents).

**Section 10.2 <u>Procedure and Effect of Termination</u>**. If either Buyer or the Members desires to terminate this Agreement pursuant to [Section 10.1](#iad153e23c3af4c5d94fd367f56a26c38_40), such party shall give written notice of such termination to the other party. In the event that this Agreement shall be terminated pursuant to [Section 10.1,](#iad153e23c3af4c5d94fd367f56a26c38_40)this Agreement shall be of no further force or effect and all further obligations of the parties under this Agreement (other than under [Section 7.2(a),](#iad153e23c3af4c5d94fd367f56a26c38_40) this [Section 10.2](#iad153e23c3af4c5d94fd367f56a26c38_40) and [Article XI](#iad153e23c3af4c5d94fd367f56a26c38_40)) shall be terminated without further liability of any party to the other; *provided, however*, that nothing herein shall relieve any party from liability for breach of any representation, warranty, covenant or agreement hereunder occurring prior to such termination. Nothing contained in this Agreement shall prevent any party from electing not to exercise any right it may have to terminate this Agreement and, instead, seeking any remedies, including equitable relief (including specific performance), to which it would otherwise be entitled in the event of breach of any other party hereto.

**ARTICLE XI**

**MISCELLANEOUS**

**Section 11.1 <u>Expenses</u>**. Except as otherwise expressly provided herein, all costs and expenses, including fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.

**Section 11.2 <u>Notices</u>**. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given:

&nbsp;&nbsp;&nbsp;&nbsp;(a)when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent (i) during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) on the third Business Day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance w[ith this Section 11.2](#iad153e23c3af4c5d94fd367f56a26c38_40)):

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;If to the Members, or to the Company prior to Closing: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chansu Vascular Technologies, LLC 715 North Pastoria Avenue Sunnyvale, CA, 94085<br>Attn: Philippe Marco, CEO Email: pmarco@chansuvt.com<br>with a copy to: |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4725 College Park, Suite 200 San Antonio, TX 78249 Attn: John Asel, CFO<br>Email: jasel@chansuvt.com |

---

57

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;If to Buyer, or to the Company from and after Closing: | &nbsp;&nbsp;&nbsp;c/o Cardiovascular Systems, Inc. 1225 Old Highway 8 NW<br>St. Paul, MN 55112<br>Attention: Chief Financial Officer<br>with a copy to (which shall not constitute notice): <br>c/o Cardiovascular Systems, Inc.<br>1225 Old Highway 8 NW <br>St. Paul, MN 55112<br>Attention: General Counsel |
|  | &nbsp;&nbsp;&nbsp;with a copy to:<br>Dorsey & Whitney LLP <br>Suite 1500<br>50 South Sixth Street <br>Minneapolis, MN 55402<br>Facsimile: (612) 395-5247 <br>Attention: Brian G. Moore |

---

**Section 11.3 <u>Interpretation</u>**. For purposes of this Agreement: (a) the words "include," "includes" and "including" shall be deemed to be followed by the words "without limitation"; (b) the word "or" is not exclusive; and (c) the words "herein," "hereof," "hereby," "hereto" and "hereunder" refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and Sections of, and Disclosure Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.

**Section 11.4&nbsp;&nbsp;&nbsp;&nbsp;<u>Actions By Members</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Each Member, by the execution of this Agreement, hereby irrevocably appoints Philippe Marco as the representative, proxy and attorney-in-fact (with full power of substitution) for such Member for the limited purpose of carrying out any actions or decisions required by the "Members" under this Agreement or the Escrow Agreement. Where this Agreement provides for actions or decisions by the "Members", Philippe Marco shall have the sole power and authority to act on behalf of the Members and Buyer shall be entitled to rely only on

58

------

communications from Philippe Marco unless provided otherwise in a joint written communication from the Members to Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Within the scope of the authority granted to Philippe Marco under[Section 11.4(a),](#iad153e23c3af4c5d94fd367f56a26c38_43)each Member grants Philippe Marco the full and exclusive power and authority to represent and bind such Member (including the taking by Mr. Marco of any and all actions and the making of any decisions required or permitted to be taken on such Member's behalf), to: (a) execute and deliver the Escrow Agreement on behalf of the Members; (b) bring, defend and/or resolve any claim made or threatened pursuant to [Article IX](#iad153e23c3af4c5d94fd367f56a26c38_40); (c) negotiate, settle, adjust or compromise any such claims, bring suit or seek arbitration with respect to any such claims, and comply with orders of courts and awards of arbitrators with respect to any such claims; (d) act on behalf of such Member in any dispute, claim, litigation or arbitration that, in the judgment of Mr. Marco, may result in a claim pursuant to [Article IX](#iad153e23c3af4c5d94fd367f56a26c38_40); (e) act on behalf of such Member in connection with the matters contemplated by [Section 2.5](#iad153e23c3af4c5d94fd367f56a26c38_37); (f) cause to be paid from the Escrow Fund any amounts owed pursuant to [Section 2.5](#iad153e23c3af4c5d94fd367f56a26c38_37)or any indemnification claims, in each case in accordance with the terms and subject to the provisions of this Agreement and the Escrow Agreement; and (g) take all actions necessary in the judgment of Mr. Marco for the accomplishment of the foregoing. A decision, act, consent or instruction of Philippe Marco as to any of the foregoing matters shall constitute a decision of all Members and shall be final, binding and conclusive on each Member. EACH MEMBER AGREES THAT SUCH AGENCY AND PROXY ARE COUPLED WITH AN INTEREST, ARE THEREFORE IRREVOCABLE WITHOUT THE CONSENT OF PHILIPPE MARCO AND SHALL SURVIVE THE DEATH, INCAPACITY, BANKRUPTCY, DISSOLUTION OR LIQUIDATION OF ANY MEMBERS.

**Section 11.5 <u>Headings</u>**. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

**Section 11.6 <u>Severability</u>**. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Except as provided in Section 8.9, upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.

**Section 11.7 <u>Entire Agreement</u>**. This Agreement and the other Transaction Documents constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous representations, warranties, understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents and the Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body

59

------

of this Agreement will control. This Agreement replaces the Original Agreement in its entirety and the Original Agreement shall be of no further force or effect.

**Section 11.8 <u>Successors and Assigns</u>**. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. No party may assign its rights or obligations hereunder without the prior written consent of the other parties, which consent shall not be unreasonably withheld or delayed; *provided*, that, notwithstanding the foregoing, Buyer shall have the right to assign this Agreement without consent to any Affiliate of Buyer, in which case Buyer will remain liable for its obligations under this Agreement. No assignment shall relieve the assigning party of any of its obligations hereunder.

**Section 11.9 <u>No Third-party Beneficiaries</u>**. Except as provided in [Section 7.1](#iad153e23c3af4c5d94fd367f56a26c38_40) and [Article IX,](#iad153e23c3af4c5d94fd367f56a26c38_40)this Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

**Section 11.10 <u>Amendment and Modification; Waiver</u>**. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

**Section 11.11 <u>Governing Law; Submission to Jurisdiction; Waiver of Jury</u>**

**<u>Trial</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)This Agreement shall be governed by and construed in accordance with the

internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY MAY BE INSTITUTED IN THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE COUNTY OF NEWCASTLE, DELAWARE OR IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE, AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO SUCH PARTY'S ADDRESS SET FORTH HEREIN SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY SUIT, ACTION OR OTHER PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND

60

------

IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THI[S Section 11.11(c).](#iad153e23c3af4c5d94fd367f56a26c38_46)

**Section 11.12 <u>Specific Performance</u>**. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity. Any action or proceeding for any such remedy shall be brought exclusively in the Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware (or, only if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal court within the State of Delaware), and each party waives (i) any objection that it may have to the venue of any such action or proceeding, and (ii) any requirement for the securing or posting of any bond in connection with any such remedy. The parties further agree that (x) by seeking the remedies provided for in this [Section 11.12](#iad153e23c3af4c5d94fd367f56a26c38_46), a party shall not in any respect waive its right to seek any other form of relief that may be available to a party under this Agreement, including monetary damages and

&nbsp;&nbsp;&nbsp;&nbsp;(y) nothing contained in this [Section 11.12](#iad153e23c3af4c5d94fd367f56a26c38_46)shall require any party to institute any proceeding for (or limit any party's right to institute any proceeding for) specific performance under this[Section 11.12](#iad153e23c3af4c5d94fd367f56a26c38_46)before pursuing damages nor shall the commencement of any action pursuant to this[Section 11.12](#iad153e23c3af4c5d94fd367f56a26c38_46)or anything contained in this [Section 11.12](#iad153e23c3af4c5d94fd367f56a26c38_46)restrict or limit any other remedies under this Agreement that may be available then or thereafter.

**Section 11.13 <u>Counterparts</u>**. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

[SIGNATURE PAGE FOLLOWS]

61

------

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

---

| | |
|:---|:---|
| CARDIOVASCULAR SYSTEMS, INC. | CARDIOVASCULAR SYSTEMS, INC. |
| By: | /s/ Scott Ward |
| Name: | Scott Ward |
| Title: | Chairman, President and Chief Executive Officer |

---

---

| | |
|:---|:---|
| CHANSU VASCULAR TECHNOLOGIES, LLC | CHANSU VASCULAR TECHNOLOGIES, LLC |
| By: | /s/ Philippe Marco |
| Name: | Philippe Marco |
| Title: | Manager |
| MEMBERS: | MEMBERS: |
| /s/ Philippe Marco | /s/ Philippe Marco |
| Philippe Marco | Philippe Marco |
| /s/ Cathy Mantor | /s/ Cathy Mantor |
| Cathy Mantor | Cathy Mantor |
| /s/ John Ansel | /s/ John Ansel |
| John Ansel | John Ansel |

---

------

**EXHIBIT A: FORM OF ESCROW AGREEMENT**

**EXHIBIT B: FORM OF JOINDER AGREEMENT**

**DISCLOSURE SCHEDULES**

## Exhibit 10.3

**Exhibit 10.3**

**EXECUTION VERSION**

**PRODUCT DEVELOPMENT AGREEMENT**

This Product Development Agreement (this "<u>Agreement</u>"), effective as of January 29, 2021 (the "<u>Effective Date</u>"), is made by and between Cardiovascular Systems, Inc., a Delaware corporation with its principal place of business at 1225 Old Highway 8 NW, Saint Paul, Minnesota 55112 ("<u>CSI</u>"), and Chansu Vascular Technologies, LLC, a Delaware limited liability company, with its principal place of business at 715 North Pastoria Avenue, Sunnyvale, CA, 94085 ("<u>CVT</u>" and, together with CSI, the "<u>Parties</u>" and each a "<u>Party</u>").

**WHEREAS**, concurrently with the execution of this Agreement, CSI and CVT have entered into the Acquisition Option Agreement (the "<u>Acquisition Option Agreement</u>"), the Loan Agreement (the "<u>Loan Agreement</u>"), the Security Agreement (the "<u>Security Agreement</u>" and, together with the Loan Agreement, the "<u>Loan Documents</u>"), each dated as of the Effective Date (the "<u>Related Agreements</u>"); and

**WHEREAS**, this Agreement sets forth the terms and conditions of the performance of certain product development services CVT will be performing for CSI.

**NOW, THEREFORE**, in consideration of the foregoing, including the potential payments to CVT under the Acquisition Option Agreement and the Loan Documents and the mutual covenants, conditions and provisions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties agree as follows:

**ARTICLE I**

**DEFINITIONS**

When used in this Agreement, each of the following terms shall have the meaning specified in this <u>Article I</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Affiliate</u>" of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term "control" (including the terms "controlled by" and "under common control with") means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Background Information</u>" means any Information that, as evidenced by a Party's written records, is owned, licensed or controlled, in whole or in part, directly or indirectly, by such Party or its Affiliates: (a) prior to the Effective Date of this Agreement; or (b) that results from any activity, acquisition, development or other work by such Party or its Affiliates (including if performed concurrently with the Project or the Agreement) that is independent from or unrelated to the Project as set forth the Development Plan or the Agreement. Background Information does not include Foreground Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Background IP</u>" means IP that is based on Background Information or IP that, as evidenced by a Party's written records, is owned, licensed or controlled, in whole or in part,

------

directly or indirectly, by a Party or its Affiliates: (a) prior to the Effective Date of this Agreement; or (b) that results from any activity, acquisition, development or other work by such Party or its Affiliates (including if performed concurrently with the Project or the Agreement) that is independent from or unrelated to the Project as set forth in the Development Plan or the Agreement. Background IP does not include Foreground IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Business Day</u>" means any day except Saturday, Sunday or any other day on which commercial banks located in Wilmington, Delaware are authorized or required by law to be closed for business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Confidential Information</u>" means any Information that is treated as confidential by a Party or its Affiliates, whether in oral, written, electronic, or other form or media, whether or not such Information is marked, designated, or otherwise identified as "confidential," and includes any Information that due to the nature of its subject matter or circumstances surrounding its disclosure, would reasonably be understood to be non-public, confidential, or proprietary, including, without limitation: (a) all Information concerning past, present, and future business affairs including finances, customer information, supplier information, products, services, organizational structure and internal practices, forecasts, sales and other financial results, records and budgets, and business, marketing, research, development, sales and other commercial strategies; (b) all Information concerning unpatented inventions, ideas, methods, discoveries, know-how, trade secrets, unpublished patent applications, invention disclosures, invention summaries, and other confidential intellectual property; (c) all designs, specifications, documentation, components, schematics, drawings, protocols, processes, and other visual depictions, in whole or in part, of any of the foregoing; and (d) all notes, analyses, compilations, reports, forecasts, studies, samples, data, statistics, summaries, interpretations, and other materials that contain, are based on, or otherwise reflect or are derived from, any of the foregoing in whole or in part.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Deliverables</u>" means those items to be furnished by CVT under this Agreement, as specified in the Development Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Design Verification Milestone</u>" means completion of the first review of design verification testing ("<u>DVT</u>") per CVT Design Control procedure in support of first in human study of a Product to occur in accordance with this Agreement in form and substance reasonably acceptable to CSI prior to filing of the DVT to the competent authority, as set forth in the Development Plan under "Calendar Quarter ending September 30, 2021: DVT Completion – FIH Initiation," which shall be determined in accordance with the following process:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7.1.&nbsp;&nbsp;&nbsp;&nbsp;If CVT reasonably and in good faith determines that the Design Verification Milestone has been achieved, CVT shall provide written notice thereof to CSI along with evidence in reasonable detail of the achievement of the Design Verification Milestone (the "<u>DVT Notice</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7.2.&nbsp;&nbsp;&nbsp;&nbsp;A final determination of Design Verification Milestone shall be deemed to have occurred (A) as of the date that CSI confirms in writing that Design Verification Milestone has been achieved, or (B) as of the date that is ten (10) Business Days after the date of the DVT

------

Notice if CSI fails to object to CVT's determination that Design Verification Milestone has been achieved prior to such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7.3.&nbsp;&nbsp;&nbsp;&nbsp;In the event that CSI objects to CVT's determination, the Parties will negotiate in good faith to resolve any disagreement regarding whether Design Verification Milestone has been achieved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Development Plan</u>" means the plan for development of the Products, including the scope of work, objectives, milestones and Specifications, and which is attached as <u>Exhibit A</u> and may be amended from time-to-time in accordance with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9.&nbsp;&nbsp;&nbsp;&nbsp;"<u>FDA</u>" shall mean the United States Food and Drug Administration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.&nbsp;&nbsp;&nbsp;&nbsp;"<u>FIH Study Completion</u>" means receipt by CVT of a study report establishing that CVT has successfully demonstrated clinical performance in a first-in-human study (a) with a study size that is sufficient to support IDE Approval (i.e., replaces the need for an IDE feasibility study) for a coronary use with an in stent restenosis (ISR) indication with respect to the PTCA-DCB Product or a superficial femoral arterial (SFA) use indication with respect to the PTA-DCB Product and (b) that meets the study objectives by achievement of pre-specified safety and effectiveness endpoints that are defined in the study protocol that has been agreed to in writing by CVT and CSI, which shall be determined in accordance with the following process:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.1.&nbsp;&nbsp;&nbsp;&nbsp;If CVT reasonably and in good faith determines that the FIH Study Completion for a Product has been achieved, CVT shall provide written notice thereof to CSI along with evidence in reasonable detail of the achievement of FIH Study Completion (the "<u>FIH Notice</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.2&nbsp;&nbsp;&nbsp;&nbsp;A final determination of FIH Study Completion shall be deemed to have occurred (A) as of the date that CSI confirms in writing that FIH Study Completion has been achieved, or (B) as of the date that is ten (10) Business Days after the date of the FIH Notice if CSI fails to object to CVT's determination that FIH Study Completion has been achieved prior to such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.3&nbsp;&nbsp;&nbsp;&nbsp;In the event that CSI objects to CVT's determination, the Parties will negotiate in good faith to resolve any disagreement regarding whether FIH Study Completion has been achieved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11.&nbsp;&nbsp;&nbsp;&nbsp;"<u>First FIH Study Milestone</u>" means the occurrence of the first FIH Study Completion with respect to a Product, provided, that such FIH Study Completion occurs on or before the Target Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Foreground Information</u>" means Information that arises during the term of this Agreement and within the scope of the Project as set forth in the Development Plan or the Agreement. Foreground Information does not include Background Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Foreground Information and IP</u>" means Foreground Information and Foreground IP.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Foreground IP</u>" means IP that is based on Foreground Information or IP that arises under this Agreement and within the scope of the Project as set forth in the Development Plan or this Agreement. Foreground IP does not include Background IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.15.&nbsp;&nbsp;&nbsp;&nbsp;"<u>IDE Approval</u>" means the receipt of an FDA Letter stating that a Product has achieved unconditional pivotal FDA Investigational Device Exemption approval (i.e., "full approval") that enables the conduct of a pivotal clinical trial: (a) with respect to the PTCA-DCB Product, for coronary use of the PTCA-DCB Product that is designed to achieve Premarket Approval Application approval for a coronary use with an in stent restenosis indication; and/or (b) with respect to the PTA-DCB Product, for use in superficial femoral artery of the PTA-DCB that is designed to achieve Premarket Approval Application approval for an SFA indication.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.16.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Information</u>" means any and all ideas, concepts, data, know-how, discoveries, improvements, methods, techniques, technologies, systems, specifications, analyses, products, practices, processes, procedures, protocols, research, tests, trials, assays, controls, prototypes, formulas, descriptions, formulations, submissions, communications, skills, experience, knowledge, plans, objectives, algorithms, reports, results, conclusions, and other information and materials, irrespective of whether or not copyrightable or patentable and in any form or medium (tangible, intangible, oral, written, electronic, observational, or other) in which such Information may be communicated or subsist. Without limiting the foregoing sentence, Information includes any technological, scientific, business, legal, patent, organizational, commercial, operational, or financial materials or information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.17.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Intellectual Property</u>" or "<u>IP</u>" means all patentable and unpatentable inventions, works of authorship or expression, including computer programs, data collections and databases, and Trade Secrets, and other Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.18.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Key Supplier</u>" means the suppliers of coating formulation, balloons, packaging and sterilization for the Products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.19.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Losses</u>" means all losses, damages, liabilities, demands, actions or causes of action (including third party claims), charges, interest, judgments, sanctions, fines, penalties, settlements, costs or expenses, including reasonable attorneys' fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.20.&nbsp;&nbsp;&nbsp;&nbsp; "<u>Person</u>" means any individual, corporation, partnership, limited liability company, joint venture, association, organization, governmental entity or other legal entity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.21.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Products</u>" means the PTA-DCB Product and the PTCA-DCB Product, and "<u>Product</u>" means either Product as the context requires.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.22.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Project</u>" means CVT's performance of development services and furnishing of functional prototype samples as described more fully in the Development Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.23.&nbsp;&nbsp;&nbsp;&nbsp;"<u>PTA-DCB Product</u>" means a drug coated balloon catheter to treat superficial femoral arterial lesions of patients with peripheral vascular disease, as more fully described in the Development Plan, as modified by mutual agreement of the Parties in writing, along with any improvements thereto as developed by CVT pursuant to this Agreement.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.24.&nbsp;&nbsp;&nbsp;&nbsp;"<u>PTCA-DCB Product</u>" means a drug coated balloon catheter to treat superficial coronary lesions of patients with cardiovascular disease, as more fully described in the Development Plan, as modified by mutual agreement of the Parties in writing, along with any improvements thereto as developed by CVT pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.25.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Second FIH Study Milestone</u>" means the occurrence of the FIH Study Completion with respect to the Second Product, provided, that such FIH Study Completion occurs on or before the Target Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.26.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Second Product</u>" means the second Product to achieve FIH Study Completion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.27.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Specifications</u>" means the technical specifications for the Products as set forth in, or to be developed in accordance with, the Development Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.28.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Target Date</u>" means December 31, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.29.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Third Party Materials</u>" means all materials, software, Information, inventions, methods, procedures and technology owned by third parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.30.&nbsp;&nbsp;&nbsp;&nbsp;"<u>Trade Secrets</u>" means proprietary and confidential know-how and other Information of a Party which is unpublished and not made available to third parties except under a confidentiality obligation, including, but not limited to, Intellectual Property resulting from the Project. For purposes of this Agreement, all such Information shall be deemed to be, and treated by the Parties as, Trade Secrets regardless of whether or not it may be protectable as a "trade secret" under applicable federal or state law.

**ARTICLE II<br>PROJECT DEVELOPMENT**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Purpose</u>. CVT shall use commercially reasonable efforts, including, but not limited to, allocating the necessary funds and personnel, to develop the Products according to the Specifications and achieve the development milestones set forth in the Development Plan (the "<u>Development Milestones</u>") in accordance with this Agreement. CSI shall designate appropriate personnel to work with CVT in connection with the Development Milestones. The Development Plan contains the specific phases, milestones and Deliverables of the Project and identifies the respective responsibilities of the Parties in developing the Products. The Parties may agree to amend the Development Plan, from time-to-time, as circumstances may require, in accordance with Sections 2.5 and 7.10.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Steering Committee</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.1.&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall, within five (5) Business Days after the Effective Date, establish a review team for the Project that shall include two (2) members designated by CVT and one (1) member designated by CSI (the "<u>Steering Committee</u>"). In accordance with the provisions and objectives of this Agreement, the Steering Committee shall coordinate and review the Parties' respective activities under the Project and ensure communication between the Parties concerning the status and results of the Project.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.2.&nbsp;&nbsp;&nbsp;&nbsp;The Steering Committee shall meet as needed as determined by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.3.&nbsp;&nbsp;&nbsp;&nbsp;The Steering Committee has only the powers specifically delegated to it by this Agreement and has no authority to act on behalf of any party in connection with any third party. Without limiting the foregoing, the Steering Committee has no authority to, and shall not purport to or attempt to (a) negotiate agreements on behalf of any Party; (b) make representations or warranties on behalf of any Party; (c) waive rights of any party; (d) extend credit on behalf of any Party; or (e) take or grant licenses of, transfer ownership, or otherwise encumber Intellectual Property on behalf of any Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.4.&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall bear all expenses of its respective Steering Committee members related to their participation on the Steering Committee and attendance at Steering Committee meetings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Meetings and Reports</u>. At least once a month, or at some other frequency set forth in the Development Plan, CVT shall provide to CSI a written status report including, at a minimum, the following: (a) description of the work carried out by CVT in the previous month pursuant to the Development Plan; (b) transcripts of meetings with, and copies of correspondence and submissions to or from, any regulatory bodies or other governmental authorities regarding the Project or a Product; (c) current status against the Deliverables listed in the Development Plan; (d) how the Project is tracking against the schedule in the Development Plan; and (e) current problems or challenges related to the work under the Development Plan, if any, and a resolution plan to address them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delays</u>. Each Party will promptly notify the other Party in the event of any actual or anticipated delay that may affect its ability to meet any date set forth in the Development Plan. The Parties recognize the need to maintain the development schedule so notification at the earliest awareness of a potential schedule impact to permit efforts to be made to recover lost time in order to maintain the development schedule. Following such notice, the Parties will cooperate and use their respective commercially reasonable efforts to solve any problems identified.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Modifications to the Development Plan</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.1.&nbsp;&nbsp;&nbsp;&nbsp;Each Party may from time-to-time request a modification to the Development Plan. All such requests must be in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.2.&nbsp;&nbsp;&nbsp;&nbsp;Following a request by CSI, CVT will promptly deliver to CSI an evaluation specifying whether the proposed change is feasible and setting forth the impact, if any, the proposed modification will have on the Development Plan and the budget. Following receipt of CVT's evaluation, CSI will promptly notify CVT whether it wishes to have the proposed modification implemented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.3.&nbsp;&nbsp;&nbsp;&nbsp;Any request by CVT will include the rationale for the modification and specify the impact, if any, the modification will have on the Development Plan and the budget. Following receipt of CSI's evaluation of CVT's request, including any limitations or restrictions of the proposed modification, CVT will promptly notify CSI whether it wishes to have the proposed modification implemented.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.4.&nbsp;&nbsp;&nbsp;&nbsp;Any modification agreed to by the Parties resulting in a change to the Development Plan must be documented in a written revision to the Development Plan in accordance with Section 7.10.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Subcontracting</u>. CVT may not subcontract any portion of the work associated with the Development Plan or utilize any Key Suppliers without CSI's prior written consent signed by an authorized representative of CSI; provided, however, that CVT may identify subcontractors and Key Suppliers in the Development Plan. Any subcontracting will be subject to the following terms:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6.1.&nbsp;&nbsp;&nbsp;&nbsp;The subcontracting must be under a written agreement which obligates the subcontractor to comply with substantially similar relevant terms and conditions of the Agreement and the Development Plan as though it were CVT.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6.2.&nbsp;&nbsp;&nbsp;&nbsp;CVT is responsible to CSI for all acts and omissions of the subcontractor in relation to this Agreement, including breaches of confidentiality or misuse of Intellectual Property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7.&nbsp;&nbsp;&nbsp;&nbsp;<u>[Reserved]</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Warranties</u>. CVT represents and warrants to CSI that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8.1.&nbsp;&nbsp;&nbsp;&nbsp;CVT will render services to CSI hereunder in a lawful, businesslike and professional manner in accordance with generally accepted standards for the nature of the work performed and will act in a manner reasonably calculated to protect the good name and business reputation of CSI;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8.2.&nbsp;&nbsp;&nbsp;&nbsp;CVT will use commercially reasonable efforts to satisfy its obligations under the Development Plan and provide Deliverables free of defects on delivery. Further, CVT warrants that it will not incorporate into any Deliverable the Confidential Information, Intellectual Property or Trade Secrets of any third party without the authorization of any such third party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8.3.&nbsp;&nbsp;&nbsp;&nbsp;CVT is not now, and will not be at any time during the term of this Agreement, under any obligation of a contractual or other nature to any Person which is inconsistent or in conflict with this Agreement, or which would prevent, limit or impair the execution of this Agreement or the performance by CVT of CVT's obligations hereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8.4.&nbsp;&nbsp;&nbsp;&nbsp;CVT has or will obtain any necessary permits or licenses to perform the services contemplated hereunder and otherwise comply with all applicable laws or regulations in performance of services described herein; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8.5.&nbsp;&nbsp;&nbsp;&nbsp;all Deliverables shall be (i) free and clear of all liens and encumbrances, (ii) original and not copied, and (iii) to the best of CVT's knowledge free and clear of all claims, or demands of third parties, including any claims by any such third parties of any right, title or interest in or to such Deliverables arising out of any Trade Secret, copyright or patent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification</u>.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9.1&nbsp;&nbsp;&nbsp;&nbsp;Each Party (an "<u>Indemnifying Party</u>") shall indemnify, defend, and hold harmless the other Party, its Affiliates and their respective customers, officers, directors, employees, agents, successors, and assigns (collectively, the "<u>Indemnified Parties</u>") against all Losses arising out of or resulting from any third-party claim, suit, action, or proceeding related to or arising out of or resulting from (a) the other Party's breach of any representation, warranty, covenant, or obligation under this Agreement; or (b) use by a Party of the other Party's Background IP in connection with any activities performed pursuant to the Project (each an "<u>Action</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9.2&nbsp;&nbsp;&nbsp;&nbsp;Each Indemnified Party shall promptly notify the Indemnifying Party in writing of any Action and cooperate with the Indemnified Party at the Indemnifying Party Party's sole cost and expense. The Indemnifying Party shall immediately take control of the defense and investigation of the Action and shall employ counsel reasonably acceptable to the Indemnified Party to handle and defend the Action, at the Indemnifying Party's sole cost and expense. The Indemnifying Party shall not settle any Action in a manner that adversely affects the Indemnified Party's rights without the Indemnified Party's prior written consent, which shall not be unreasonably withheld or delayed. The Indemnified Party's failure to perform any obligations under this <u>Section 2.9.2</u> shall not relieve the Indemnifying Party of its obligation under this <u>Section 2.9.2</u> except to the extent that the Indemnifying Party can demonstrate that Indemnifying Party has been materially prejudiced as a result of the failure. The Indemnified Party may participate in and observe the proceedings at its own cost and expense with counsel of Indemnified Party's own choosing.

**ARTICLE III**

**CONFIDENTIALITY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Disclosure</u>. The Parties acknowledge that CSI and CVT have previously executed a certain Mutual Non-Disclosure Agreement, dated August 21, 2020 (the "<u>Confidentiality Agreement</u>"), which Confidentiality Agreement will continue in full force and effect in accordance with the its terms and each of CSI and CVT will hold, and will cause its respective directors, officers, employees, agents and advisors (including attorneys, accountants, consultants, bankers and financial advisors) to hold, any Confidential Information (as defined in the Confidentiality Agreement) confidential in accordance with the terms of the Confidentiality Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Publicity</u>. Unless otherwise required by applicable Law or stock exchange requirements (based upon the reasonable advice of counsel), neither Party shall make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of the other Party (which consent shall not be unreasonably withheld or delayed), and the Parties shall cooperate as to the timing and contents of any such announcement. Notwithstanding the foregoing, (a) CSI shall be entitled to make any public disclosure required by applicable Laws and any rules or regulations of any supervisory, regulatory or other governmental authority having jurisdiction over it or any of its Affiliates (including the Securities and Exchange Commission and the New York Stock Exchange), including disclosure of this Agreement as a material contract in its filings with the Securities and Exchange Commission and any subsequent disclosures and press releases related thereto and (b) nothing contained in this Agreement will limit CSI's (or its Affiliates')

------

rights to disclose the existence of this Agreement and the general nature of the transaction described herein on any earnings call or in similar discussions with financial media or analysts, stockholders and other members of the investment community.

**ARTICLE IV**

**INTELLECTUAL PROPERTY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>General</u>. The Parties acknowledge and agree that, except as expressly provided in this Agreement or the Development Plan, no rights under either Party's Intellectual Property are granted to the other Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Identification</u>. CVT shall identify in the Development Plan which portion of the Deliverables it anticipates will be comprised of Background Information, Background IP and Third Party Materials. If CVT desires to change the portion of the Deliverables it anticipates will be comprised of Background Information, Background IP or Third Party Materials during performance of the Development Plan, any such changes require CSI's prior written consent through the procedure in <u>Section 2.5</u>. Any portion of the Deliverables which is not described in the Development Plan as Background Information, Background IP or Third Party Materials shall be deemed Foreground Information or Foreground IP. CVT shall not use Third Party Materials except as permitted in this <u>Section 4.2</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Ownership</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Background Information and IP</u>. Except as expressly provided herein otherwise, all right, title and interest in and to any and all Background Information and Background IP shall remain solely and exclusively with the respective Party or its Affiliates, or its third party suppliers, as the case may be.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Foreground Information and IP</u>. All right, title and interest in and to Foreground Information and IP to the Products shall vest in CVT regardless of whose employee or employees made an invention or creation or the Party that commissioned a third party to make an invention or creation on its behalf, resulting in such Foreground Information or Foreground IP. Accordingly, CSI hereby irrevocably and unconditionally grants and assigns to CVT in perpetuity, now and in the future, all rights, title, and interest whatsoever throughout the world in and to Foreground Information and Foreground IP to the Product made by CVT, alone or with others, except as set forth in <u>Section 4.4</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>License for Project</u>. Each Party hereby grants to the other Party and its Affiliates a non-exclusive, non-transferable, world-wide, royalty-free and fully paid-up license, without the right to grant sublicenses, under any and all Intellectual Property Rights during the Term solely for the purpose of performing activities necessary for the Project and in accordance with the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>License of Background IP</u>. CSI grants to CVT and its Affiliates a non-exclusive, irrevocable, perpetual, world-wide, transferable, royalty-fee, fully-paid license, with the right to sublicense, in and to Background IP to the extent embodied in, practiced by or used in any Deliverable provided under this Agreement, to make, have made, use, offer to sell or rent, sell,

------

rent, import, otherwise dispose of and/or practice or prepare derivative works based upon, the Products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Exceptions to Licenses</u>. Notwithstanding anything to the contrary in this Agreement, no licenses are granted pursuant to this <u>Article IV</u> by either Party under Third Party Materials which are not licensable, or, if licensable, would require payment of a royalty or other consideration by the licensing Party to a third party other than an Affiliate of that Party.

**ARTICLE V**

**TERM, TERMINATION AND LIABILITY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Term</u>. This Agreement shall become binding and enforceable on the Effective Date, and this Agreement shall continue in force until all obligations outlined in the Development Plan have been fulfilled or discharged, unless terminated sooner in accordance with <u>Section 5.2</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>. Notwithstanding <u>Section 5.1</u>, this Agreement may be terminated in accordance with the following provisions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2.1.&nbsp;&nbsp;&nbsp;&nbsp;CSI may terminate this Agreement and the Development Plan upon written notice to CVT if CVT is in default under any Related Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2.2.&nbsp;&nbsp;&nbsp;&nbsp;Either Party may terminate this Agreement and the Development Plan upon thirty (30) days' written notice to the other Party if the other Party is in default in any material obligation under this Agreement, including failure to achieve a milestone or other material requirement of the Development Plan, and the other Party fails to cure said default within said thirty (30)-day period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2.3.&nbsp;&nbsp;&nbsp;&nbsp;Either Party may terminate this Agreement at any time by giving written notice to the other Party should the other Party file a petition of any type as to its bankruptcy, be declared bankrupt, become insolvent, make an assignment for the benefit of creditors or go into liquidation or receivership.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2.4.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall terminate upon either closing of the transactions contemplated by the Acquisition Option Agreement or termination of the Acquisition Option Agreement or the Loan Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights and Obligations on Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.1.&nbsp;&nbsp;&nbsp;&nbsp;In the event of termination of this Agreement by CSI, on request by CSI, CVT shall immediately cease to perform the work contemplated hereunder. In the event the termination relates to only part of the services to be rendered under this Agreement, then the Parties' obligations for performance under this Agreement shall not be affected and shall continue in accordance with the Development Plan. The Parties may agree to provide alternate termination procedures in the Development Plan and the terms concerning termination in the Development Plan shall supersede the terms set forth in this Agreement for the Development Plan.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.2.&nbsp;&nbsp;&nbsp;&nbsp;The termination of this Agreement shall not affect either Party's right to pursue any other remedy at law or in equity which it may have against the other Party for breach of contract or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. The rights and obligations of the Parties set forth in this <u>Section 5.4</u> and <u>Article I</u> (Definitions), <u>Section 2.9</u> (Indemnification), <u>Article III</u> (Confidentiality), <u>Section 4.3</u> (Ownership), Article VI (Dispute Resolution) and <u>Article VII</u> (Miscellaneous), and any right, obligation, or required performance of the Parties in this Agreement which, by its express terms or nature and context is intended to survive termination or expiration of this Agreement, shall survive any such termination or expiration.

**ARTICLE VI**

**DISPUTE RESOLUTION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Discussions</u>. The Parties recognize that disputes may arise that might not be resolved by the Steering Committee. Except as otherwise provided in this Agreement, and except for equitable relief, the Parties shall use their best efforts to resolve any dispute between them promptly and amicably and without resort to any legal process if feasible within thirty (30) days of receipt of a written notice by one Party to the other Party of the existence of such dispute. Upon receipt of such notice, the chief executive officers of the Parties shall promptly meet in good faith to discuss such dispute. The foregoing requirement in this <u>Section 6.2</u> shall be without prejudice to either Party's rights, if applicable, to terminate this Agreement under <u>Section 5.2</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>JURISDICTION</u>. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY MAY BE INSTITUTED IN THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE COUNTY OF NEWCASTLE, DELAWARE OR IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE, AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO SUCH PARTY'S ADDRESS SET FORTH HEREIN SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY SUIT, ACTION OR OTHER PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>WAIVER OF JURY TRIAL</u>. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE,

------

EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <u>SECTION 6.4</u>.

**ARTICLE VII**

**MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Waiver</u>. The failure of either Party to enforce at any time or for any period any of the provisions of this Agreement shall not be construed to be a waiver of those provisions or of the right of that Party thereafter to enforce each and every provision hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment</u>. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns. No Party may assign its rights or obligations hereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided, that, notwithstanding the foregoing, CSI shall have the right to assign this Agreement without consent to any Affiliate of CSI, in which case CSI will remain liable for its obligations under this Agreement. No assignment shall relieve the assigning Party of any of its obligations hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given: (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent (i) during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient; or (d) on the third Business Day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with this <u>Section 7.3</u>):

If to CVT:

Chansu Vascular Technologies, LLC<br>715 North Pastoria Avenue

Sunnyvale, CA, 94085

Attn: Philippe Marco, CEO

With a copy to:

Chansu Vascular Technologies, LLC

------

4725 College Park, Suite 200

San Antonio, TX. 78249 <br>Attn: John Asel, CFO

If to CSI:

Cardiovascular Systems, Inc.<br>1225 Old Highway 8 NW<br>Saint Paul, Minnesota 55112<br>Attn: VP of Corporate Development

With a copy to:

Cardiovascular Systems, Inc.<br>1225 Old Highway 8 NW<br>Saint Paul, Minnesota 55112<br>Attn: General Counsel

Any such notice, report or statement sent in accordance with this <u>Section 7.3</u> shall be deemed duly given upon dispatch, subject to proof of receipt.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Independent Contractor Status</u>. The relationship between CVT and CSI established hereby is that of independent contractors, and nothing contained herein shall be deemed to create a relationship of employer and employee, principal and agent, partners, or otherwise. Neither Party shall have any authority to obligate the other in any respect nor hold itself out as having any such authority. All personnel of CVT shall be solely employees of CVT and shall not represent themselves as employees of CSI, and all personnel of CSI shall be solely employees of CSI and shall not represent themselves as employees of CVT. CVT shall bear sole responsibility for payment of compensation to its personnel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Titles of Articles and Sections</u>. The titles of the Articles and Sections of this Agreement are used for convenience of reference only and are not intended to and shall not in any way enlarge or diminish the rights or obligations of the Parties or affect the meaning or construction of this document. All references to "Sections" or "Articles" mean the Sections and Articles of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. Unless otherwise expressly provided, all remedies hereunder are cumulative, are in addition to any other remedies provided for by law and may, to the extent permitted by law, be exercised concurrently or separately, and the exercise of any one remedy shall not be deemed to be an election of such remedy or to preclude the exercise of any other remedy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. In the event that any provision of this Agreement would be held in any jurisdiction to be invalid, prohibited or unenforceable for any reason, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction. Notwithstanding the foregoing, if such provision could be more narrowly drawn so as not to be

------

invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Interpretation</u>. For purposes of this Agreement, (a) the words "include," "includes" and "including" shall be deemed to be followed by the words "without limitation"; (b) the word "or" is not exclusive; and (c) the words "herein," "hereof," "hereby," "hereto" and "hereunder" refer to this Agreement as a whole. Whenever the singular is used in this Agreement, the same shall include the plural, and whenever the plural is used herein, the same shall include the singular, where appropriate. Any reference to an Article, Section, Exhibit, Schedule, clause, subclause, paragraph or subparagraph is a reference to an Article, Section, Exhibit, Schedule, clause, subclause, paragraph or subparagraph.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Investigation; Joint Preparation</u>. Each Party acknowledges that it has had adequate opportunity to make whatever investigation or inquiry it deems necessary or desirable in connection with the subject matter of this Agreement prior to the execution hereof. Each Party further acknowledges that it has read and understands each provision of this Agreement. This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party, it being agreed that each Party has had an opportunity to consult with counsel of its own choosing regarding the terms and conditions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Integration/Modification/Entire Agreement</u>. This Agreement (including, but not limited to, any Exhibits, which are incorporated by reference and made a part of this Agreement) sets forth the entire agreement and understanding between the Parties as to the subject matter hereof, and supersedes, integrates and merges all prior discussions, correspondence, negotiations, understandings or agreements and except for any confidentiality agreements between CVT and CSI (or any of their respective Affiliates) which, in each case, shall continue in full force and effect (as modified by this Agreement, if applicable). This Agreement (including the Development Plan) may not be altered, amended, modified or otherwise changed in any way except by a written instrument, which specifically identifies the intended alteration, amendment, modification or other change and clearly expresses the intention to so change this Agreement, signed by an authorized representative of the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

*Signature page follows.*

------

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

CHANSU VASCULAR TECHNOLOGIES, LLC

By: <u>/s/ Philippe Marco&nbsp;&nbsp;&nbsp;&nbsp;</u>

Name: <u>Philippe Marco&nbsp;&nbsp;&nbsp;&nbsp;</u>

Title: <u>CEO&nbsp;&nbsp;&nbsp;&nbsp;</u>

CARDIOVASCULAR SYSTEMS, INC.

By: <u>/s/ Scott Ward&nbsp;&nbsp;&nbsp;&nbsp;</u>

Name: Scott Ward

Title: Chairman, President and Chief Executive Officer

[Signature Page to Product Development Agreement]

------

**EXHIBIT A: DEVELOPMENT PLAN**

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Scott R. Ward, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q of Cardiovascular Systems, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;

---

| |
|:---|
| /s/ Scott R. Ward |
| Scott R. Ward<br>Chairman, President and Chief Executive Officer |
| Dated: February 9, 2023 |

---

&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jeffrey S. Points, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q of Cardiovascular Systems, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| /s/ Jeffrey S. Points |
| Jeffrey S. Points<br>Chief Financial Officer |
| Dated: February 9, 2023 |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the filing of the Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 (the "Report") by Cardiovascular Systems, Inc. ("Registrant"), I, Scott R. Ward, the Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

&nbsp;&nbsp;&nbsp;&nbsp;

---

| |
|:---|
| /s/ Scott R. Ward |
| Scott R. Ward<br>Chairman, President and Chief Executive Officer |
| Dated: February 9, 2023 |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the filing of the Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 (the "Report") by Cardiovascular Systems, Inc. ("Registrant"), I, Jeffrey S. Points, the Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| |
|:---|
| /s/ Jeffrey S. Points |
| Jeffrey S. Points<br>Chief Financial Officer |
| Dated: February 9, 2023 |

---

<br>